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Abstract 
 
  
Accelerated atherosclerosis is a complication of the rheumatic disease systemic lupus 
erythematosus (SLE). I questioned the role of invariant Natural Killer T (iNKT) cells in this 
process, since they are known to be defective in SLE but also promote atherosclerosis in 
response to CD1d-mediated lipid presentation. SLE patients with asymptomatic plaque 
(SLE-P) had an altered iNKT cell phenotype to those without plaque (SLE-NP), 
characterised by differences in activation marker expression and increased IL-4. This SLE-
P iNKT cell phenotype correlated with differences in serum lipids including VLDL and coud 
be recapitulated in vitro by culturing healthy PBMCs with serum from SLE-P patients, an 
effect that was inhibited in the presence of anti-CD1d. Whilst differences in CD1d and lipid 
raft co-localisation and recycling were found in SLE patients, no difference was observed 
between SLE-NP and SLE-P patients. Isolation of phospholipids from SLE-P patients 
confirmed that differences in the lipids being presented were driving the anti-inflammatory 
iNKT cell phenotype in SLE-P patients. The finding that healthy iNKT cells, differentiated in 
the presence of healthy monocytes and serum from SLE-P patients, could induce THP-1 
macrophage polarisation towards an anti-inflammatory M2-like phenotype suggested a 
protective role for iNKT cells in SLE patients with subclinical atherosclerosis. This was 
confirmed by studying a group of SLE patients who had suffered a cardiovascular event, 
where this protective iNKT cell phenotype seen in asymptomatic patients was lost.   
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Introduction 
 
1.1 Systemic lupus erythematosus and cardiovascular risk: overview 
 
1.1.1 Introduction to SLE 
 
Systemic Lupus Erythematosus (SLE) is a highly heterogeneous autoimmune disorder, 
currently of unknown etiology.  It the United Kingdom it has a variable prevalence depending 
on ethnicity, affecting between 40 (Caucasian) and 200 (Afro-Caribbean) in every 100,000 
people [1]. It is associated with considerable morbidity and mortality through severe 
inflammation and organ damage, and is significantly more common in women of child 
bearing age who are 8-15 times more likely than men to develop SLE [2, 3]. Despite 
significant improvements in mortality rate from a 50% 5 year survival in 1955 to an 85% 10 
year survival in recent times [4], SLE still remains difficult to control with the the therapeutics 
currently available meaning that patients’ quality of life is substantially diminished [5]. This 
issue is highlighted in a recent study, which demonstrated that only 15% of SLE patients 
attending an academic clinic sustained good to excellent disease control over the course of 
one year [6]. The improved lifespan for SLE patients has lead to the emergence of several 
co-morbidities including an increased risk of cardiovascular disease and recurrent infections, 
of which patients with high disease activity are thought to be at greater risk [7, 8]. 
Accelerated atherosclerosis is particularly prevalent in SLE patients, where between 30 and 
40% of patients are affected in studies, which have used vascular ultrasound [9]. 
 
As a systemic autoimmune disorder, SLE exhibits a range of clinical manifestations including 
arthritis, pleurisy, pericarditis, skin rashes, renal damage, blood disorders  and neurological 
disorders [10, 11]. Such complications are a result of chronic inflammation, which occurs as 
a consequence of defective apoptosis, and T and B cell hyper-responsiveness to self-
antigen such as dsDNA. Subsequent production of autoantibodies causes tissue damage 
directly or indirectly through a type III hypersensitivity reaction, resulting in excessive 
immune complex formation. These immune complexes become trapped in the 
microvasculature, resulting in a chronic inflammatory response which damages organs such 
as the skin, heart and kidneys and leads to the development of distinguishing clinical 
features such as the butterfly rash. 
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1.1.2 Etiopathogenesis of SLE 
 
Whilst the etiology of SLE remains unclear, a combination of genetic, environmental and 
hormonal factors has been shown to be associated with the disease. Genetics factors have 
been implicated in the development of SLE for over 40 years. This is evident from the finding 
that the prevalence of SLE is approximately 1 in 100 in first-degree relatives of SLE patients, 
or approximately 20 times greater than the general population [12]. Moreover, increased 
concordance rates have been observed amongst monozygotic twins compared to dizygotic 
twins – rates of approximately 25% and 2% respectively [13]; together suggesting a large 
genetic basis for the disease. 
 
However, disease inheritance does not follow traditional Mendelian rules of genetics, 
suggesting that SLE is a result of a combination of multiple genetic variations; some of which 
may be common in the general population. So far, over 10 genome-wide association studies 
have identified over 50 genes associated with SLE in the form of single nucleotide 
polymorphisms (SNPs), polymorphisms leading to alternative splicing, and polymorphisms 
in the 3’ untranslated region such as miRNAs, which influence gene expression [14].  
 
Genetic polymorphisms include those that influence lymphocyte function such as Signal 
Transducer and Activator of Transcription (STAT) 4 [15], Protein tyrosine phosphatase, non-
receptor type 22 (PTPN22) [16], Lyn [17] and interleukin (IL)-10 [18], which have all been 
linked to defective B cell function. Other polymorphisms include interferon regulatory factor 
(IRF)-5, -7 and -8 [19-21], and Toll-like receptor (TLR)-7 and -9 [22, 23], which are involved 
in innate immune signaling, as well as Autophagy protein 5 (ATG5) and DNase1 [24, 25], 
which are involved in immune complex clearance.  
 
Of the genetic factors which predispose to SLE, female gender is probably the strongest, for 
reasons which are not yet completely understood. One explanation is that estrogen 
contributes to disease development; a theory which has been proven in animal models, 
where estrogen treatment worsened disease [26]. But the presence of SLE in children and 
postmenopausal women suggests that other female-specific factors play a role, such as 
differences in the immune system between men and women. This has been hypothesized 
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to be a result of inappropriate activation of normally-silenced immune genes located on the 
X chromosome due to DNA demethylation [27, 28].  
 
Environmental factors, notably ultra-violet light exposure may also contribute to SLE 
development [29]. Despite many large-scale epidemiological studies only silica dust 
exposure [30], and to a lesser extent smoking [31, 32], have been identified as possible 
factors which contribute to SLE by acting as a trigger and influencing DNA methylation. 
Certain drugs such as procainamide and hydralazine have previously been shown to induce 
SLE-like immune features but rarely cause full-blown SLE [33, 34], whilst low vitamin D 
levels have been hypothesised to play a role in SLE development [35].  
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1.1.3 Current approaches in SLE diagnosis and treatment 
 
A widely used set of classification criteria are the 1997 Revised American College of 
Rheumatology (ACR) Criteria. Individuals must display at least four of the 11 clinical and 
laboratory classification criteria (Table 1.1) [36]. Patients’ disease activity varies 
substantially over time and may be assessed through a variety of indices. Probably the best 
known are the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British 
Isles Lupus Assessment Group (BILAG) [37]. In particular, the BILAG index scores disease 
activity in 9 distinct organs or systems [38]. Scores ranging from A (most active) to E (never 
active) are converted numerically (A=12, B=8, C=1, D=0, E=0) and combined to give a global 
score [38, 39]. Laboratory tests used to reflect disease activity include the measurement of 
complement protein C3, lymphocyte count and anti-dsDNA antibodies in the blood [40]. 
 
SLE is treated according to both organ involvement and disease severity. Therapeutic 
strategies include the use of hydroxychloroquine, steroids and immunosuppressive agents 
such as methotrexate and mycophenolate  [41].  More recently several biological therapies 
have been developed, which target various aspects of B cell and T cell dysfunction in SLE. 
These include abatacept, which binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-
4) on T cells to inhibit interactions with antigen presenting cells [42], belimumab, which 
neutralizes B cell activation Factor (BAFF) to prevent of B cell over-activation [43], and 
rituximab, which binds CD20 to deplete B cells [44]. Successful results have been observed 
in clinical trials for belimumab [45], which has since been approved for use in SLE by the 
US Food and Drug Administration (FDA) [46]. Promising results have been observed for 
rituximab, which has been used to treat over 700 SLE patients in nearly 30 trials [47]. Whilst 
the majority of patients demonstrated improvement in both clinical features of the disease 
and biomarkers such as anti-dsDNA levels [48, 49], two major trials (EXPLORER and 
LUNAR) failed to meet their primary endpoints [44]. However, this was likely a consequence 
of poor trial design and specifically the excessive use of concomitant steroids and 
immunosuppressives [50]. Despite improvements in patient life expectancy and quality of 
life, it is unknown whether current therapeutic intervention could be contributing to other 
complications in SLE patients such as increased cardiovascular risk, the focus of this study 
[9]. 
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Symptom Description 
Malar rash Also known as the butterfly rash, characterized by 
red or purple scaly skin 
Discoid rash Affects the face and scalp; characterized by red 
scaly patches which clear in places to leave scarring 
Photosensitivity Skin rash as a result of unusual reaction to 
sunlight 
Oral ulcers Oral   or   nasopharyngeal   ulceration,   usually   
painless 
Arthritis Non-erosive  arthritis  involving  two  or  more  
peripheral joints, characterised by tenderness or 
swelling  
Serositis Pleuritis: history of pleuritic pain or rub heard by a 
physician or evidence of plural effusion or pericarditis 
documented   by   electrocardiogram  
Renal disorder Persistent proteinuria greater than 0.5 grams per 
day or greater than 3+ if quantification not 
performed or cellular casts may be red cell, 
haemoglobin, granular, tubular or mixed. 
Neurological disorder Seizures  in  the  absence  of  offending  drugs or 
known metabolic derangements;  e.g. uraemia, 
ketoacidosis,  or electrolyte  imbalance  or  psychosis   
Hematological disorder Hemolytic anaemia with reticulocytosis, leukopenia 
(less than 4000mm3 on two or more occasions) or 
lymphopenia (less than 1500mm3 on two or more 
occasions) or thrombocytopenia (less than 
100000mm3)  
Immunologic disorder Anti-DNA antibody to native DNA in abnormal 
titre or anti-Sm presence of antibody to Sm 
nuclear antigen or positive finding of 
antiphospholipid antibodies based on: 1. An 
abnormal serum level of IgG or IgM anticardiolipin 
antibodies, 2.A positive test result for lupus 
anticoagulant using a standard method or 3. A 
false-positive serologic test for syphilis known to be 
positive for at least 6 months and confirmed by 
Treponema pallidum immobilisation or fluorescent 
treponemal antibody absorption test 
Antinuclear antibody An abnormal  titer of  antinuclear    antibody by 
immunofluorescence or an equivalent assay at any 
point in time and in the absence of drugs known to 
be associated with “drug-induced lupus” syndrome 
 
Table 1.1 Diagnostic criteria for SLE  
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1.1.4 SLE and Cardiovascular Risk 
 
As a major cause of death in SLE patients, the relationship between SLE and cardiovascular 
disease is well known and is thought to be independent of traditional risk factors. In 1976 
Urowitz et al. first identified an association between SLE and death by myocardial infarction 
(MI) in a cohort of SLE patients in Toronto, with 6 out of 11 deaths occurring within a year 
of diagnosis [51].  Furthermore, patients were calculated to have a five-fold greater risk of 
MI compared to the general population, the average age for which occurred at 49, compared 
to 65-74 in the general population. Since then multiple  studies have evaluated the link 
between SLE and cardiovascular disease with emphasis on atherosclerosis, which is 
responsible for around 30% of deaths in SLE patients [52].  
 
The first major study to analyse the association between SLE and cardiovascular events 
was carried out by Manzi et al. where 498 women with SLE were assessed for MI and angina 
over a period of 13 years [53]. Data were compared to 2208 age-matched healthy women 
from the Framingham Offspring Study [54]. They observed a disturbingly higher incidence 
of cardiovascular events in younger SLE patients, particularly those under 55 years who 
normally would be unlikely to suffer a cardiovascular event [53]. Based on this cohort, they 
calculated that the risk of MI in female SLE patients aged 35-44 years was over 50 times 
greater than the general population [53].  
 
The association between SLE and cardiovascular disease has since been confirmed by 
numerous studies, most notably by Roman et al. which used a case-control approach and 
assessed atherosclerotic plaque by ultrasound [55]. Whilst atherosclerosis in SLE patients 
was not found to be associated disease activity in this study, associations with longer 
disease duration, a higher damage-index score and less aggressive immunosuppressive 
therapy suggested that inflammation was responsible for the development of atherosclerosis 
in these patients [55]. However, specific disease-related factors which influence the rate of 
atherosclerosis progression in SLE patients remain elusive. Whilst several studies have 
implicated age of SLE onset as a determinant of atherosclerosis [56, 57], studies which 
adjusted for patient age have shown this not to be the case [58, 59]. The LASER study 
suggested that persistently high disease activity was a major contributing factor towards 
cardiovascular disease in SLE patients, which could not be prevented by therapeutics such 
as corticosteroids and azathioprine [60].  However, the extent to which this is true remains 
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under question since Kiani et al. for example found that SLE disease activity (quantified by 
SLEDAI and anti-dsDNA) did not predict subclinical atherosclerosis in SLE patients [58]. 
 
1.1.5 Traditional cardiovascular risk factors in SLE patients 
 
 
In the general population cardiovascular risk factors play a large role in the development of 
atherosclerosis and include environmental factors such as diet, physical activity and 
smoking in combination with genetic factors [61].  In particular the combination of obesity, 
diabetes and hypertension (termed metabolic syndrome) has been shown to greatly 
enhance cardiovascular disease risk [62]. Such risk factors have repeatedly been identified 
by the Framingham Heart Study as being significantly associated with cardiovascular 
disease mortality [63].    
 
However, there is a lack of consensus on the importance of cardiovascular risk factors in 
SLE patients, and the extent to which they contribute to the development of atherosclerosis 
in patients. Evidence suggests that SLE patients consistently carry more Framingham 
cardiovascular risk factors compared to healthy controls including dyslipidemia, 
hypertension and diabetes mellitus [53, 64]. Moreover, several studies have observed an 
increased incidence of metabolic syndrome in SLE compared to the general population. 
Parker et al. observed an incidence of 30% in SLE patients compared to 20% in a control 
population [65], whilst Sabio et al. observed an incidence of 20% compared to 13% in 
healthy controls [66]. A study on a Mexican cohort of SLE patients found that the absence 
of traditional cardiovascular risk factors was associated with a lack of subclinical myocardial 
ischemia [67], highlighting the importance of cardiovascular risk factors as major 
determinants of cardiovascular disease in SLE patients. It is unknown however whether 
metabolic syndrome manifests itself as a result of SLE itself, or due to preventable risk 
factors such as smoking, which has previously been shown to be associated with metabolic 
syndrome in SLE patients [68].   
 
Most studies agree that whilst important in predicting cardiovascular disease in SLE 
patients, the increased prevalence of atherosclerosis cannot be explained by traditional 
Framingham risk factors alone. This is evident from large population based studies including 
Roman et al, who found SLE presence to be the most important correlate of atherosclerosis 
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other than age [55]. Similarly, Asanuma et al. reported that the presence of atherosclerosis 
could not be accounted for through traditional cardiovascular risk factors, indicating that the 
presence of SLE alone is enough to significantly increase an individual’s risk of 
cardiovascular disease [69]. This is supported by Esdaile et al. who found that the increased 
risk of coronary heart disease and stroke in 263 SLE patients could not be explained by 
Framingham risk factors alone [70]. Studies have therefore focused on identifying non-
traditional cardiovascular risk factors which predict atherosclerosis development, as well as 
other biomarkers which can identify patients most at risk [69]. A summary of traditional and 
non-traditional cardiovascular risk factors in SLE patients is shown in Table 1.2. 
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Traditional Risk Factors Non-traditional Risk Factors 
Hypertension Corticosteroid use 
Hypercholesterolemia Endothelial cell apoptosis 
Hypertriglyceridemia Anti-heat shock protein autoantibodies 
Low HDL cholesterol Increased oxidised LDL (oxLDL) 
High body mass index (BMI) High levels of immune complexes 
Insulin resistance High levels of ADMA 
Diabetes mellitus Increased levels of proinflammatory 
cytokines 
Renal impairment Dendritic cell CD86 overexpression 
Early menopause T cell CD40L upregulation 
Increased C reactive protein  
Smoking  
Family history of cardiovascular disease  
Table 1.2 Traditional and non-traditional cardiovascular risk factors in SLE 
patients 
Table adapted from Westerweel et al [71]. HDL – high density lipoprotein; BMI-body mass 
index; LDL – low density lipoprotein; ADMA - asymmetric dimethylarginine 
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1.1.6 Other determinants of cardiovascular disease in SLE patients 
 
In order to explain the increased cardiovascular risk in SLE patients, studies have 
investigated a wide range of non-traditional cardiovascular risk factors including genetics, 
inflammatory biomarkers associated with SLE and patient medication. Several genetic 
polymorphisms are associated with increased cardiovascular disease risk in SLE including 
interferon regulatory factor 8 (IRF8) [72], matrix metalloproteinase (MMP)-2 [73], 
plasminogen activator inhibitor (PAI)-1 [74] and mannose binding lectin (MBL)-2 genes [75]. 
These polymorphisms are associated with altered immune cell function in SLE, which has 
been shown to contribute to and the development of atherosclerosis in these patients. 
 
Oxidative stress is known to play a major role in endothelial dysfunction, which precedes 
many of the latter arterial changes in atherosclerosis.  SLE patients have higher levels of 
oxidative stress compared to their healthy counterparts [76], which may occur as a 
consequence of increased traditional cardiovascular risk factors such as smoking, 
hypertension and insulin resistance [77]. This leads to the formation of advanced glycation 
end products which are toxic to endothelial cells [78], whilst the consequential oxidation of 
lipids induces endothelial secretion of monocyte chemotactic protein 1 (MCP-1), IL-6 and 
IL-8 which promote inflammation of the vasculature [64].  
 
In support of this, several cytokines have been associated with the presence of 
atherosclerosis in SLE patients. For example, Zhu et al. observed elevated IL-6 and IL-17 
and together with decreased IL-10 levels in SLE patients with carotid plaque, which was 
correlated with a T helper 17 (Th17)/ T regulatory cell (Treg) imbalance [79]. Additionally, 
Ruiz-Limon et al. demonstrated that both cardiovascular events and presence of 
atherosclerosis in SLE patients were correlated with several inflammatory biomarkers 
including MCP-1, monocyte inflammatory protein (MIP)-1α and tissue factor (TF) [80].  
 
Interferon (IFN)-α is a cytokine associated with active disease in SLE patients [81] that has 
been found to play a role in the development of atherosclerosis. Specifically, IFN-α has been 
shown to induce platelet aggregation, vascular thrombosis, immune cell activation and the 
secretion of cytokines and MMPs by plasmacytoid dendritic cells (pDCs) [82]. IFN-α also 
mediates endothelial progenitor cell death, thus inhibiting many of the repair processes 
within the endothelium [83].  
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Autoantibodies associated with SLE may also contribute to cardiovascular disease risk, with 
those against phospholipids, apoA1, oxidised LDL (oxLDL) and annexin V hypothesised to 
play a role in plaque development. Approximately 20 to 40% of SLE patients have anti-
phospholipid (APL) antibodies [84], which are thought to contribute the early stages of 
endothelial cell dysfunction through interactions with β2 glycoprotein 1 [9]. However, clinical 
studies have shown variable results since higher APL levels have been shown to correlate 
with an increased risk of MI in otherwise healthy men [85, 86] yet patients with primary 
antiphospholipid syndrome (APS), which occurs in up to 70% of SLE patients [84], do not 
have significantly increased endothelial cell dysfunction in comparison [87, 88].  
 
Anti-apoA1 autoantibodies are present in 10-35 % of SLE patients, the presence of which is 
associated with SLE disease activity [89, 90]. Due to the anti-inflammatory role of the apoA1-
component of HDL, it is thought that that anti-apoA1 autoantibodies inhibit the 
atheroprotective effects of apoA1 and HDL [9]. Recently however, Croca et al. found no 
association between apoA1 and SLE patients who had suffered a cardiovascular event, 
suggesting that it may not pay a large role in the development of atherosclerosis in SLE 
patients [90]. 
 
Autoantibodies against oxLDL play a pathogenic role in SLE patients with high disease 
activity, and often appear following detection of antilipoprotein lipase autoantibodies [91].  
The underlying mechanism is unclear, but it is believed that the presence of oxLDL 
complexes in the subendothelial space coupled with defective clearance of immune 
complexes may play a role in plaque development [9]. Interestingly, IgG anti-oxLDL 
autoantibodies appear to contribute to atherosclerosis, whilst IgM anti-oxLDL antibodies 
may even be considered protective [92].  
 
SLE patients show elevated levels of anti-annexin-V antibodies [93], which inhibit the 
atheroprotective interactions between annexin-V and the phospholipid bilayer of the 
endothelium [94]. Autoantibodies can also induce the formation of neutrophil extracellular 
traps (NETs) [95], which induce IFN-α production by pDCs as well as endothelial cell 
apoptosis [96]. 
 
Other serum factors postulated to promote atherosclerosis in SLE patients include 
homocysteine and adipokines. Homocysteine levels are higher in SLE patients, which may 
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be due to renal dysfunction [97, 98]. Studies show that homocysteine can induce endothelial 
cell death [99], decrease nitric oxide bioavailability [100] and promote thickening of the 
intimal-medial wall [101]. Leptin is an adipokine which, in addition to its role as an appetite 
suppressant, may contribute to atherosclerosis development [102]. Increased leptin levels 
have been observed in the serum of both juvenile and adult SLE patients [103, 104], where 
it may play a role in plaque development. In contrast, one study found another adipokine, 
adiponectin to be protective against cardiovascular disease in both healthy individuals and 
SLE patients [105]. Data however is currently limited and the mechanisms as such remain 
unknown. 
 
C reactive protein (CRP) is another biomarker that may be useful in predicting 
cardiovascular risk in otherwise healthy individuals, however it appears to be less effective 
in SLE patients. Whilst in the general population CRP levels have been shown to strongly 
correlate with atherosclerosis, in SLE data are inconsistent and despite high levels of other 
inflammatory markers, CRP levels are generally low [106]. In the LUMINA study as well as 
a smaller study in Sweden, high CRP concentrations were associated with a minimal 1.5 to 
3.3 fold increase in cardiovascular risk in SLE patients [107, 108].   
 
SLE patient medication is another factor which could significantly increase cardiovascular 
disease risk. Bessant et al. observed a significant association between cardiovascular 
disease risk and steroid treatment [109], whilst no association was observed for azathioprine 
and cyclophosphamide. Conversely, other forms of medication for SLE patients such as 
hydroxychloroquine have been shown to reduce cardiovascular risk [109, 110]; however this 
is likely dependent on patient responsiveness to treatment in terms of disease activity. 
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1.1.7 Current treatment of cardiovascular disease in SLE patients  
 
Primary prevention of cardiovascular disease involves the management of pre-existing 
conditions included in the metabolic syndrome [111]. These include abdominal (central) 
obesity, high blood pressure, high serum triglycerides and low serum high density 
cholesterol (HDL) levels; treatment for which, reduces the likelihood of a cardiovascular 
event. However, there is increasingly more emphasis on recognising the initial stages of 
atherosclerosis development, which may precede the development of conditions such as 
dyslipidemia and hypertensison. Methods to diagnose early atherosclerosis in asymptomatic 
patients include vascular imaging by ultrasound scan, which is sensitive enough to detect 
plaques at the preclinical stage [112], as well as surrogate measures such as flow mediated 
dilation to detect subtle changes in arterial function [113]. Such methods could prove 
beneficial in diseases such as SLE where analysis of serum biomarkers may not always be 
as useful compared to the general population.      
 
In the general population dyslipidaemia is treated by changes in diet followed by statins, 
where patients’ lipids are difficult to control. Despite studies identifying SLE and 
dyslipidaemia as significant co-morbidities [114], not all SLE patients are considered 
dyslipideamic since clinical lipid measures often fall within normal ranges, which may be 
attributable to the various therapeutics available for SLE [115, 116]. Statins are therefore 
not routinely prescribed to patients due to greater clinical emphasis on treating the root 
cause of SLE – the patient’s disease activity.  Statins have numerous effects on the immune 
system, which make them suitable as a way of reducing cardiovascular risk in SLE patients. 
These include the inhibition of cholesterol biosynthesis, reduced inflammatory cytokine 
production and upregulation of nitric oxide (NO) synthesis [117]. Statin treatment has been 
shown clinically to decrease cardiovascular mortality by reducing inflammation within 
atherosclerotic plaques, through inhibition of monocyte-endothelial cell interactions and 
decreased expression of TF and MMPs [118, 119]. For example, fluvastatin has recently 
been shown to reduce the thrombotic tendency of monocytes from anti-phospholipid 
patients, accompanied by a reduction in protease activated receptor (PAR) and vascular 
endothelial growth factor (VEGF) expression [120].   
 
Several clinical trials have explored the potential for statin use in SLE patients with mixed 
results. Ruiz-limon et al. observed several positive benefits of statin treatment in SLE 
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patients including downregulation of several inflammatory markers [80]. For instance, 
several members of the nuclear factor kappa B (NFκB) signalling pathway including protein 
kinase A (PKA), Rho Kinase and cyclic adenosine monophosphate (cAMP) showed 
diminished expression following Fluvastatin treatment, supporting the notion that statins 
inhibit NFκB signalling in healthy individuals. Fluvastatin also downregulated IκBKG 
expression in SLE patients, which regulates NFκB signalling, as well as NFκBIA, which 
inhibits nuclear import of NFκB [80]. A similar effect was seen for ETS1, a transcription factor 
regulating MCP-1 and phospholipase expression. Furthermore, treatment of SLE patients 
with fluvastatin upregulated genes involved in mitochondrial biogenesis resulting in greater 
numbers of mitochondria with a lower oxidative potential [80]. Since the redox potential of 
lipids can influence atherosclerosis in SLE, this indicates that statin treatment may be 
beneficial in reducing cardiovascular risk in SLE patients.     
 
In a different study, Rosuvastatin was found to reduce levels of high sensitivity CRP 
(hsCRP), homocysteine and several endothelial markers in stable SLE patients with 
subclinical atherosclerosis [121]. Moreover, low doses (10mg/day) were found to 
significantly decrease LDL cholesterol and hsCRP after 12 months therapy. This was 
associated with a reduction in P-selectin and thrombomodulin in patients with very low 
disease activity (SLEDAI <2).  
 
Whilst it is clear statins may be beneficial in SLE, other reports are less convincing [122, 
123]. For example, the Lupus Atheroclerosis Prevention Study (LAPS), a randomised control 
trial of 200 patients who were treated with 20mg atorvastatin over a 2 year period observed 
no effect of statin treatmaent on atherosclerosis development [123]. Similarly, Schanberg et 
al. found no significant difference in SLE disease activity or atherosclerosis risk following 
treatment with atorvastatin in a cohort of 221 juvenile SLE patients [124]. Possible 
explanations for these differences include the variable sample sizes and follow-up periods 
in these studies, suggesting that further clinical trials are needed [122].    
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1.2 Systemic lupus erythematosus and atherosclerosis: immune 
mechanisms 
 
1.2.1 SLE: immune mechanisms overview 
 
As an autoimmune disease, SLE occurs as a result of innate and adaptive immune 
dysregulation, and is characterised by a loss of tolerance and hyper-responsiveness to self-
antigens such as double- stranded DNA (dsDNA) (Figure 1.1). A range of genetic and 
immunopathological defects have been identified in cellular processes including apoptotic 
cell clearance, the complement cascade and lipid metabolism [125-127].  
 
Under normal homeostatic conditions, cell death occurs through apoptosis – a programmed 
cell death where intracellular components are retained within apoptotic vesicles (rather than 
released into the extracellular milieu), before being engulfed by phagocytes and 
macrophages, which rapidly clear apoptotic debris [128]. During apoptosis, 
phosphatidylserine is exposed on the external membrane, along with the expression of 
modified or “cryptic” self-antigens not normally exposed to the immune system [129]. Such 
antigens are thought to play a role in recognition by macrophages, resulting in a tolerogenic 
response characterised by release of transforming growth factor β (TGFβ) and IL-10, which 
prevents inflammation [128]. 
 
In SLE however, monocyte-derived macrophages show impaired adhesion and phagocytic 
activity resulting in secondary necrosis whereby the lysis of apoptotic vesicles releases 
intracellular contents into the extracellular environment [128, 130]. This gives rise to an 
abundance of nuclear antigens not normally present in healthy individuals, which are 
subsequently recognised as foreign by the immune system through activation of nucleic 
acid-sensing TLR3, TLR7, TLR8, and TLR9 on dendritic cells (DCs) [131]. In particular this 
drives IFN-α production by pDCs, which exerts a range of immunological effects including B 
cell differentiation, immunoglobulin class switching and production of autoantibodies, as well 
as T cell and B cell survival (Figure 1.2) [132]. Alternatively, self-antigen or immune 
complexes may also be presented by myeloid DCs (mDCs) directly to T and B cells in the 
presence of co-stimulatory signals, thus promoting an autoimmune response as opposed to 
the tolerogenic response seen under normal homeostatic conditions [133]. This is 
attributable to T and B cell dysfunction whereby lymphocytes have a lower threshold for 
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activation resulting in hypersensitivity, which is well described in SLE [134].  Inflammation 
may also be perpetuated through an imbalance in CD4+ T cell subsets, with an increase in 
T helper 17 (Th17) cells [135], which are associated with autoimmunity and a reduction in 
Tregs, which antagonise other T cell subsets to induce tolerance [136].  In addition to their 
role in B cell activation, autoreactive T cells infiltrate sites of inflammation, secrete cytokines 
and chemokines, and perpetuate the immune response by inducing recruitment of other 
immune cell types. 
 
Due to their importance in autoantibody production, B cells are major players in the 
pathogenesis of SLE. They can either be activated classically by T lymphocytes, or 
alternatively through autoantigen recognition via TLR3, 7, and 9, resulting in the production 
of autoantibodies against a plethora of nuclear, cytoplasmic and surface antigens. Defective 
B cell responses are maintained through polyclonal B cell activation and expansion, 
mediated through B cell activating factor (BAFF) which is increased in SLE patients [137]. 
The finding that autoantibodies are of high affinity and IgG class-switched indicate a major 
role for T cells in providing B cell help; supported by the finding of increased CD40 ligand 
(CD40L) expression on T cells [138], and the demonstration of nucleosome specific T cells 
in patient blood [48]. 
 
Importantly, the presence of autoantibodies in SLE patients contributes to SLE disease 
pathogenesis by inducing the formation of large immune complexes with the potential to 
cause tissue damage. This is worsened by defects in the complement cascade, as a result 
of C1q deficiency or low C2 and C4, and leads to reduced agglutination, opsonisation and 
impaired uptake by antigen presenting cells.  These large immune complexes may become 
trapped in the microvasculature, resulting in direct organ damage to the skin, joints or the 
kidneys in the form of a flare. Alternatively, tissue damage may occur indirectly through a 
type III hypersensitivity reaction whereby immune complex recognition and phagocytosis is 
FcγR-mediated, i.e. the immune response becomes directed against the autoantibodies 
themselves. This results in the activation of proinflammatory genes such as NFκB, and the 
secretion of vast amounts of cytokines and inflammatory mediators, resulting in systemic 
inflammation.  
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Figure 1.1 SLE immunopathogenesis 
SLE is characterized by both a failure in B cell and T cell self-tolerance, and defects in 
apoptotic cell clearance, which both occur as a result of unknown external triggers. Nuclear 
antigens, which are exposed as a result of defective cell death, are recognized by B cell 
autoantibodies to form antigen-antibody complexes. Subsequent interactions between T 
cells and B cells results in class switching to IgG, whilst recognition of nuclear antigens 
through TLRs present on B cells and DCs induces type I IFN production. Such cellular 
interactions perpetuate disease through inflammatory cytokine production and further 
immune complex formation. 
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Figure 1.2 Immune mechanisms of SLE 
SLE is characterised by aberrant immune responses to antigen present in apoptotic cells, 
which upon presentation to T cells results in excessive proinflammatory cytokine release by 
Th1 and Th17 effector T cells. These autoreactive T cells provide B cell help, which enables 
class switching and release of autoantibodies which are reactive against double stranded 
DNA and RNA. Excessive autoantibody release results in immune complex formation, 
followed by dendritic cell activation and the release of IFN-α, which perpetuates the process 
by supporting IgG class switching and B cell survival. Poor immunoregulation (e.g. by Tregs) 
combined with defective immune complex clearance (e.g. by complement) results in a type 
III hypersensitivity reaction, mediated by persistent immune complexes and ultimately 
resulting in chronic inflammation and tissue damage.  
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1.2.2 Atherosclerosis: immune mechanisms overview 
 
Atherosclerosis is an inflammatory disorder characterised by the desposition apolipoprotein 
B (ApoB)-containing lipoproteins within the vasculature and subsequent uptake by immune 
cells within the intimal arterial layers. The deposition and oxidation of lipids initiates an 
inflammatory cascade resulting in vascular swelling and arterial occlusion, which can 
ultimately result in a stroke or MI (Figure 1.3) [139]. Particular regions of the arterial tree 
such as the aorta are more prone to this, as they are exposed to high shear stress blood 
flow [139]. This previously described “response to retention” model of atherosclerosis pins 
this root cause as the ApoB lipoproteins themselves [139]; modified lipoproteins which now 
act as antigens within susceptible areas of the vasculature. 
 
A causal relationship between lipoprotein and subendothelial matrix interactions and the 
development of atherosclerosis has previously been demonstrated in genetically engineered 
mice [140, 141]. This is supported by epidemiological studies, demonstrating the link 
between high circulating concentrations of cholesterol and atherosclerotic cardiovascular 
disease [92]. In the blood cholesterol is transported by low density lipoprotein (LDL) in 
complexes comprised of an esterified cholesterol and triglyceride core, surrounded by a 
phospholipid and ApoB shell [139].  
 
The initial stage of atherosclerotic plaque development is characterised by the “fatty streak”, 
which is comprised of subendothelial lipids and cholesterol-laden foam cells formed upon 
excessive lipid uptake by macrophages [92]. The mechanisms involved in foam cell 
formation have yet to be fully characterised but likely combines a range of cellular processes. 
These include macropinocytosis, receptor-mediated endocytosis, scavenger receptor-
mediated uptake and direct uptake via dendritic processes, which protrude through the 
endothelium [142]. Once engulfed by macrophages lipoproteins are processed within the 
endoplasmic reticulum and free cholesterol is re-esterified, resulting in lipid droplet 
formation, characteristic of foam cells [143]. This process is perpetuated through persistent 
dyslipidaemia, characterised by an abundance of LDL, which undergoes oxidation to form 
the pro-atherogenic oxLDL. The activation of endothelial cells by oxLDL results in enhanced 
expression of adhesion molecules E-selectin and vascular cell adhesion protein 1 (VCAM) 
on endothelial cells, which facilitates transendothelial migration of monocytes, DCs and T 
cells [92].  The abundance of trapped oxLDL within the intima results in a localised immune 
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response characterised by influx of immune cells, and permanent structural changes within 
the arteries. 
 
Vulnerable plaques, which are liable to rupture, are characterised by a large necrotic core, 
fibrous cap and decreased smooth muscle and extracellular matrix content [144]. This loss 
of plaque stability is often a result of smooth muscle cell apoptosis, which exacerbates 
inflammation and is associated within fibrous cap thinning and an expanded necrotic core 
[145]. Loss of smooth muscle and cell matrix occurs through several mechanisms, including 
secretion of MMP-7 from macrophages [146], and tryptase and chymase release from mast 
cells; all of which act directly on smooth muscle cells leading to defects in inducible nitric 
oxide synthase (iNOS) production and cell adhesion [147]. 
 
Immunocytochemistry and flow cytometry of atherosclerotic specimens with antibodies 
specific for a range of cell types has confirmed the presence of macrophages, DCs, CD4+ T 
cells, CD8+ T cells, B lymphocytes, mast cells and occasionally neutrophils within the 
atherosclerotic plaque [148].  This range of cell types has subsequently been shown to 
contribute to all stages of plaque development and will be explored in subsequent sections 
[92].  
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Figure 1.3 Immunopathogenesis of atherosclerosis 
Atherosclerosis is initiated as a result of dyslipidemia, in particular by oxidised LDL which is 
endocytosed by macrophages via scavenger receptor activation. This results in the release 
of proteases, matrix metalloproteinases and reactive oxygen species, which contribute to 
remodelling of the endothelium as well as increased lipid oxidation. Moreover, chemokine 
release by macrophages combined with increased endothelial cell adhesion molecule 
expression results in increased monocyte transendothelial migration into the intima. The 
presence of lipid-reactive T cells (such as iNKT cells) combined with the abundance of lipid 
antigen results in activation of adaptive immune cells (NK cells, Th1 cells and CTLs) which 
act in a positive feedback manner to induce macrophage differentiation through IFN-γ, as 
well as contributing to the inflammatory response. Progression of atherosclerotic plaques is 
characterised by foam cell formation and formation of a necrotic core, observed in advanced 
lesions, where macrophages are unable to process endocytosed lipid antigen. This results 
in the release of peptide antigen, which exacerbates the inflammatory response, resulting in 
tissue damage to smooth muscle cells and narrowing of the lumen. 
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1.2.3 Antigen presenting cells: overview  
 
An antigen presenting cell (APC) is a cell that is capable of presenting antigen complexed 
with major histocompatibility complex (MHC) to T cells. Whilst many cells in the human body 
function as APCs professional APCs include dendritic cells, monocytes/macrophages and 
B cells. With the exception of B cells, APCs are considered part of the innate immune 
system, which is characterised by its ability to process and present antigen in a non-specific 
manner to T cells to generate an adaptive immune response.  
 
In contrast to non-professional APCs which are mostly concerned with presenting 
endogenous antigen (such as self-antigen or viral antigen during infection), professional 
APCs are extremely efficient at internalising exogenous antigen through phagocytosis or 
receptor-mediated endocytosis. One method of antigen recognition occurs through 
activation of scavenger receptors, which recognise commonly occuring ligands including 
lipoproteins, apoptotic cells, phospholipids and proteoglycans in response to inflammation 
[149]. In addition to facilitating receptor-mediated endocytosis, scavenger receptors also 
induce various signalling cascades resulting in activation of multiple inflammatory genes 
[150] (Figure 1.4).  
 
One particularly abundant class of scavenger receptor are class A scavenger receptors (SR-
A), which are involved in recognising modified or oxidised LDL particles and as a result have 
been implicated in the development of atherosclerosis [149]. This is apparent due to the 
finding that SR-A is upregulated on endothelial cells upon exposure to oxidative stress, 
whilst SR-A activation in macrophage is thought to induce maturation to foam cells. 
Following recognition, SR-A undergoes internalization via clathrin dependent or 
independent endocytosis. 
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Figure 1.4 Lipid uptake by scavenger receptors 
Overview of the signalling pathways activated upon oxLDL recognition by scavenger 
receptors LOX-1, CD36 and SRA-1. Upon binding of oxLDL, differential endocytosis 
pathways are activated including (1) caveolae-mediated uptake, (2) lipid-raft dependent 
uptake, and (3) clathrin-independent pathway. Figure based on Zani et al. [150] LOX-1 - 
Lectin-like oxidized low-density lipoprotein (LDL) receptor-1 
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CD36 (also known as SR-B2) recognises oxidised phospholipids and lipoproteins, as well 
as long chain fatty acids and apoptotic cells [151], and is upregulated on macrophages 
where it functions as an “eat me” signal to induce further uptake of oxLDL and subsequent 
foam cell formation [152].  Moreover, CD36 expression is closely linked to lipid metabolism 
since it is upregulated through several mechanisms including peroxisome proliferator-
activated receptor γ (PPARγ) signalling and de novo ceramide synthesis [153, 154]. Other 
roles of CD36 include the recognition of cells undergoing apoptosis via a modified 
phosphatidylcholine/serine ligand [155, 156], as well as angiogenesis and oxidative stress, 
which all contribute to atherosclerosis [157].  
 
Lectin-like oxidised low density lipoprotein receptor (LOX-1) recognises a variety of ligands 
including oxLDL, bacterial components, and phosphatidylserine which is present on 
apoptotic cells [158]. It is upregulated on macrophages in response to the proinflammatory 
cytokines IFN-γ and tumour necrosis factor (TNF)-α [159], as well as in response to the 
hypertensive-related stimuli angiotensin-II and endothelin-1 [160]. Importantly, LOX-1 
expression is markedly increased within atherosclerotic lesions compared to healthy 
individuals, where it plays roles in atherosclerosis progression [161]. 
   
The low density lipoprotein receptor (LDLR) family of receptors mediate uptake of low 
density lipoprotein (LDL), intermediate density lipoprotein (IDL) or very low density 
lipoprotein (VLDL), and play a crucial role in the clearance of ApoE-containing lipoprotein. 
The LDLR is a major determinant of plasma cholesterol levels due to its role in removing 
cholesterol from the blood through receptor-mediated endocytosis [162]. Its expression is 
regulated by the liver x receptor (LXR) genes, which control lipid biosynthesis [162]. 
 
Not much is known about the role of scavenger receptors on other immune cells including 
B cells, T cells and monocytes or whether their functions are altered in SLE patients.  A 
study by Chen et al. observed that SLE patients produce autoantibodies against SR-A, 
which may prevent the phagocytosis of apoptotic cells and thus result in the loss of self-
tolerance in SLE patients [163]. In addition, Reiss et al. previously showed that SLE patient 
serum upregulated scavenger receptor CD36 expression in THP-1 human monocytes to a 
much greater extent than serum from healthy donors [164], which could result in increased 
lipid uptake by macrophages and thus a greater propensity for developing atherosclerosis. 
This is supported by the finding that IFN-α can upregulate SR-A in human monocytes and 
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macrophages [165], which potentially results in increased lipid uptake and foam cell 
formation - factors which could influence cardiovascular risk in inflammatory diseases such 
as SLE.   
 
1.2.4 Monocytes in SLE and atherosclerosis 
 
Monocytes originate from monocyte-DC precursors within the bone marrow, from which the 
classical, intermediate and non-classical monocytes arise, which can be characterised 
based mainly on CD14 and CD16 expression (Table 1.3).  
 
Classical or CD14++ monocytes are analogous to Ly6Chi monocytes in mice, and have been 
shown to upregulate MHC class II upon extravasation [166]. Remarkably, Ly6chigh and 
Ly6clow monocytes demonstrate plasticity in response to a range of stimuli, polarisation of 
which is driven according to the balance between Th1 and Th2 cytokines, which results in 
the generation of M1 or M2 macrophages [166]. 
 
Several studies have shown that monocytes play major roles in the initiation and 
development of atherosclerotic plaque [17, 18]. In mice proinflammatory Ly6Chigh monocytes 
(which are analogous to CD14+CD16+ monocytes in humans) expressing TNF-α, MMPs and 
cathepsins are recruited initially following MI in mice. This is followed by the predominance 
of Ly6Clow monocytes which express high levels of VEGF and are thought to play a role in 
tissue repair [167]. In humans, numbers of CD16+ (intermediate) monocytes have been 
found to correlate with traditional cardiovascular risk factors such as body mass index and 
intima-media thickness (IMT) [168-170]. Intermediate monocytes are also thought to 
produce higher amounts of reactive oxygen species (ROS), TNF-α and IL-1β, which 
contribute to plaque development [171]. Data on the frequency and functions of different 
monocyte subsets in SLE is confusing due to conflicting reports [172-174], which is thought 
to be due to differences in gating strategy [175]. Interestingly, intermediate and non-classical 
monocytes have been shown to have higher expression of TLRs and co-stimulatory 
molecules indicating a role in antigen presentation, whilst high expression of scavenger 
receptors have been observed on classical monocytes supporting a role for these cells in 
phagocytosis [175]. 
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 Inflammatory/Classical Intermediate Resident/Nonclassical 
Surface 
markers 
(human 
monocytes)  
CD14++CD16- CX3CR1lo 
CD62L+ CD115+ 
CD14+CD16+  
CX3CR1hi 
CD62L- CD115+ 
CD14+CD16+ CCR2- 
VCAMhi CD64lo 
Recruitment Early in acute 
inflammation 
Early in acute 
inflammation 
Late in acute 
inflammation 
Reservoirs Spleen Unknown Unknown 
Acute 
Inflammation 
Accumulate in inured 
myocardium and 
perform inflammatory 
and proteolytic functions 
Inflammation? Assumed role in 
granulation tissue 
formation and 
angiogenesis, later 
mobilization 
Chronic 
Inflammation 
Accumulate in 
atherosclerotic plaque 
Given 
scavenger 
receptor 
(CD163 and 
CD204) 
expression, 
accumulation in 
plaque is likely. 
Accumulate in plaque 
via CCR5 and 
CX3CR1. 
 
Table 1.3 Characteristics of different monocyte subsets in humans 
Human monocytes can be divided into classical (inflammatory), intermediate and non-
classical (tissue resident) subpopuations based on CD14 and CD16 expression other 
markers. Each population play various roles during different stages of atherosclerosis. 
Figure adapted from Ghattas et al. 2013 [176]. 
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There is evidence implicating  that monocytes are defective in SLE patients in terms of 
cytokine secretion; indeed it is recognized that mouse models of SLE are characterised by 
increased IFN-α production by monocytes in response to immune complexes [177, 178]. 
Moreover, monocytes from SLE patients have impaired IL-12p70 (T cell stimulating factor) 
production, which is compensated for by increased IL-10 production [12]. IL-10 subsequently 
acts in a pathogenic manner by inducing anti-dsDNA release [13]. A study by Korman et al. 
suggests that monocytes from SLE patients are programmed to differentiate into 
macrophages with increased pathogenic potential upon entering sites of vascular 
inflammation, thus promoting atherosclerosis progression [179]. Moreover, several signal 
transduction genes were found to be differentially regulated in SLE patients during monocyte 
to macrophage differentiation. These included Janus kinase 2 (JAK2), STAT6, TLR8, TLR2, 
VEGFB, macrophage scavenger receptor 1 (MSR1) and CD163, which have previously 
been shown to be involved in the pathogenesis of atherosclerosis [180-182].   
 
Interestingly, monocytes can also differentiate into cells with DC-like properties in the 
presence of serum from SLE patients, and could subsequently stimulate conventional CD4+ 
T cell proliferation [183]. The finding that this could be blocked by IFN-α neutralising antibody 
suggests that the ability of SLE serum to induce T cell expansion via DC differentiation is an 
IFN-α-dependent process. Moreover, the addition of IFN-α to autologous healthy serum was 
able to mimic the T cell expansion observed with SLE serum treatment [183]. The ability of 
monocytes from SLE patients to differentiate into DCs could therefore act as a mechanism 
to compensate for the lack of pDCs in SLE patients [183]. These monocyte-derived dendritic 
cells (MDDCs) in SLE patients are believed to play a pathogenic role by efficiently capturing 
apoptotic cells and nucleosomes and presenting them to T cells [184].  
 
1.2.5 Macrophages in SLE and atherosclerosis 
 
Monocytes circulate in the blood and only become macrophages upon infiltration into the 
tissues and activation. They participate in both innate and adaptive immune cells as APCs, 
and play other roles such as the clearance of apoptotic cells and reverse cholesterol 
transport. It has been proposed that defective clearance of apoptotic bodies by 
macrophages in SLE may contribute to the development of atherosclerosis by providing a 
source for autoantigen production and inducing local inflammation through natural 
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degradation and enzyme release [185]. Macrophages can be categorised according to their 
in vitro and in vivo functions, as either proinflammatory, M1 cells or anti-inflammatory, M2 
cells [186]. Importantly, polarisation towards M1 and M2 phenotypes is not dependent upon 
T cells, as has been demonstrated using recombination activating gene 1 (RAG1) knockout 
mice (which lack T cells) [187].   
 
M1 macrophages can be induced in vitro by IFN-γ and through TLR stimulation, in particular 
by lipopolysaccharide (LPS) [186]. Characterised by CD68 and CXCR2, they are 
proinflammatory in nature and express iNOS, TNFα, IL-1β, IL-6, IL-12 as well as proteolytic 
enzymes [186].  In contrast, M2 macrophages are induced by T helper 2 (Th2) cytokines 
such as IL-4 and IL-13, and are characterised by expression of CD163 and Mannose 
receptor I (CD206) [186]. They are considered anti-inflammatory as they are major 
producers of TGFβ, IL-1RA and IL-10. However, it is important to note that there are 
inconsistencies in the literature regarding the markers used for M1 and M2 macrophages, 
which must be considered when comparing different studies.     
 
Vulnerable plaques are generally characterised by M1 macrophage polarisation, however 
the role of M2 macrophages remains less clear [188]. One recent study observed that M1 
macrophages were found almost exclusively in plaques from symptomatic patients with 
unstable plaques, whereas M2 macrophages were found in plaques from both symptomatic 
and asymptomatic patients and were associated with increased plaque stability [189].  
Studies using mouse models of atherosclerosis suggest that there could be differences in 
M1 and M2 macrophage polarisation depending upon the stages of plaque development 
since M2 macrophages infiltrate atherosclerotic lesions during the early stages of disease 
in atherosclerosis-susceptible ApoE knockout mice, and convert to the M1 phenotype with 
plaque progression - a finding associated with a switch from IFN-γ to IL-4 production [190]. 
 
Moreover, evidence suggests that M1 and M2 macrophages may be confined to particular 
regions of the plaque. For example, M1 macrophages are abundant in rupture-prone areas, 
whilst M2 macrophages are found within the vascular adventitia, with no dominant 
phenotype within the fibrous cap [191]. It is therefore possible that macrophages from 
patients with unstable plaque could be more polarised towards the M1 phenotype, whilst 
those with stable plaque could exhibit more polarisation towards the M2 phenotype. M1 
macrophages have also been shown to contribute to SLE and are associated with increased 
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disease activity; conversely adoptive transfer of M2 macrophages was found to be protective 
in a mouse model of SLE [192]. This pathogenic role for M1 macrophages in SLE is also 
supported by Iwata et al. where increased M1 macrophage polarisation was observed in a 
mouse model of Lupus nephritis [193]. 
 
1.2.6 Dendritic cells in SLE and atherosclerosis 
 
Dendritic cells (DCs) are identified according to their major histocompatibility complex 
(MHC) class II molecules and integrin CD11c expression, as well as their ability to migrate 
to lymphoid organs and activate T cells. Classical dendritic cells (cDCs) reside within most 
tissues of the body including the skin, gastrointestinal and respiratory tracts. Upon uptake 
of self or foreign antigen, they migrate to lymph nodes to present antigen to T cells in the 
context of MHC. Under normal physiological conditions they exist in an inactivated state, 
only acquiring an activated surface phenotype such as the upregulation of costimulatory 
molecules following stimulation by TLRs. Activated cDCs secrete IFN-α, IL-12 and IL-23. 
 
In contrast, pDCs circulate in the blood and lymphoid organs where they form the first line 
of defense against viral infections through high expression of TLR7 and TLR9 within 
endosomal compartments[194].  Upon recognition of nucleic acids pDCs contribute to the 
inflammatory response through secretion of IFN-α [194], or alternatively can play a 
tolerogenic role through the induction of IL-10-secreting natural Tregs (nTregs) [195]. SLE 
patients have been shown to have lower numbers of HLA-DR+CD11c-CD123+ pDCs 
compared to both healthy controls and other autoimmune diseases such as juvenile 
diabetes mellitus [183]. 
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1.2.7 B lymphocytes in SLE and atherosclerosis 
 
B lymphocytes (along with T lymphocytes) are cells of the adaptive immune system, 
meaning that they orchestrate very specific responses to a particular antigen, often following 
activation by cells of the innate immune system (e.g. APCs), resulting in long term memory 
formation.  B cells may require T cell help for activation upon encountering antigens, which 
enables them to differentiate into antibody-producing effector plasma cells [196]. 
Alternatively, B cells can be activated in the absence of T cells through TLR signalling, for 
example upon recognizing microbial viral components, commonly through TLR4 and TLR9 
[197].  B cells are diverse in terms of the cytokines they produce following activation which 
include IL-4, IL-6, IL-10, IL-21, IL-23, TNF and lymphotoxin [196-198].    
 
Importantly B cells also function as APCs due to the expression of MHC class I and II which 
enables them to interact with the T cell receptor, necessary for the presentation of protein. 
B cells are thought to present lower doses of peptide antigen compared to dendritic cells or 
macrophages. To ensure optimal T cell activation, costimulatory molecules on B cells such 
as CD80, CD86 and OX40L must bind their co-receptors on T cells [199, 200]. B cells can 
be divided into various subsets based on expression of surface markers CD24 and CD38. 
The CD19+CD24hiCD38hi population are referred to as immature B cells, which include 
regulatory B cells (Bregs), characterized by high IL-10 production. The suppressive capacity 
of Bregs has been demonstrated both in vitro and in vivo, where they have been shown to 
inhibit Th17 responses [166, 167, 201]. Current evidence on whether they can support or 
enhance Treg function remains inconclusive.       
 
The role of B cells in autoimmunity extends beyond autoantibody production since B cells 
can exert positive and negative effects on immune balance [189, 194, 195]. Unlike T cell 
subsets, Bregs express no definitive transcription factor, and are instead functionally defined 
through their high IL-10 production following stimulation. These cells express a similar 
surface phenotype to immature B cells, and are characterized by CD19+CD24hiCD38hi 
expression. Interestingly, Bregs produce higher levels of IL-10 in untreated rheumatoid 
arthritis (RA), systemic sclerosis (SS) and SLE patients compared to healthy controls [202]. 
 
Autoreactive B cells have been identified in both SLE patients and mouse models of the 
disease, and are thought to play a key role in SLE pathogenesis [203]. Such B cells have a 
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lower threshold for activation, upon which they produce excessive amounts of 
autoantibodies leading to immune complex formation throughout the body [203].  Evidence 
shows that B cells from SLE patients have several molecular defects, which contribute to B 
cell autoreactivity. These include the Fcγ receptors, the B cell receptor (BCR), TLR and Lyn 
signalling [203].  Such cellular and molecular abnormalities make B cells attractive 
therapeutic targets for SLE with drugs such as belimumab and rituximab currently in use 
[43, 50]. 
 
Whilst B cells have been identified within atherosclerotic plaque, their role in the 
development of atherosclerosis remains unclear. In addition to their function as APCs, 
interactions between B cells and Th2 cells are responsible for antibody class switching, 
mediated by the Th2 signature cytokine IL-4, which is present in preclinical atherosclerotic 
plaques [204]. This protective role for B cells is supported by Major et al. who demonstrated 
that adoptive transfer of B cells could attenuate atherosclerosis in LDLR-/- mice [205]. This 
was later supported by Doran et al. in B cell deficient ApoE-/- mice, which had reduced 
atherosclerosis compared to ApoE single knockouts [206]. In contrast, knockout of BAFFR 
(present on follicular and marginal zone B cells) in combination with ApoE reduced 
atherosclerosis, suggesting a pathogenic role for B cells in the disease [207]. This 
pathogenic role for B cells is supported by the finding that B cells in humans produce IgM 
antibodies against modified lipid antigens in the blood [208]. The discrepancy on the role of 
B cells in atherosclerosis could be due to differences in the stage of plaque development 
under investigation, or due to differences in B cell subsets whereby the B-1 subset, for 
example, has been shown to be atheroprotective [209].      
 
1.2.8 T lymphocytes in SLE and atherosclerosis 
 
T lymphocytes, and specifically CD4+ T helper cells are key players in the adaptive immune 
system due to their importance in regulating B cell humoral responses, as well as CD8+ 
cytotoxic T cell responses (Figure 1.5). Upon peptide recognition by MHC class II, naïve T 
cells become activated and differentiate into T effector cells with clonal expansion ensuring 
long lasting memory to that particular antigen. During this process CD4+ T cells differentiate 
into several distinct T helper lineage according to factors such as the particular antigen 
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encountered, the strength of the signal, the cytokine milieu and the presence of co-
stimulatory molecules [66].  
 
Th1 cells are characterised by the signature cytokine IFN-γ, and the expression of 
transcription factor T-bet (TBX21). They can be induced in the presence of IL-12, which is 
associated with viral infections, during which they provide help to CD8+ cytotoxic T cells.  In 
contrast Th2 cells are characterised by IL-4 production, and expression of transcription 
factor GATA-3. Th2 cells are essential in providing help to B cells to induce a humoral 
immune response characterised by antibody class switching and plasma cell formation. 
 
More recently Th17 cells have been described, characterised by production of IL-17, and 
expression of transcription factor RORγt. Th17 cells are induced in the presence of TGFβ 
and IL-21, IL-6 and IL-23, or IL-1β and have been shown to play roles in the immune 
response to extracellular pathogens, as well as in autoimmune diseases  [65, 67, 210]. 
Whilst TGF-β and IL-21 induce naïve CD4+ T cells to become Th17 cells, recent evidence 
suggests that IL-23 is important for the inflammatory potential and survival of Th17 cells 
[163, 165, 210]. Despite the lack of surface markers on Th17 cells, it has been shown that 
human Th17 cells express high levels of CCR6, CD161 and CD49d [129, 149, 151, 164].  
 
The presence of T cells within atherosclerotic plaque was first reported 30 years ago by 
Hansson et al. where they can be detected from as early as the fatty streak stage [211, 212], 
reaching up to 10-20% of leukocytes in advanced human lesions [213]. The majority of T 
cells within atherosclerotic lesions are CD4+ T helper cells, and are primarily of the Th1 
lineage, although other subsets have been identified [214]. The importance of T cells to 
atherosclerosis is highlighted by animal models, where adoptive transfer of CD4+ T cells 
aggravates the disease [215].  Whilst atherosclerosis is classically considered as a Th1 
mediated disease, data for Th2 cell involvement is somewhat confusing due to the fact that 
both pro- and anti-atherogenic roles have been reported. 
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Figure 1.5 Conventional αβ T cell subsets in humans  
Conventional T cells express an αβ T cell receptor formed through V, D, J recombination, 
which results in a multitude of possibilities for TCR gene rearrangements. (1) CD4+ T cells 
(or T helper cells are reactive to peptide antigen presented via MHC class II on APCs. 
Activation of naïve T cells results in the acquisition of various transcription factors, which 
drives T helper cells towards a particular subset and dictates their cytokine profile. This 
enables them to communicate with other cells of the immune system to elicit the appropriate 
response to the particular antigen. (2) CD8+ T cells or cytotoxic lymphocytes are reactive to 
peptide antigen presented via MHC class I, which is present on every cell in the body. Upon 
recognition of foreign antigen, CD8+ T cells exert multiple killing mechanisms including 
secretion of perforin and Granzyme B as well as the induction of apoptosis through FAS-
FASL signalling. 
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The role of regulatory T cells (Tregs) in homeostasis and the prevention of autoimmune 
responses has been well described [210, 216, 217] and are generally characterised as 
CD4+CD25+CD127- T cells. Importantly, CD25 (IL-2-α receptor subunit) plays a role in 
sequestering IL-2 and preventing clonal expansion of other potentially autoreactive T cells 
[218, 219]. The transcription factor Forkhead box protein 3 (Foxp3), which is often used to 
identify Tregs, is a critical factor for Treg development and function, although this has since 
been challenged [220, 221]. Tregs can be subdivided into natural (nTregs) and induced 
Tregs (iTregs). However, since both subtypes are phenotypically and functionally similar in 
the periphery, it is unclear what percentage of each contributes to the total Treg pool. 
Differentiation of other T cell subsets into iTregs can be recreated ex vivo in response to 
TGF-β signalling which induces Foxp3 expression [222, 223]. In addition IL-2 and all-trans 
retinoic acid may act to enhance iTreg development and function [224-226]. Interestingly, 
iTregs have been reported to be more stable than nTregs in inflammatory conditions, which 
may make them a better therapeutic target for treating cancer or autoimmune diseases.  
 
Tregs are viewed as protective in atherosclerosis and have been identified within 
atherosclerotic plaques in both humans and mice; albeit in low numbers [227, 228]. 
However, it is thought that the balance between Tregs and other T helper cell subsets may 
be more important in determining plaque progression. This is evident from a study by 
Mengya et al. which showed that the balance between Treg and Th17 function may play a 
role in the development of atherosclerosis in SLE patients [79]. Moreover, SLE patients with 
plaque had fewer Foxp3+ T cells, with reduced suppressive capacity, as well as an increase 
in expression of the Th17 transcription factor RORγt, compared to plaque negative patients 
and healthy controls [79]. This was further associated with increased serum IL-6; a cytokine 
known for its Th17-inducing properties [79].   
 
Presentation of peptides via MHC class I on APCs results in CD8+ T cell activation, clonal 
expansion and initiation of cytotoxic T lymphocyte (CTL)-mediated killing, directed towards 
cells expressing the particular peptide antigen [135]. Two pathways are involved in the killing 
of target cells by CTLs; these are the release of the cytolytic enzymes perforin and granzyme 
B, and the induction of the Fas signalling pathway, which culminates in the apoptosis of 
target cells [135]. Interestingly patients with SLE, multiple sclerosis (MS) and Sjogren’s 
syndrome have increased perforin and granzyme B expression [135-137]. In SLE this was 
associated with a CCR7-CD45RA+ differentiated effector phenotype, and increased disease 
activity [136].  Furthermore, SLE patients have been reported to have increased membrane 
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TNFα on CTLs, which is believed to be important in increased apoptosis and the generation 
of autoantibodies [138]. Similarly CD8+ T cells play a pathogenic role in atherosclerosis; as 
the dominant lymphocyte type in advanced plaques they are known to target vascular 
endothelial and smooth muscle cells for apoptosis, and play a role in the development of the 
necrotic core in advanced lesions [229, 230]. 
 
Several unconventional T cell populations exist in the immune system, which possess a 
specialised T cell receptor in contrast to the diverse αβ TCR present on conventional T cells 
(Figure 1.6). Among those with a limited repertoire diversity are γδ T cells [130], Natural 
Killer T cells [133], and mucosal associated invariant T (MAIT) cells [134]. All these 
populations are considered highly conserved and tissue specific, and play a role at the 
interface between innate and adaptive immunity. Interestingly, NKT cell levels percentages 
found to correlate with MAIT cell percentages in SLE patients but not RA patients, indicating 
a general defect in innate T cell lymphocytes in SLE [132]. 
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Figure 1.6 Unconventional T cells in humans  
Unconventional T cells include iNKT cells, MAIT cells and γδ T cells. (1) iNKT cells are 
responsive to lipid antigen presented via CD1d and (2) MAIT cells are responsive to a 
riboflavin derivative presented via MR1 , whilst (3) γδ T cells respond to an unknown ligand. 
All unconventional T cell types are innate-like meaning that they respond rapidly to antigen, 
yet have poor memory unlike conventional T cell subsets. 
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Essentially, many of these unconventional T cell lineages are thought to be important in 
immunoregulation where they are capable of mediating a balance between activation and 
tolerance in the same individual. It is therefore unsurprising that these cell types are often 
deficient in autoimmune diseases. MAIT cells, which are important in mucosal immunity, 
have been shown to be numerically and functionally deficient in SLE patients, whereby they 
produce less IFN-γ upon stimulation compared to healthy controls [132]. Similarly, a 
particular subset of Vδ1 T cells, expressing CD25, CD27 and Foxp3 has been shown to be 
substantially decreased in SLE patients [131].  
 
SLE patients also have numerical and functional deficiencies in Natural Killer T (NKT) cells, 
which specifically recognize and respond to lipid antigens [231-233]. This seemingly 
protective or tolerogenic role for NKT cells in autoimmunity is in contrast to their pathogenic 
role reported in animal models of atherosclerosis [234]. Hence a dichotomy exists on their 
role in humans, in particular for SLE patients who go on to develop atherosclerosis. The role 
of iNKT cells and how they are defective in SLE patients with atherosclerosis will be explored 
in more detail in the following sections.  
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1.3 Invariant natural killer T cells and their role in SLE and 
atherosclerosis 
 
1.3.1 iNKT cells: overview 
 
Natural killer T cells are a small population of specialized immune cells, which straddle the 
gap between innate and adaptive immunity due to their ability to undergo rapid activation 
without the requirement for co-stimulation. They were first identified in mice in 1987 by three 
independent research groups, but it was not until 1995 that the term “NKT cell” was coined 
[235-238]. Although they constitute less than 1% of peripheral blood mononuclear cells 
(PBMCs), NKT cells have an important role in immune homeostasis and diseases such as 
cancer, bacterial, viral and fungal infection.  Unusually however, they are restricted in terms 
of antigen recognition by CD1d, a major histocompatibility complex (MHC) class I-like 
molecule. Indeed, the initial observation that they were seemingly activated through CD1d 
alone lead many to believe that NKT cells were autoreactive [239]. 
 
Similar to conventional T cells NKT cells express an αβ TCR, yet instead of responding to 
peptide antigen in the context of MHC class I or II, NKT cells have evolved to exclusively 
recognize and respond to lipid antigens in the context of CD1d [240]. Two types of NKT cells 
exist in humans, categorised based on their αβ TCR expression. Type I or iNKT cells, are 
the predominant class in humans and express an invariant T cell receptor (iTCR) formed of 
an alpha chain comprised of Vα24 and Jα18 and a beta chain comprised of Vβ11 [241], 
which is homologous to the semi-invariant TCR in mice formed of Vα14, Jα18 and 
Vβ8.2/Vβ7/Vβ2 chains [234]. In contrast, type II NKT cells express diverse αβ TCRs yet 
relatively little is known about them due to their lack of distinct surface markers or functional 
characteristics. As a result, far fewer studies have looked at the role of type II NKT cells in 
disease, particularly in humans [240]. Here, the focus of this project is the type I or iNKT 
cells and their role in SLE and atherosclerosis.  
 
In terms of gene expression, iNKT cells are a complete hybrid between NK cells and T cells 
and are no closer to either lineage in terms of transcriptional profile [242]. This enables them 
to orchestrate a multitude of innate and adaptive immune responses, with the specificity of 
T cells and rapid nature of NK cells.  Existing in a “poised effector state”, they rapidly 
downregulate their iTCR expression upon activation, whilst secreting copious amounts of 
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both pro- and anti-inflammatory cytokines [243]. Indeed, iNKT cells have a strong 
immunomodulatory potential; they are capable of influencing both activation and tolerance 
in different health and disease states. Despite their potency however, very little is known 
about the mechanisms which regulate their different effector responses, particularly in 
autoimmune diseases where iNKT cells are known to be defective.  
 
1.3.2 iNKT cell development 
 
 
Innate-like T cells are defined by expression of the transcription factor promyelocytic 
leukaemia zinc finger (PLZF), which is evolutionarily conserved amongst Vγ1-Vδ6.3 T cells, 
MAIT cells and iNKT cells and involved in iNKT cell development [244] (Figure 1.7). iNKT 
cells are first selected for in the thymus, specifically in the presence of CD4+CD8+ 
thymocytes (rather than thymic epithelial cells), which present glycolipid antigens in the 
context of CD1d to NKT precursors [245]. These double positive thymocytes also deliver 
crucial signals for iNKT cell development through expression of signaling lymphocyte 
activation molecule (SLAM) and the glycoprotein Ly108 [246]. This thymic education is 
extremely important in promoting self-tolerance, whilst preventing autoimmunity and may 
therefore be important in determining the balance between the tolerogenic and pathogenic 
functions of iNKT cells in diseases such as SLE and atherosclerosis. 
 
Following selection, iNKT cell thymocytes undergo elevated TCR signalling through 
Ras/MAP kinase and the calcineurin/NFAT pathways, resulting in elevated early growth 
response protein (Egr)1 and Egr2 expression compared to conventional T cells. This is 
known as stage 0 or the CD69+CD24high transitional stage, where iNKT cell development 
branches off from that of conventional T cells [247-249]. During this stage Egr2 is expressed 
by 100% of NKT thymocytes and promotes cell survival through Bcl2 and FasL induction. 
Egr2 binds to a site proximinal to PLZF, thus inducing its expression which is required for 
the acquisition of effector properties [244, 249]. In the absence of PLZF however, iNKT cells 
revert to naïve-like cells and produce IL-2, rather than IL-4 or IFN-γ [244]. The importance 
of PLZF to iNKT cell function has further been demonstrated by expression in transgenic 
mice under the CD4 promoter. PLZF was found to induce an iNKT cell-like phenotype, where 
CD44 and LFA-1 expression were induced, CD62L was downregulated and cells were able 
to simultaneously produce both IL-4 and IFN-γ [250]. Despite its requirement in iNKT cell 
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development, iNKT cells lacking PLZF have recently been described, indicating that PLZF 
expression may not necessarily be a defining feature of all iNKT cells [251].   
 
iNKT cell development has mainly been studied in mice, where it is divided into stages or 
checkpoints based on CD24 and CD44 expression. For example, thymocytes deficient in 
the transcription factor PLZF are blocked at stage 1 (CD44lowNK1.1+) and show properties 
of naïve T cells such as ineffective expansion and preferential localization to lymph nodes 
[252-254].  At stage 2 CD44hi NK1.1- cells migrate from the thymus, and preferentially 
localize to the liver, spleen and bone marrow [252]. Constitutive expression of activation 
markers CD69 and CD44 is a distinct feature of naïve iNKT cells compared to naïve T cells 
[255]. These markers are normally found on mature T cells which have previously been 
exposed to antigen, suggesting that iNKT cells may already be specific for certain lipid 
antigens upon leaving the thymus. Other factors regulating iNKT cell “responsiveness from 
birth” include the tyrosine kinase Fyn, NF-κB transcription factors and IL-15, which in 
conventional T cells are more important for secondary immune responses [256].   
 
Importantly, distinct signaling pathways are required for the development of mature iNKT 
cells. For example, iNKT cells fail to mature in the absence of phosphoinositide dependent 
protein kinase-1 (PDK-1), mechanistic/mammalian target of rapamycin (mTOR), myc and 
Fyn signalling, despite normal development of conventional αβ T cells [257-262]. Recent 
studies have also suggested that iNKT cell development is under the control of miR181a 
[263]. The high proliferative capacity of iNKT cells during early thymic development is 
thought to be linked to activation of mTOR and myc, which are key regulators of T cell 
proliferation and metabolism [262]. In addition, these signaling molecules have also been 
proposed to play a role in nuclear translocation of PLZF during iNKT cell development [264]. 
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Figure 1.7 iNKT cell development  
A. Following acquisition of CD24 during stage 0, the iNKT cell lineage diverges from 
that of conventional T cells, where presentation of self-lipids in the thymus (stage 1) 
initiates several unique signaling events resulting in the induction of PLZF 
expression. Further signaling events in the periphery (stage 2-3) result in 
upregulation of CD69 and NK cell receptors upon recognition of CD1d and lipid 
antigen.  
B. Linear model of iNKT cell development based on Chandra and Kronenberg [265]. 
Stage 1 occurs in the thymus where a decrease in CD24 expression upon self-lipid 
recognition is followed by the induction of PLZF and an increase in CD44 expression. 
Stage 2 thymic emigrants subsequently upregulate NK1.1 (in mice) upon recognition 
of CD1d-lipid antigen complexes, resulting in stage 3 quiescent iNKT cells.   
 
 
iNKTcell
Stage 1 (Thymus)
CD4+CD8+
SLAM+
Ly108+
Ras/MAPK
Calcineu rin/NFAT
Egr1/2
PLZF
CD1d
iTCR
Thymocyte
Stage 2 (Liver, spleen & bone marrow)
iTCR
CD44+
CD69+
 PLZF+
iNKTcell
Dendritic
cell
CD1d
PDK1
c-myc Fyn
mTOR
A. iNKTcell selection
B. iNKTcell development
DP Stage 0 Stage 1 Stage 2 Stage 3
CD24hi CD24lo CD24lo CD24lo
CD44loCD44lo CD44hi CD44hi
NK1.1-NK1.1- NK1.1- NK1.1+
PLZF
60 
 
Under normal conditions iNKT cell responsiveness is regulated to prevent autoimmunity. For 
example, iNKT cells have been shown to upregulate the inhibitor SHP-1 and reduce iTCR 
responsiveness upon encountering DCs [266]. This functional education ensures that iNKT 
cell reactivity is fine-tuned towards stronger stimulatory signals normally seen during 
inflammation. The importance of PLZF expression in iNKT cells is highlighted by the finding 
that CD8+ iNKT cells expressing PLZF are reduced in patients with autoimmune disease, 
suggesting that a defect in PLZF may be responsible for improper iNKT cell development in 
these patients [267].  
 
1.3.3 CD1d-dependent iNKT cell activation  
 
The most widely accepted mechanism of iNKT cell activation is through CD1d-mediated lipid 
antigen presentation, although other mechanisms have been published including cytokines 
alone and activation of natural killer receptors which will be discussed in later sections.  
CD1d is a member of the CD1 family of glycoproteins of which five isotypes exist in humans 
(CD1a-e); all of which involved in the presentation of lipid antigens [268]. They are 
expressed by a range of immune cells including monocytes, macrophages, B cells, dendritic 
cells (DCs) and thymocytes (but not mature T cells) [269], as well as cells outside of the 
hematopoietic system e.g. epithelial and vascular smooth muscle cells [270]. The CD1 
molecule is structurally homologous to major histocompatibility complex (MHC) class I 
molecules due to their antigen-binding groove being defined by two α helices on an 
antiparallel β sheet (Figure 1.8). CD1a-d are involved in the presentation of lipid antigens to 
T cells at the cell membrane, whilst CD1e functions intracellularly to regulate glycolipid 
processing and loading of other CD1 isotypes [268]. CD1a-d can further be divided into 
group I (CD1a-c) and group II (CD1d) and characterized by differences in the size of the 
binding groove and the species which express each isoform (Table 1.3). 
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Figure 1.8 Interaction between CD1d and iTCR in humans 
The way lipids interact with the CD1d binding groove and the iTCR, compared to how 
peptides are presented to a typical T cell receptor (LC13) via MHC class I.  (a) iNKT TCR– 
α-GalCer – CD1d complex. (b) TCR-peptide-MHC class I complex. (c) Parallel docking 
mode of iNKT iTCR CDR loops onto human CD1d–α-GalCer. (d) Diagonal docking mode of 
a typical TCR interaction with pMHC-I. (e) Footprint of the iNKT cell iTCR on the surface of 
human CD1d–α-GalCer. (f) Footprint of LC13 on the surface of HLA-B8-FLR. Figure 
obtained from Borg et al. Nature 2007 [271]. 
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Table 1.3 CD1 expression shows cross-species variation, with each isoform displaying 
differences in groove size and as a result, lipid-binding specificity [268]. 
 
  
CD1 family  Species expressed in Binding groove size 
CD1a humans Small 
CD1b humans Large 
CD1c humans Intermediate 
CD1d humans, mice, rats Intermediate 
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CD1d is the most extensively studied of the CD1 molecules and in particular is highly 
expressed by CD11c+ DCs and marginal zone B cells. It is the only CD1 isoform present in 
mice and rats, and as a result the mechanisms involved in the processing and presentation 
of lipids via CD1d are extremely well characterised compared to the other isoforms. Early 
research showed that CD1d contained 2 deep hydrophobic pockets [272], suggesting that it 
may be involved in lipid antigen presentation. This was later confirmed in 1997 when the 
iNKT cell ligand α-galacytosylceramide (α-GalCer) was isolated from marine sponge [273]; 
the potency of which has rendered it an invaluable tool in studying the uptake of lipid 
antigens and presentation via CD1d [274].  
 
The capture and internalization of lipid antigens by APCs occurs through a number of 
different mechanisms including the uptake of exogenous lipids by scavenger receptors 
which is described in Section 1.2.3 [275]. This is necessary for CD1d-mediated antigen 
presentation, with αGalCer uptake mainly being controlled by SR- A [276]. Due to their 
hydrophobic nature, lipids require the binding of proteins or lipoproteins for extracellular 
transport [276]. This may occur through the binding of ApoE to lipid complexes, and 
subsequent internalization via the LDLR [275]. Alternatively, B cells have been reported to 
internalize lipid antigens directly via the B cell receptor (BCR)[277]; a concept which may 
prove useful in the design of vaccines containing lipid-bound adjuvants [278].  
 
Lipid antigen processing and presentation is controlled by a number of chaperones, which 
prevent inappropriate binding of lipids to the CD1d molecule (Figure 1.9). During this 
process, CD1d undergoes internalization and vesicular trafficking to endosomal and 
lysosomal compartments, where CD1d exchanges its ligand with lipids which are either 
endogenous to the cell, or obtained from exogenous sources through endocytosis [279].  
CD1d then returns to the cell surface to present the lipid to the iTCR present on iNKT cells. 
Whilst the pathways involved in CD1d-mediated lipid antigen presentation have been well 
characterized, some of the mutant mouse models used develop associated lysosomal 
storage disorders, meaning that there are potential inaccuracies with the current theories 
[245].  
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Figure 1.9 CD1d recycling and lipid loading 
Assembly of CD1d takes place in the endoplasmic reticulum, where it forms a complex with 
β2m. Subsequently lipid ligands such as glycosylphosphatidylinositol are loaded onto CD1d, 
facilitated by microsomal triglyceride transfer protein. These complexes are trafficked to the 
cell surface through the Golgi network, before being internalized through the endosomes 
and lysosomes under the control of adaptor protein 2 (AP2) and AP3. Within the lysosomes, 
ER-derived lipids are exchanged for lysosomal lipid antigens, mediated by saposins and 
Niemann-pick type C2 protein (NCP2). CD1d then traffics back to the cell membrane, where 
presentation of lipid antigens to the invariant T cell receptor occurs [245]. 
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Lipid antigens presented via CD1 are known as lipid-linked antigens. This is because, with 
the exception of mycolic acid, the hydrophilic head groups interact with the binding pockets 
of CD1 and are presented. Mass spectrometry has identified a range of chemical moieties 
that fit the CD1d binding groove, which are mainly categorized as sphingolipids and 
glycerolipids with one, two or four aycl chains [268] (Figure 1.10).  
 
Most functional studies on iNKT cells have used the NKT cell agonist α-GalCer which differs 
from other activating lipids because it normally induces iNKT cell anergy following antigen 
presentation, whereas phenyl-containing analogues do not – even following repeated 
administration [280]. This suggests that the response to α-GalCer is very unique, and 
uncharacteristic of normal physiological antigens. α-GalCer induced iNKT cell anergy has 
been shown to occur through the egr2/3 pathway, which upregulates PD-1 and cbl-b in NKT 
cells [280]. α-GalCer can also induce other effects in vivo such as the expansion of myeloid 
derived suppressor cells (MDSCs) in mice, as well as upregulating the death receptors 
TRAIL and FASL and stimulating IL-33 secretion from Kupffer cells in the liver [280].    
 
The potency of α-GalCer makes it a suitable candidate for a vaccine adjuvant to enhance 
immunity to cancers [281] and infections such as malaria [282] and is most effective when 
delivered mucosally to DCs [283]. This is due to the ability of iNKT cells to bridge the gap 
between innate and adaptive immunity, resulting in maturation of DCs by upregulation of 
CD40, CD80 and CD86 and secretion of proinflammatory cytokines such as IL-12 and TNFα 
[284]. Subsequent presentation of peptide antigen such as irradiated sporozoites or tumour 
antigen results in the activation of CD4+ and CD8+ T cells, which are specific for either 
Plasmodium or the particular tumour [281, 282]. In the case of malaria the use of α-GalCer 
adjuvants (such as KRN7000) can enhance immunogenicity by 1000 fold compared to just 
an anti-malarial adjuvant alone, for example[285]. The challenge now is to optomise the 
structure of iNKT cell ligands to generate a potent Th1-biasing  cytokine response in the 
case of cancer and infections [283], whereas Th2-biasing ligands could prove more suitable 
for treating autoimmune diseases.  
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Figure 1.10 The chemical structure of α-GalCer and similar derivative 
analogues.   
These molecules are glycosphingolipids characterised by a galactose carbohydrate linked to 
a ceramide lipid with variable length acyl and sphingosine chains.  Figure from Van Kaer et 
al, Nature Immunology Reviews [274]. 
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1.3.4 CD1d-independent iNKT cell activation  
 
In addition to CD1d-iTCR interactions, iNKT cells can be activated indirectly through 
cytokines such as IL-12 which may be produced following TLR stimulation on APCs [286]. 
For example, Tyznik et al. showed that APCs unable to produce IL-12 fail to induce iNKT 
cell activation suggesting that in certain situations CD1d-iTCR interactions might only play 
a minor role [287]. Furthermore, activation of iNKT cells by IL-12 appears to be more 
effective in combination with small amounts of either IL-18 or type I IFN, and results in the 
secretion of mainly IFN-γ [288]. 
 
Whilst CD1d-iTCR interaction is still generally required for activation, it is thought that iNKT 
cells may be activated through cytokines alone if they’ve experienced previous iTCR 
engagement. This is due to the finding that infections with microbes lacking foreign lipid 
antigens such as S. Typhimurium were unable to induce expression of a reporter gene 
associated with iTCR-mediated activation [289]. Moreover, transfer of iNKT cells to a CD1d-
deficient mouse or deletion of the iTCR α chain of iNKT cells has shown that “former” iNKT 
cells are still able to respond to inflammatory stimuli in the absence of CD1d-mediated lipid 
antigen presentation [289, 290]. iNKT cell activation through cytokines alone couold 
therefore represent an innate-like mechanism to reactivate iNKT cells during times of 
infection.      
 
Activation of iNKT cells can also occur through the NK receptors CD161 and NKG2D; even 
in the absence of CD1d [291, 292]. CD161 recognizes lectin-like transcript 1 (LLT1), a 
marker present on activated leukocytes and DCs [222], whilst NKG2D recognizes ligands 
associated with MHC class-I, which are altered due to cellular stress [292].  Interestingly, 
iNKT cell activation via NKG2D has been shown to induce perforin and granzyme-mediated 
cytolytic effector functions, as well as functioning as a costimulatory molecule to enhance 
signaling downstream of the iTCR [293]. 
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Figure 1.11 Different mechanisms of iNKT cell activation 
iNKT cells can be activated either through presentation of endogenous or exogenous lipid 
antigens via CD1d, as well as through IL-12. Endogenous lipid presentation is the 
presentation of self-lipids, which may be altered through changes in lipid metabolism during 
times of cellular stress, and is associated with IFN-γ secretion. Alternatively, exogenous 
antigen can be endocytosed and presented directly, leading to both IFN-γ and IL-4 secretion. 
Finally, stimulation of TLRs on antigen presenting cells can result in the production of IL-12, 
which induces IFN-γ secretion by iNKT cells. 
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1.3.5 Exogenous lipid antigens 
 
One would assume by nature that the lack of diversity in the iTCR restricts the possibilities 
of lipid antigens capable of recognition. However, this could not be further from the truth as 
the iTCR has been reported to bind a vast array of chemically distant antigens [294]. These 
include α-GalCer itself as well as analogues with the potential to skew the immune response 
towards a Th1 or Th2 response [295, 296]. These synthetic analogues known as “altered 
glycolipid ligands” are formed through minor alterations in the head group, acyl chain or 
sphingosine chain [285, 297-299].   
 
The ability of iNKT cells to recognise different activating lipids can be seen through studying 
those of bacterial origin. Such foreign lipids can act in either a direct manner to induce iNKT 
cell activation, or through inducing the expression of endogenous iNKT cell ligands [300]. 
Microbes capable of directly activating iNKT cells include the Sphingomonadaceae family of 
Gram-negative bacteria, which express GSL-1 on their outer membrane [301].  GSL-1 is 
comprised of a mono- or oligo-saccharide bound to a ceramide lipid, with an α linkage on 
the 1’ carbon, which strikingly resembles α-GalCer in structure [302]. However, GSL-1 is not 
as strong an antigen as α-GalCer due to the presence of a glucuronosyl head group in GSL-
1 instead of a galactosyl head group, which alters its affinity for CD1d [303]. Another 
bacterium, Bacteroides fragilis produces a GSL named α-GalCerBF or GSLBf-717, which 
resembles α-GalCer apart from minor differences in their fatty acid and sphingosine bases, 
but unlike α-GalCer is thought to play an immunoregulatory role [304]. Recently, Aspergillus 
fumigatus was identified as the first fungal antigen for iNKT cells. Its antigen aperamide B 
was found to have a β-linked sugar (instead of α-linked), with modified acyl and sphingosine 
chains compared to α-GalCer, and has been implicated in promoting airway hypersensitivity 
[305]. 
 
Diacylglycerols (DAG), such as BbGL-II from Borrelia burgdorferi, have also been reported 
to activate iNKT cells [306]. There are several different forms of DAG with different affinities 
for CD1d, which is determined by the length and saturation of the acyl chain [307].  
Compared to GSLs, fewer hydrogen bonds with the F’ pocket of CD1d are required for DAG 
to bind, which enables more flexible arrangements [268]. This results in various orientations 
of the carbohydrate head groups, and therefore alternate levels of antigenicity [307].  
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Despite being largely uncharacterized, phosphotidylinositols have been shown to activate 
iNKT cells, but not through the conventional means of occupying both A’ and F’ pockets of 
CD1d due to the lack of a hexose sugar and two acyl groups.  For example, during 
Helicobacter pylori infection, the host cell synthesizes a cholesterol-galactoside antigen, 
which can activate both human and mouse iNKT cells [308].  The LPPG antigen from the 
protozoan Entamoeba histolytica can also activate iNKT cells, the antigen moiety consisting 
of a diacylated phosphoinositol [309]. However, it is unknown whether the LPPG antigen 
activates iNKT cells directly, or through TLR2 stimulation and the subsequent induction of 
self-antigen. 
 
1.3.6 Endogenous lipid antigen  
 
During iNKT cell development, iNKT cells become activated in the thymus in the absence of 
foreign antigen, suggesting that there are iNKT cell-specific self-antigens in humans. Self-
lipids also play a role during infection where they are produced due to external stimuli such 
as TLR activation. Although the identity of self-lipids is contentious, such iNKT cell antigens 
are thought to include isoglobotrihexosylceramide (iGb3), β-glucosylceramide (β-GlcCer) 
and β-galactosylceramide (β-GalCer).  
 
iGb3 was first identified as a self-antigen for iNKT cells in mice as mice lacking the enzyme 
β-hexosaminidase, responsible for the generation of iGb3, had significantly fewer iNKT cells 
compared to wild type mice [310]. iGb3 has also been shown to be produced during 
Salmonella typhimurium infection, where it is thought to act as a danger signal following 
TLR4 activation [300].  However, the role of iGb3 has since been questioned by several 
studies showing that the decrease in iNKT cell function in these mice was attributable to 
altered lysosome function, having consequential implications on CD1d trafficking [311, 312].  
Nevertheless, iGb3 itself is unlikely to be an important antigen in humans due to a single 
amino acid variation between human and mouse CD1d, which renders its binding ineffective 
in humans [313]. 
 
To identify other self-lipid antigens, Cox et al. eluted natural (endogenous) lipids from the 
CD1d molecule and observed lyso-phosphatidylcholine (LPC) to be antigenic for human cell 
lines [314, 315]. Importantly, LPC is produced by phospholipase A2 (PLA2) during 
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inflammatory conditions such as atherosclerosis, where it may play a role in altered iNKT 
cell responses [316]. Structural analysis of LPC-CD1d complexes provided insight into the 
particular amino acids required for antigen binding within the variable or CDR3β region, 
indicating that LPC may only serve as an antigen for a subset of iNKT cells [317].    
 
A more recently identified self-antigen is β-GlcCer, which is abundant in the thymus and 
peripheral lymphoid tissues and accumulates in response to danger signals [318].  There 
have been several recent breakthroughs involving other physiologically relevant iNKT cell 
agonists, but mainly from a therapeutic perspective. For example, β-GlcCer has been shown 
to induce anti-tumour immunity as well as enhancing the immune response to Hepatitis B, 
in an iNKT cell-dependent manner [319, 320]. However, CD1d-bound β-GlcCer has been 
reported not to stimulate iNKT cells directly, suggesting that this is due to presentation of its 
derivatives instead [321], which was since confirmed by Brennan et al [322]. Additionally, 
certain lipids such as the ganglioside GD3 have dose-dependent inhibitory effects on iNKT 
cells, through a CD1d-specific mechanism [323].  
 
Identification of such self-antigens has been extremely challenging due to differences in in 
lipid antigen uptake, intracellular transport, loading efficiency onto CD1d, stability of the 
CD1d-binding cleft, clustering of CD1d (e.g. in lipid rafts) and antigen half life [324]. Even 
once at the cell surface, individual CD1d-lipid complexes vary in the affinity for the iTCR; 
some may persist at the cell surface, whilst others rapidly decay, which can alter the 
dynamics of the iNKT cell response and lead to cytokine skewing [325]. However, since no 
physiologically relevant agonists as strong as α-GalCer have been identified in humans, 
further characterisation of iNKT cell antigens is necessary, particularly in disease states 
where altered self-antigens may be present. 
 
The innate ability of such endogenous antigens to activate iNKT cells also poses the 
question of how autoreactivity is prevented under normal physiological circumstances. As 
extremely abundant and heterogeneous components of cell membranes, certain 
phospholipids have also been shown to bind CD1d and activate iNKT cells. Those identified 
include phosphotidylethanolamine, phosphatidylinositol and phospholipase E (PLE) [326-
328]. However,  it appears that in healthy individuals the signalling induced by endogenous 
antigens is far too weak to trigger iNKT activation [294]. In the disease state however, 
alterations in the biosynthesis or degradation of intracellular lipids may augment iNKT cell 
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signalling resulting in activation, cytokine secretion and proliferation [326]. In addition to 
providing early danger signals during infection, disrupted lipid metabolism may also 
contribute to autoimmune diseases such as SLE through enhanced iNKT cell signalling 
[318]. 
 
1.3.7 Molecular basis for CD1d-iTCR interactions 
 
It is unsurprising that conventional T cells have a diverse TCR repertoire given the high rate 
of polymorphism in classical MHC molecules and the large diversity of possible peptide 
antigens capable of recognition. For this reason, iNKT cells were originally thought to have 
a single iTCR which lacked variability, enabling its interaction with non-polymorphic MHC-
like molecules such as CD1d. This clearly is not the case from the finding that several 
different iTCR clones exist in the peripheral blood of both mice and humans [329].  However, 
it has been extremely challenging to assess the roles of different iTCR clones due to their 
relatively small size [330]. 
 
Compared to humans, the iTCR β chain in mice appears more diverse since it includes  
include Vβ2, Vβ7 and Vβ8 compared to only Vβ11 in humans  [329]. However, sequencing 
of Vβ11 chains revealed extensive N-region diversity in multiple clones from a single donor 
demonstrating that these clones were derived from V-(D)-J recombination and subsequent 
positive selection, as with T cells [331].  Moreover, Van Schaik et al. found 16 clones to be 
expanded in healthy donors, indicating that these iTCR clones play an important role in 
normal physiological conditions [332].  
 
In vivo expansion of iNKT cell clones is thought to occur through two different mechanisms: 
homeostatic iNKT cell expansion and antigen-specific iNKT cell expansion [330]. The former 
occurs in response to cytokines or other inflammatory signals which drive general expansion 
of all T cells expressing stimulatory receptors other than TCRs (e.g. cytokine receptor) [332]. 
The latter occurs in response to a specific antigen, and results in clonal expansion of iNKT 
cells containing an iTCR specific for that particular antigen [332]. This is achieved through 
differences in the interactions between the Vβ chain, CD1d and the lipid in question [324].  
Crystal structures have revealed that the iTCR-α chain is predominantly responsible for the 
interaction with CD1d and lipid antigen (up to 65% of the buried surface area)[271], through 
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interactions mediated by the CDR1α and CDR3α loops. The iTCRVβ loop forms most of its 
contacts through the CDR2β loop, which solely binds the α1 helix of CD1d, and is dependent 
on the presence of two tyrosines and a glutamic acid [333]. Importantly, specific regions of 
the iTCR are required for binding of different CD1d-antigen complexes. For example, whilst 
the galactose moiety of αGalCer binds CDR1/3α, the inositol ring of phosphatidylinositol 
instead binds CDR1/2α but not CDR3α, and the trisaccharide head group of iGb3 interacts 
with all three CDRα loops [334].  
 
Previous binding affinity measurements have shown that different TCRVβ compositions can 
drastically affect the kinetics and affinity of CD1d-α-GalCer complexes [334]. This has further 
been explored in mutational studies which found that the CDR2β loop in mice and the 
CDR3β loop in humans can influence the binding avidity of CD1d tetramers and various lipid 
antigens [335-337]. Though this mechanism, gradual alterations to the iTCR during clonal 
expansion enable iNKT cells to alter their range of antigen recognition with increased iTCR 
affinity [324]. In support of this, iNKT cells with both naturally occurring or genetically 
modified high affinity iTCRs are able to recognise less potent self-lipids (e.g. iGb3 and 
phospholipids), in addition to more potent lipids such as α-GalCer [335]. 
 
Other molecular interactions influence the stability of the CD1d-lipid complex, which for Gb3 
occurs between the most distal galactose and the α2 helix of CD1d [338]. However, this is 
not the case for iGb3 and β-lactosylceramide (β-LacCer) which lack this residue rendering 
such interactions impossible [338]. As a result these lipids are much less potent, which 
supports previous research where substitution of the terminal sugar on iGb3 was able to 
influence antigenicity [339]. Furthermore, lipids with bulky head groups such as gangliosides 
are even able to block interactions between CD1d and the iTCR, possibly acting as a 
homeostatic mechanism, as demonstrated by Mallevaey et al. who observed that 
engineered high affinity iTCRs were only able to weakly bind CD1d tetramers loaded with 
gangliosides [335].  
 
Studies have shown that β-linked antigens adopt a perpendicular orientation with protruded 
head groups [340-342], yet it is unclear how iNKT cells cope with such drastic structural 
changes. One theory puts it down to remodelling of the CD1d-antigen landscape [338], in a 
similar way to the “induced fit” hypothesis in conventional T cells. For example, published 
structures suggest that the iGb3 trisaccharide head group is pushed away from the iTCR 
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and instead lies flat against the α2 helix of CD1d to enable tighter interactions between CD1d 
and the iTCR [343]; further maintained through polar forces and van der Waals interactions. 
Similar remodelling of the iTCR has also been shown to occur in response to other lipids 
including β-LacCer and β-GalCer [338]. 
 
Whilst it is possible to quantify the strength of interactions between the MHC and the 
conventional TCR, it is more of a challenge for interactions between CD1d and the iTCR. In 
the case of T cells, the rate of association and dissociation between the TCR and the MHC 
antigen complex can be measured through surface plasmon resonance [324]. Evidence 
suggests that the outcome of MHC-peptide interactions with T cells can be clearly defined 
[344]; with low-strength interactions generally promoting Th2 differentiation and IL-4 
secretion, and high strength interactions inducing a Th1 phenotype with IFN-γ. Similarly for 
iNKT cells, the study of Th2-inducing lipid antigens such as C:20 and OCH9 analogues have 
indicated that such antigens bind with lower affinity compared to α-GalCer, and have a 
higher rate of dissociation [334]. α-GalCer on the other hand, which predominantly induces 
IFN-γ secretion, binds with stronger affinity and leads to increased stability between CD1d 
and the iTCR [334, 345]. The ability to induce both IFN-γ and IL-4 secretion simultaneously 
could therefore be due to interactions of intermediate affinity, which are dictated by antigen 
structure.  
 
Whilst antigen affinity and dissociation rate may prove a valuable measure to characterise 
iNKT cell responses, in reality it becomes extremely difficult to measure long term 
interactions (over 2h), since iNKT cells downregulate their receptors following prolonged 
stimulation, meaning they can no longer be tracked [324]. Furthermore, iNKT cells are 
known to contain preformed cytokine messenger RNA (mRNA) [346], which raises the 
question on whether iNKT responses depend more on the nature of their previously 
transcribed DNA, rather than the effects following antigen recognition in the periphery. 
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1.3.8 iNKT cell activation and responsiveness 
 
When considering iNKT cell activation in response to lipid antigens, one should not only 
consider cytokine production by the individual cell, but the effect on the whole iNKT cell 
population and transactivation of other immune cell types.  Following activation via the iTCR, 
iNKT cells rapidly proliferate and secrete a vast range of cytokines and chemokines, 
mediated by the presence of preformed mRNA (Figure 1.6) [234]. The response which 
ensues, results in immune cell transactivation either through cytokine and chemokine 
production, or through contact-dependent mechanisms. Reciprocal signals provided by the 
iNKT cell can also increase CD40, CD80 and CD86 expression on the APC, and in the case 
of B cells, can provide stimuli for class switching, expansion and memory cell formation.  
 
The potential for iNKT cells in immunity is often underemphasized. Despite displaying 
phenotypic markers from the adaptive immune system, iNKT cells behave more like innate 
immune cells in terms of their proliferation and cytokine release upon contact with lipid 
antigens.  iNKT cells exhibit poor memory and secondary responsiveness due to the fact 
that they become anergic following activation, through downregulation of the iTCR [234]. 
The reason for this is unknown but in healthy individuals may represent a negative feedback 
mechanism to limit the extent of the inflammatory response. 
 
In humans, iNKT cells are either CD4 or CD8 positive whereas in mice most cells are CD4 
single positive, with a small population expressing CD8α alone.  Other surface markers 
expressed by iNKT cells include NK surface receptors such as CD161 in humans (NK1.1 in 
mice), as well as activated or memory T cell markers including CD44, CD69 and CD122 
[234]. However, not all iNKT cells express NK cell markers, so in addition to the iTCR, the 
characterization of these cells must also rely on their functional characteristics [231].  
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Figure 1.12 iNKT cell effector functions and transactivation of other immune 
cells 
iNKT cells can produce a range of pro- and anti-inflammatory cytokines and chemokines, as 
well as carrying out cytotoxic functions mediated by FASL and TRAIL expression or 
Granzyme and Perforin release. iNKT cell cytokine release results in transactivation of many 
different cell types.    
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Studies have also characterized iNKT cells based on their CD4 and CD8 positivity. However, 
there seems to be little consensus on the roles of these subsets in human health and 
disease; perhaps due to low iNKT cell frequencies in certain individuals. A study by Lee et 
al found CD4+ iNKT cells to have a Th2 cytokine response characterized by IL-4 and IL-13, 
whilst double negative and CD8+ iNKT cells were found to have a Th1 pro-inflammatory 
cytokine response following stimulation with α-GalCer in mice [347]. This is supported by 
Crowe and colleagues who discovered CD4+ iNKT cells to be tolerogenic,  and CD4- iNKT 
cells to have better inducers of anti-tumor responses in animal models of cancer [348]. A 
different study showed that CD4+ NKT cells are producers of both Th1 and Th2 cytokines 
and can induce FasL following ionomycin stimulation.   
 
In humans, Osada et al. found CD4+ iNKT cells in healthy individuals to be Th2-biased and 
characterized by IL-4, IL-10 and IL-13 secretion [349], whereas Takahashi et al. observed 
that CD8+ iNKT cells predominantly produced IFN-γ [350]. However, iNKT cells had been 
expanded using α-GalCer, meaning that data may not represent the ex vivo characteristics 
of these subsets in humans. 
 
1.3.9 iNKT cell subsets 
 
Functional iNKT cell subsets have been described including NKT1, NKT2, and NKT17, 
which mostly resemble CD4+ conventional Th1, Th2 and Th17 cells in terms of their 
transcription factor expression and cytokine production [351-354] (Figure 1.13). However, 
several differences have been observed. For example, whilst NKT1 cells express T-bet and 
produce IFN-γ, they are also capable of producing Th2 cytokines such as IL-4. NKT17 cells 
on the other hand express RORγt; a transcription factor which is not found in any of the 
other subsets.  Alternatively, NKT1, NKT2 and NKT17 cells can be distinguished based on 
the level of PLZF expression, whereby NKT2 cells express the most and NKT1 cells express 
the least. The high expression of PLZF on NKT2 cells is essential for Th2 function, since 
PLZF has been shown to induce c-Maf, whose expression is necessary for both IL-4 and IL-
10 production [355].   
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Similar to conventional T cells, iNKT cell subsets can also be characterized based on their 
surface marker expression. In mice NKT1 cells express NK1, yet NKT17 cells lack both 
NK1.1 and CD4 expression, and instead express CCR6 [351, 354]. iNKT cell subsets also 
vary in terms of their cytokine receptor expression whereby  NKT1 cells high levels of IL-
12R, whilst NKT2 cells express high IL-17Rβ, and NKT17 cells express high IL-23R. Most 
research has focused on NKT1 cells as they are the predominant subset in C57BL/6 mice 
[352], although other inbred strains have been described with a predominance for NKT2 or 
NKT17 cells.  
 
Other iNKT cell subsets include NKT10 cells which exert immunoregulatory functions and 
are present at a very low frequency [356].  This particular subset is characterized by 
expression of several T cell markers and IL-10 production following activation by α-GalCer, 
as well as expression of transcription factor Foxp3 [357]. Surprisingly, NKT10 cells were 
found not to downregulate their receptor following activation [357]. Interestingly, regulatory 
iNKT cells lack PLZF expression and instead express the transcription factor E4BP4, which 
is responsible for IL-10 production. NKTFH cells have also been described, which are similar 
to T follicular helper cells in that they provide help for B cells to undergo immunoglobulin 
class switching and clonal expansion [358]. 
 
Interestingly, different NKT cell subsets have been shown to localize to different tissues in 
the body. NKT1 cells preferentially localizing to the liver [352]. NKT2 have been shown to 
reside in the thymic medulla and the T cell zone of lymph nodes, where their high STAT6 
expression promotes IL-4 secretion, enabling them to condition neighbouring cells [359]. 
NKT17 cells reside in the lymph nodes, skin and lung [351].   
 
Different routes of antigen administration can also influence the iNKT cell pool in various 
locations of the body. For example intravenous injection of α-GalCer stimulates systemic 
IFN-γ and IL-4 secretion by NKT1 cells in the liver and spleen, whereas oral administration 
of α-GalCer induced only local secretion of IL-4 by NKT2 cells in the mesenteric lymph nodes 
[359].  
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Figure 1.13 Main functional subsets of iNKT cells 
The NKT1, NKT2 and NKT17 iNKT cell subsets are similar to Th1, Th2 and Th17 cells in 
terms of the cytokines that they produce. They can be defined based on their expression of 
transcription factors PLZF, T-bet and RORγt as well as differences in surface marker 
expression.  
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1.3.10 Determinants of iNKT cell responses 
 
The innate ability of iNKT cells to respond in a proinflammatory versus a tolerogenic manner 
is governed by a number of factors including the lipid antigen being presented, the APC 
involved, and the association between CD1d and lipid rafts. The importance of antigen 
structure in determining iNKT cell responses was demonstrated by Aspeslagh et al. using a 
synthetic α-GalCer analogue naphthylurea-α-GalCer (NU-α-GalCer) [298]. Whilst α-GalCer 
and NU-αGalCer were both shown to induce IFN-γ and IL-4 secretion, α-GalCer was found 
to stimulate greater amounts of IL-4, whereas NU-α-GalCer predominantly stimulated IFN-
γ secretion [360]. Such studies demonstrate that iNKT cell responses can be drastically 
altered by even minor variations in the structure of the lipid (such as the addition of a napthyl 
or urea group).  
 
It is thought that different cell types may determine the extent of iNKT cell cytokine 
production and transaction of other immune cells in vivo through [361]. These include 
differences in expression of CD1d between B cells, monocytes and dendritic cell subsets, 
which may each have different influences on the iNKT cell response which follows.  This is 
particularly evident in the case of α-GalCer, where use of a microparticle-formulated α-
GalCer-based cancer vaccine enabled the targeting to dendritic cells instead of B cells, 
preventing the anergy normally associated with iNKT cell responses [362].  Arora et al. have 
suggested that different dendritic cell subsets contribute to altered iNKT cell function, with a 
predominant role for the CD8α+ DEC205+ DC subset, which are capable of presenting 
multiple forms of α-GalCer to induce either a Th1 or Th2 response [361]. 
 
Furthermore, different B cell subsets have been shown to have an influence on iNKT cell 
function. CD1d is expressed on immature, naïve and mature B cells, as well as plasma cells.  
Blair et al. demonstrated that immature B cells defined by CD19+CD24hiCD38hi express 
higher levels of CD1d compared to naïve, mature and memory B cells [363]. In addition, 
immature B cell population were found to be more important than mature or memory B cells 
for both iNKT cell proliferation and cytokine secretion [233].  
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1.3.11 Lipid rafts and CD1d-mediated antigen presentation 
 
Lipid rafts are highly ordered areas of the plasma membrane, which play a role in regulating 
immune cell activation and function. Cholesterol constitutes approximately 25% of the 
plasma membrane of human cells, where it aggregates due to its rigid hydrophobic 
properties to form lipid raft microdomains [364]. Differences in the cholesterol composition 
of cell membranes determine the fluidity of cell membranes, with cholesterol acting to 
stabilise cell membranes and to reduce permeability of polar molecules [364]. Several 
methods have been widely used to characterise both the composition and properties of lipid 
rafts. Visualisation of lipid rafts relies on the use of molecular probes; commonly cholera 
toxin B subunit (CTB) binding to the glycosphingolipid GM1, which is particularly abundant 
in cell membranes [365]. Filipin, which is a fluorescent mixture of antibiotics, recognises 
membrane cholesterol [366].     
 
Previous work by Jury and colleagues has shown that lymphocytes from SLE patients have 
differences in lipid raft composition; namely increased levels of glycosphingolipids and 
cholesterol in the membrane of lymphocytes (Figure 1.14) [367]. These differences influence 
the position of key signaling molecules, such as lymphocyte-specific protein tyrosine kinase 
(Lck), linker for activation of T cells (LAT), Zeta-chain-associated protein kinase 70 (ZAP-
70) and CD45 in T cells, or Lck/Yes novel tyrosine kinase (Lyn) expression on B cells [368-
370]. Such signaling molecules are critical for regulating immune cell function, meaning their 
dysregulation in SLE increases cell susceptibility to prolonged activation and hyper-
responsiveness [365, 371, 372]. Evidence for a defect in lipid metabolism and cell signalling 
in SLE is strengthened by the finding that atorvastatin has the capacity to normalize Lck and 
CD45 distribution, as well as lipid raft-associated signaling in T cells from SLE patients [373].   
 
Lipid raft expression can be influenced by alterations in lipid biosynthesis, for example 
through LXR activation which acts to regulate the cholesterol content, and therefore stability 
of plasma membranes [374].  This can have functional consequences regarding immune 
cell activation, potentially influencing iNKT cell activation. This will be discussed in section 
1.3.12.  
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Figure 1.14 Role of lipid rafts in T cell activation in healthy donors and Lupus 
patients 
Changes in the membrane of lupus T-cells may associate with their autoimmune phenotype. 
The higher cholesterol and GM1 content of lupus T-cell membrane may result in larger 
and/or less mobile lipid rafts. This in combination with the increased association of CD45 
with lipid rafts, higher Lck activity, and changes in the actin cytoskeleton seen in these cells 
could reduce the threshold for activation. Figure from Karbourdis et al, 2008 [375]. 
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CD1d association with lipid rafts was first described by Lang et al. in 2004 [376], suggesting 
that lipid rafts may play an important role in the presentation of glycolipid antigens to iNKT 
cells. Moreover, disruption of lipid rafts ex vivo using the short chain ceramide C2-Cer was 
found to inhibit co-localisation between murine CD1d and the lipid raft surrogate marker GM-
1 [376]. This resulted in subsequent inhibition of IL-2 secretion following iNKT cell 
presentation, which was especially evident at low concentrations of α-GalCer (1000ng/ml) 
[376], thus suggesting an ability for lipid rafts on APCs to regulate iNKT cell responses. 
 
The importance of lipid rafts is epitomized by the finding that different analogues of the iNKT 
cell agonist α-GalCer can induce different levels of colocalisation between CD1d and lipid 
rafts. Using the monoclonal antibody L363, which recognizes CD1d-α-GalCer complexes, 
Im and colleagues demonstrated that α-GalCer C:20 induces strong colocalisation between 
CD1d-α-GalCer and lipid rafts, in contrast to α-GalCer C:10 where CD1d-α-GalCer was 
excluded from lipid rafts [377]. Moreover, treatment of DCs with MβCD, in addition to 
different α-GalCer agonists showed that cholesterol rich plasma membrane lipid rafts were 
required for the Th1 and Th2 iNKT cell cytokine response to αGalCer C:26, but were 
dispensable for the Th2-biased response to α-GalCer C:10 and α-GalCer C:20 [377]. This 
is supported by earlier work in mice showing that lipid raft colocalisation promoted Th1 
cytokine release, whilst lipid raft exclusion induced Th2 anti-inflammatory responses (Figure 
1.15) [296].        
 
Since iNKT cell responses are determined by downstream signaling, it seems logical that 
altered CD1d and lipid raft distribution results in differential downstream effects. Indeed, 
disruption of raft microdomains by β-Glycosphingolipids was associated with decreased 
STAT1 and STAT3 levels in iNKT cells, an effect which was shown to be CD1d-dependent 
[378].  However, it remains to be seen whether this is also the case in humans. 
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Figure 1.15 The role of lipid rafts in CD1d-mediated lipid presentation to iNKT 
cells 
Lipid rafts on APCs play a role in regulating iNKT cell activation and responsiveness. The 
incorporation of murine CD1d into lipid rafts has been shown to induce proinflammatory 
cytokine secretion, whilst lipid raft exclusion induces the secretion of anti-inflammatory 
cytokines.    
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1.3.12 Lipid biosynthesis and CD1d-mediated antigen presentation 
 
Little is known about the consequence of altered lipid metabolism on iNKT cell number and 
function. Through studying the lysosomal storage disorder Niemann-Pick type C2 disease, 
where patients are deficient in enzymes controlling GSL degradation, we are beginning to 
understand how lipid metabolism can influence presentation to lipid-reactive T cells. 
Schumann et al. demonstrated that iNKT cell development is impaired in mice deficient in 
the lysosomal lipid transfer protein NPC2 or the enzyme β-galactosidase [312]. Moreover, 
these NPC2 knockout mice displayed an altered TCR repertoire and CD4 distribution, which 
may be a consequence of differential CD1d-lipid antigen activation complexes [312]. 
However, a more recent study found no numerical or functional deficiencies in iNKT cells 
from Niemann-Pick disease patients, which they attributed to differences in iNKT cell 
development between mice and humans [379].  
 
LXR stimulation has been shown to influence the position of lipid rafts on T cells; a factor 
contributing to T cell dysfunction in SLE [380]. As previously described, lipid rafts are 
required for signalling in a range of immune cell types. Altered lipid raft composition is 
characteristic of SLE where increased levels of Gb3 and GM1 lead to hyper-responsiveness. 
Use of an LXR antagonist was found to restore GSL metabolism and T cell function in SLE 
patients, indicating a dysfunction in LXR signalling [380]. It is unknown however, whether 
altered LXR signalling occurs in other cell types in SLE, as well as the effect on CD1d-
mediated presentation to iNKT cells. 
 
PPARγ is another regulator of lipid biosynthesis, which could influence CD1d-mediated 
antigen presentation through multiple mechanisms and thus contribute to atherosclerosis in 
SLE patients. For example, PPARγ has been shown to regulate expression of the class B 
scavenger receptor CD36, which consequentially results in enhanced oxLDL uptake and 
foam cell formation [381]. In line with this, PPARγ stimulation is thought to increase 
intracellular recycling necessary for lipid presentation. This is evident in DCs where PPARγ 
regulates the expression of the lysosomal protease Cathepsin D, which is responsible for 
the production and maturation of saposins, and is also required for lipid antigen processing 
[382]. Furthermore, global gene analysis has indicated that PPARγ activation of DCs is 
associated with increased expression of the CD1 proteins, including CD1d, required for 
presentation to iNKT cells [383]. However, the effect appears to be indirect through 
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activation of the retinoic acid receptor (RAR), and it is unknown whether this mechanism 
also exists in B cells and monocytes.  
 
This association can also between PPARγ and CD1d can also be seen in patients with 
severe obesity, which have been shown to have defective expression of both PPARγ and 
CD1d expression on adipocytes [384]. Since adipocytes can present to iNKT cells, this was 
also associated with reduced iNKT cell numbers in adipose tissue [384]. It is unknown 
whether such mechanisms could influence iNKT cell frequency in atherosclerosis.    
 
Alternatively, PPARγ can regulate LXRα expression on macrophages, which upon activation 
induces ATP Binding Cassette A1 (ABCA1) expression to increase lipid export from the cell 
[385]. In a review by Mosser and Edwards, it is hypothesised that such differences may be 
attributable to macrophage plasticity, depending upon whether they are closer in phenotype 
to the classically activated M1 macrophage or the alternatively activated M2 macrophage 
[386], which play immunogenic and regulatory roles respectively. 
 
Other factors which play a role in the control of CD1d-mediated lipid presentation include 
Vitamin D, which has been implicated in iNKT cell development in mice due to the 
requirement of the vitamin D receptor (VDR) whereby knockout of VDR was found to 
significantly reduce iNKT cell numbers in mice [387]. Importantly, such iNKT cells were 
further found to be hypo-responsive suggesting that vitamin D is required for iNKT cell 
functional activity. This is supported by Waddell et al. who showed that Jα18-/- mice lacking 
iNKT cells were not protected against experimental autoimmune encephalomyelitis (EAE) 
upon treatment with vitamin D, to the same extent as their wild type counterparts, thus 
indicating that iNKT cells mediate the protective effects of vitamin D in EAE [304].   
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1.3.13 Co-stimulatory molecules and iNKT cells 
 
In addition to the signal provided by CD1d, costimulatory molecules are important for 
maintenance of the immune synapse for lipid presentation and iNKT cell activation to occur. 
Unlike conventional T cells, costimulatory molecules have been proposed to play less of a 
role in iNKT cells due to their lower threshold for activation [388]. In mice, interactions 
between CD28 and B7.1/B7.2 are important for intrathymic maturation as it induces the 
expression of activation markers CD44, CD69 and CD122 as well as transcription factor T-
bet to regulate IFN-γ production [389, 390]. However, it appears that unlike conventional T 
cells, CD28 is not critical to iNKT cell function since CD28 and B7 disruption in α-GalCer-
treated mice had no impact on intracellular cytokines produced by iNKT cells despite a 
reduction in serum cytokines overall [391]. Similarly, the coinhibitor (CTLA-4) is not thought 
to play a role in the iNKT cell proliferative response to α-GalCer [392], suggesting that iNKT 
cells become anergic and self-regulate themselves through an alternative mechanism.  
 
iNKT cells have been shown to constitutively express inducible costimulator (ICOS)[393], 
expression of which is further upregulated upon α-GalCer treatment, and unlike conventional 
T cells is independent of CD28 engagement [394]. ICOS is essential for iNKT cell survival 
in the periphery with a lack of ICOS signaling resulting in reduced iNKT cell numbers in the 
mouse spleen and liver [390, 393]. Inhibition of the ICOS-ICOSL signaling pathway results 
in decreased IFN-γ, IL-4, IL-5, IL-10 and IL-13 production, suggesting an important role for 
ICOS in the rapid cytokine production characteristic of iNKT cells [393, 394].  
 
Expression of CD40L on iNKT cells is induced mainly in CD4+ populations following 
presentation of glycolipid antigen by APCs [395]. CD40L is necessary for providing help to 
B cells to enable maturation and class switching of antibodies [396], as well as enabling 
crosstalk with DCs to stimulate IL-12 production [397]. IL-12 subsequently acts in a positive 
feedback manner to skew iNKT cells towards an NKT1 type response, characterized by IFN-
γ production.  This association between CD40L and the NKT1 response has been 
characterized using mouse models of autoimmunity, where treatment with a CD40 agonistic 
antibody induced a Th1 response in vivo and exacerbated EAE [398].  
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1.3.14 iNKT cell signalling 
 
There is evidence to suggest that the signaling mechanisms used by iNKT cells are different 
to conventional T cells. For example IL-17A and IL-22 production in αβ T cells depends upon 
transcription factor interferon regulatory factor (IRF)-4, yet IL-17A and IL-22 secretion by 
iNKT cells is normal in IRF4 deficient mice, indicating the presence of an alternative 
pathway, which is thought to rely on STAT3 [399]. 
 
iNKT cell responsiveness is mostly associated with signalling through mTOR, which is an 
important serine/threonine kinase pathway controlling cell growth proliferation and survival  
[400]. Deletion of the mTOR adaptor molecule Raptor in mature iNKT cells using Raptorf/f-
CreER mice treated with tamoxifen resulted in impaired iNKT cell expansion and decreased 
IFN-γ and IL-4 production following α-GalCer stimulation [264]. Interestingly, Raptor 
deficient mice have altered ratios of iNKT cell subsets where NKT1 cells are decreased, 
NKT2 cells are increased, and NKT17 iNKT cells remain the same [400]. On the other hand, 
mice deficient in the mTOR adaptor molecule Rictor show normal NKT1 cell frequencies, 
but decreased NKT2 cell frequencies [401], together indicating that mTOR signalling is 
important in the differential expression of iNKT cell transcription factors [400]. 
 
Other signalling pathways found to be involved in iNKT cell responses following stimulation 
include ERK, JNK and p38, which play differential roles following α-GalCer stimulation [402]. 
In particular, ERK was shown to play a positive role in iNKT cell signalling, whilst p38 was 
found to be a negative regulator. More recently, work on primary iNKT cells has confirmed 
this finding that mTOR, ERK and JNK play crucial roles in regulating cytokine production 
following activation [403], yet whether any of these pathways are more important remains to 
be seen. 
 
 
iNKT cell signalling can also be influenced by the expression of suppressor of cytokine 
signaling (SOCS) genes, which inhibit the activation of inflammatory genes. In addition to 
inducing IL-10 production by APCs, SOCS3 overexpression was found to reduce iNKT cell 
activation, evident through a reduction in CD69 expression and decreased IFN-γ and IL-4 
secretion [404].  
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1.3.15 iNKT cells and B cell-mediated responses 
 
 
iNKT cells participate in the regulation and maintenance of humoral (or antibody mediated) 
immune responses by B cells in a similar way to conventional T cells. This is evident from 
the finding that α-GalCer injection in mice was able to activate B cells in an IL-4-dependent 
manner and induce IgE secretion [405]. This was associated with acquisition of a Th2 
phenotype in conventional T cells.  Furthermore, iNKT cells have been shown to participate 
in models of allergy in mice such as ovalbumin (OVA)-induced asthma [406]. Here, iNKT 
cell deficient TCRJα18-/- mice showed impaired IL-4, IL-5 and IgE production in response to 
OVA immunization, whilst iNKT cells from wild type mice were found to be more activated 
due to increased CD69 expression [406]. 
 
The mechanisms by which iNKT cells provide help to B cells (e.g. to enable class switching 
or memory formation) occur through cognate and non-cognate interactions. It was initially 
thought that iNKT cells promoted B cell proliferation and immunoglobulin production in a 
CD1d-dependent manner, as demonstrated in vitro using anti-CD1d [407].  Furthermore, 
this effect on B cells was present even in the absence of α-GalCer, indicating that self-lipids 
could also be responsible for this phenomenon [407]. More recently, through studying B cell 
chimeras lacking CD1d in vitro, it is now clear that iNKT cells can provide help to B cells 
through in a non-cognate manner [396]. This is thought to occur through presentation by 
other APCs, and subsequent activation of T follicular helper cells by iNKT cells. The long 
term consequences are stronger interactions between B cells and conventional T cells to 
induce formation of B cell memory [408].  
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Figure 1.16 The role of B cells in iNKT cell expansion 
Upon lipid antigen presentation to iNKT cells, there is a reciprocal signal inducing various 
effector functions in the antigen presenting cell. In the case of B cells (shown), this includes 
differentiation into memory and plasma B cells and the release of antibodies. Based on figure 
by previous PhD student, Anneleen Bosma.  
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1.3.16 iNKT cells and immune regulation 
 
The fact that iNKT cells are more numerous in healthy individuals compared to in 
autoimmunity suggests that they play a role in immune regulation under normal homeostatic 
conditions [409]. This regulatory function of iNKT cells is evident in the autoimmune disease 
type I diabetes. Non-obese diabetic (NOD) mice, which spontaneously develop the disease, 
can be protected from type I diabetes by adoptive transfer of iNKT cells [410]. Furthermore, 
iNKT cells have been shown to impair differentiation of autoreactive anti-islet CD4+ and 
CD8+ T cells in mice, possibly through the recruitment of tolerogenic DCs [411, 412]. Instead, 
these T cells are rendered anergic, unable to destroy pancreatic cells.          
 
A recent study suggests that under normal circumstances iNKT cells play a regulatory role 
which prevents obesity and the development of the metabolic syndrome. Martin-Murphy et 
al. demonstrated that CD1d-/- mice (which lack NKT cells) are more susceptible to weight 
gain and fatty liver following consumption of a high fat diet [413]. This was further associated 
with the induction of inflammatory genes in the liver as well as a decreased metabolic rate 
[413].  
 
Several studies have shown that iNKT cells from peripheral blood can acquire Foxp3 
expression and an immunosuppressive phenotype upon exposure to TGFβ, IL-10 or the 
mTOR inhibitor rapomycin [414, 415]. However, it appears that Foxp3 expression alone is 
not required for the suppressive function induced by IL-10, as measured according to the 
proliferation of responder T cells [416].  Instead, rapamycin is responsible for the 
suppressive capacity of iNKT cells due to its involvement in the nuclear localization of Foxp3. 
The induction of Foxp3 expression upon culture with IL-10 and rapamycin is also associated 
with the acquisition of Treg markers CD25 and CTLA-4 [221, 416]. However, Helios 
expression was only observed only in iNKT cells cultured in the presence of rapamycin, 
indicating a role for mTOR inhibition in the acquisition of natural Treg properties.  
 
This could be particularly detrimental in cancer immunotherapy where mTOR inhibitors have 
been used [417, 418], since conversion of iNKT cells to suppressive nTreg-like cells could 
make them less effective at carrying out anti-tumour responses [419]. On the other hand, 
mTOR inhibition could be useful as a potential therapeutic for autoimmune diseases due to 
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the creation of a more suppressive environment characterized by decreased iNKT cell 
activation.      
 
Another regulatory function of iNKT cells involves the crosstalk to pDCs through secretion 
of IL-10 in the pancreatic lymph nodes [420] (Figure 1.17). This promotes TGFβ secretion 
by pDCs, which promotes the passage of naïve CD4+ T cells into Foxp3+ Tregs (Figure 1.9). 
This tolerogenic influence on dendritic cells is supported by the finding that treatment of 
NOD mice with α-GalCer can increase tolerogenic mDC accumulation in pancreatic lymph 
nodes, which is associated with an increase in iNKT cell numbers [185].   
 
iNKT cell crosstalk with Tregs has also been shown in murine models allogenic 
hematopoietic stem cell transplantation, where purified CD4+ iNKT can prevent graft versus 
host disease (GVHD) through expansion of donor CD25+Foxp3+ Tregs [421]. This is 
supported by Pillai et al. who found iNKT cell-mediated Treg expansion to be IL-4-dependent 
[422].  Moreover GVHD protection was lost in donors lacking Tregs or in  Jα18-/- recipient 
mice which are deficient in iNKT cells, suggesting a requirement for both iNKT cells and 
Tregs in protection from GVHD [422].  
 
However, following iNKT cell activation, IFN-γ has been shown to suppress iTreg 
development in vivo [423]. iTregs are generated in the periphery from naïve CD4+ 
precursors, which gain CD25 and Foxp3 expression upon activation through CD3 and CD28, 
and stimulation with TGF-β and IL-2 [424]. They are characterized by secretion of the 
immunosuppressive cytokines TGFβ and IL-10, as well as IFN-γ [425].  
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Figure 1.17 Indirect iNKT cell mediated iTreg induction via plasmacytoid 
dendritic cells 
IL-10 production by iNKT cells can induce TGFβ secretion by plasmacytoid DCs, which in turn 
induces differentiation of CD4+ T cells into inducible Tregs (iTregs), thus promoting a 
regulatory environment. 
 
 
  
 
94 
 
 
Furthermore, iNKT cells have been shown to interact with Tregs through the secretion of IL-
2 and IL-4, which induces Treg expansion, as well as regulating Treg homing to the liver 
[426]. Tregs can also act in a reciprocal manner to inhibit iNKT cell proliferation and cytokine 
production in vitro. This iNKT cell priming of Tregs was found to be dependent upon cell-cell 
contact and subsequent IL-10 secretion from Tregs, and did not require the presence of 
APCs [360, 427]. This was recently confirmed in a study by Huijts et al. where iNKT cells 
couldn’t exert their suppressive function when cultured in a transwell system with responder 
T cells [416]. It is unknown however which iNKT cell receptors are responsible for contact-
dependent suppression of responder T cells, although this is not thought to occur via CTLA-
4 or latency associated peptide (LAP) due to comparable expression on both suppressive 
and non-suppressive iNKT cells [416]. 
 
Activation by strong agonists such as α-GalCer and NU-α-GalCer appeared to limit the 
suppressive ability of Tregs, in comparison to weaker agonists such as bacterial DAGs and 
activation by IL-12 and IL-18 secretion [360]. There was no preference between CD4+ and 
CD4- subsets regarding inhibition of iNKT cell cytokine production, although IL-4 was more 
prone to inhibition compared to IFN-γ [360].   Tregs can also able to exert negative feedback 
indirectly towards iNKT cells through the production of TGFβ, which activates SMAD-2, -3, 
and -4 in APCs and has been shown to inhibit CD1d-mediated lipid antigen presentation 
[428].      
 
In type I diabetes for example, both in vivo and ex vivo data from diabetes susceptible NOD 
mice has shown that repetitive stimulation of iNKT cells by α-GalCer is protective against 
disease onset [304]. This effect is due to the induction of tolerance following repetitive (but 
not single) α-GalCer stimulation, whereby iNKT cells  induce tolerogenic dendritic cells 
capable of converting naïve T cells into Tregs [304]. This occurs through the upregulation of 
CXCR3 expression on Tregs, which enables their recruitment in the pancreas thus 
preventing type 1 diabetes onset. 
 
iNKT cells can also induce immune regulation through crosstalk with myeloid derived 
suppressor cells (MDSCs). This is demonstrated by Parekh et al. in the context of 
autoimmunity in the central nervous system, where the mouse model EAE was used. iNKT 
cell activation in EAE mice was associated with MDSC expansion and enrichment of 
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immunosuppressive markers including iNOS and Arg1 [429]. In contrast, other studies have 
shown that iNKT cells can suppress MDSC development during influenza [430], and that 
activated iNKT cells can reduce the immunosuppressive capacity of MDSCs in the tumor 
environment [431].  Such studies demonstrate that other factors in the local environment 
may be driving altered iNKT cells. 
 
Immunoregulation can also be induced by iNKT cells through communication with 
macrophages, which can have an influence of the balance between the pro-inflammatory 
M1 or classical macrophage and the anti-inflammatory M2 or alternatively activated 
macrophage. This has been demonstrated during Coxsackievirus B3 infection in mice where 
the iNKT cell response was associated with increased numbers of M2 macrophages [432]. 
However, the balance was shifted in favour of the M1 macrophage in NKT cell knockout 
mice, thus demonstrating a requirement for iNKT cells in M2 macrophage polarisation [432].  
 
Likewise, in the mouse model EAE iNKT cell deficient mice were found to have fewer M2 
macrophages and worse prognosis during early stages of the disease [433]. Similar results 
have also been observed in obesity, where M2 macrophage polarisation was shown to be 
IL-4 and STAT6 dependent [229].  
 
  
96 
 
1.4 iNKT cell number and function in SLE 
 
1.4.1 iNKT cells in autoimmunity  
 
Due to their dual role in immune activation and regulation, it is unsurprising that iNKT cells 
are dysfunctional in many autoimmune disorders.  Reduced iNKT cell frequency has been 
reported in SLE, psoriasis, RA and myasthenia gravis [434].  This is particularly striking in 
SLE, where various methods have been used to confirm this association. Quantification of 
Vα24Jα18 mRNA expression indicated reduced numbers of iNKT cells in both the peripheral 
blood and synovium of SLE patients compared to healthy controls [435]. Similarly, studies 
using flow cytometry found reduction in both the proportions and absolute numbers of type 
I and type II NKT cells, with CD161+ cells within the Vα24+CD4-CD8+ and Vα24+CD4-CD8- 
iNKT cell subpopulations being reduced in SLE patients compared to healthy controls [436-
438]. Importantly, this reduction in iNKT cells was not observed in relatives of SLE patients, 
highlighting that the iNKT cell deficiency observed was disease-associated and not genetic 
[439]. This relationship has further been shown to occur independently of treatment with 
immunosuppressive drugs in SLE patients [436, 440].  
 
In addition to the numerical deficiencies observed in SLE patients, iNKT cells are also 
functionally impaired, as demonstrated by poor iNKT cell responsiveness to α-GalCer [233, 
436]. The median proliferative index following α-GalCer stimulation was significantly lower 
in SLE patients compared to healthy controls, whilst impaired IL-4 and IFN-γ mRNA 
expression and cytokine secretion were also observed [436]. Furthermore, studies have 
shown that this poor functionality is not a consequence of a defect in CD1d-mediated antigen 
presentation, as similar levels of CD1d expression were observed in PBMCs from both SLE 
patients and healthy controls [436].  This result is supported by the lack of iNKT cell 
proliferation seen when APCs from healthy controls were cocultured with iNKT cells from 
SLE patients [436]. This functional impairment of iNKT cells is also seen in other 
autoimmune diseases [441].       
 
One original hypothesis for poor iNKT cell function in SLE patients comes from the finding 
that iNKT cells from SLE patients are more susceptible to apoptosis compared to those from 
healthy controls following 7-day incubation with α-GalCer [436]. This suggests that genetic 
defects regulating activation induced cell death in iNKT cells may contribute to SLE 
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pathogenesis. Interestingly, this lack of iNKT cell responsiveness can be reversed as shown 
in mouse models. Morshed et al. found that β-GalCer with a 12 carbon acyl chain can reduce 
iNKT cell cytokine secretion in C57BL/6 mice following iNKT cell stimulation with α-GalCer, 
in addition to diminishing iNKT cell numbers in the liver and spleen [442, 443]. Furthermore, 
oral or intraperitoneal β-GalCer treatment in mice was found to improve SLE disease activity 
as measured by proteinuria, IgG-anti-dsDNA and rate of survival [442]. Such findings 
suggest that this reduction in iNKT cells seen in SLE is more than just a defect in cell death, 
but one concerned with the recognition of lipid antigens, which play a role in the 
pathogenesis of the disease.  
 
1.4.2 iNKT cells and the pathogenesis of SLE 
 
Mouse models have been used to clarify the role of iNKT cells in SLE; typically through 
elimination of iNKT cells by knocking out genes for CD1d or the iTCR.  Mice deficient in 
iNKT cells are generally healthy, but have a predisposition to developing autoimmunity and 
cancer as well as certain infections [444]. Moreover, mouse strains with a genetic 
predisposition towards SLE (MRL/lpr and NZB/W F1) show similar defects in iNKT cell 
frequency and function compared to humans [445].  However, there is evidence that the 
disease and mechanisms involved may differ considerably according to the model of SLE 
and strain used. This is highlighted in the pristine-induced nephritis model, where α-GalCer 
injection induces a protective Th2 response in BALB/c mice, but a harmful Th1 response in 
SJL/J mice [446]. Similar differences can be found in CD1d-/- mice, where CD1d deletion 
results in more advanced skin lesions in MRL/lpr mice, which develop SLE-like disease due 
to a point mutation in Fas [447], whilst in NZB/WF1 mice CD1d deficiency was shown to 
accelerate nephritis [448].  Despite this, some useful advances to the field have come from 
the study of iNKT cells in mouse models of SLE.  
 
It was previously unknown whether the iNKT cell deficiency seen in SLE patients preceded 
the onset of the disease or whether it occurred as a consequence. However, data from 
lupus-susceptible NZB/WF1 mice indicates that iNKT hypo-responsiveness to α-GalCer is 
present at a young age, prior to any physical signs of autoimmunity [449]. The finding that 
mice also had lower transactivation of T and B cells and reduced cytokine secretion suggests 
that in SLE patients, defective iNKT cell responses may have systemic consequences, even 
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before any visible signs of disease [449]. This finding is supported by Zeng et al. who 
identified age as a factor in iNKT cell responsiveness using NZB/WF1 mice with a form of 
hereditary Lupus closely resembling human disease [450]. Moreover, treatment with α-
GalCer exacerbated disease symptoms and induced IFN-γ secretion in mice aged 8-12 
weeks but improved disease in mice aged 4 weeks [448, 450]. Interestingly, transfer of 
NK1.1+ T cells from the older to younger group worsened disease, implicating that iNKT cells 
play different roles in the immune response through age.   
 
1.4.3 Autoantibody production and iNKT cells 
 
Evidence also suggests iNKT cells may promote autoimmune-like disease in mice by 
inducing IgG autoantibody production by B cells [448], through a mechanism subsequently 
shown to be dependent upon CD1d and CD40 expression in vivo [451]. Wermeling and 
colleagues subsequently observed that specific knockout of iNKT cells (using Jα18-/- mice) 
resulted in autoantibody production by B cells following injection with apoptotic cells [452]. 
Similarly, Yang et al. demonstrated that the iNKT cell ligand α-GalCer could suppress 
autoantibody production both in vivo and in vitro in mice [453], suggesting that glycolipid 
presentation to iNKT cells may contribute to SLE by promoting autoantibody production. 
Moreover, this is in line with observations in SLE patients where a reduction in iNKT cell 
number has been shown to be associated with increases in plasma IgG and anti-dsDNA 
[439]. Overall, these studies highlight the regulatory role of iNKT cells, which enables them 
to protect against the inflammatory effects in SLE, when present in adequate numbers. 
Quantification of iNKT cell frequencies, as well as phenotyping to determine iNKT cell 
activity, could therefore provide an indication of SLE prognosis in terms of immune function. 
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1.4.4 Altered self-lipids in SLE patients 
 
It has previously been hypothesized that the lack of iNKT cells in autoimmune disease 
settings may be due to altered presentation of self-lipids in these patients. This theory has 
been proposed by Tan et al. and others; supported by the finding of an altered 
glycosphingolipid profile in immune cells from SLE patients [367]. Using liquid 
chromatography mass spectrometry, Tan et al. showed that Fasf/f Cd19Cre/+ mice, which have 
a B cell-specific Fas mutation, develop an altered B cell lipidome from birth [454]. They 
observed that Fas deficient B cells had increased expression of certain 
globotrihexosylceramides (Gb3 [d34:1], Gb3 [d42:2] and Gb3 [d42:1]) and 
phosphatidylglycerol PG [32:0], with a reduction in cholesterol sulfate compared to Fas 
sufficient B cells [454].  
 
Moreover, B cells from SLE patients may have altered expression of enzymes, which 
regulate the generation of self-lipids. α-galactosidase A is involved in the generation of self-
lipids in mice; expression of which has been shown to be reduced in B cells from Fasf/f 
Cd19Cre/+ mice, which are deficient in Fas [454]. Since both Fasf/f Cd19Cre/+ and α-
galactosidase A knockout mice have reduced numbers of iNKT cells [454, 455], it stands to 
reason that reduced α-galactosidase A expression may influence the self-lipids presented 
via CD1d to iNKT cells, resulting in strong iNKT cell activation and activation induced cell 
death, which is thought to occur in SLE patients. This is in support of work by Bosma et al. 
showing that defective CD1d-mediated lipid antigen presentation by B cells contributes to 
SLE pathogenesis [233].  This was attributed to increased CD1d recycling, which could have 
resulted in altered self-lipid presentation to iNKT cells [233].  
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1.5 iNKT cells in atherosclerosis 
 
1.5.1 iNKT cells and atherosclerosis in humans 
 
Unlike SLE where iNKT cells protect against the inflammatory response, in atherosclerosis 
iNKT cells are seen as pro-atherogenic. Whilst few detailed studies have been carried out 
on atherosclerosis in humans, the presence of CD1d expression within human 
atherosclerotic lesions indicates a role for iNKT cells in plaque progression [456]. Moreover, 
the finding that CD1d expression was restricted to foam cells and areas containing T 
lymphocytes and DCs suggested a role for CD1d-mediated lipid antigen presentation to 
iNKT cells in atherosclerosis [456, 457].  
 
Previous studies investigating atherosclerosis in humans have observed that iNKT cells 
within the plaque are abundant and comprise up to 3% of total infiltrating T cells, yet are 
scarce in the peripheral blood of patients who have had a cardiovascular event [219, 458]. 
It has been hypothesized that the reduction in iNKT cells within the peripheral blood is due 
to accumulation within the plaque sites, although it may also be as a consequence increased 
iNKT cell activation and downregulation of the iTCR following stimulation [458]. 
 
1.5.2 iNKT cells and animal models of atherosclerosis  
 
On the contrary, iNKT cell numbers are generally increased in mouse models of 
atherosclerosis. When apoE-/- mice, which are extremely susceptible to atherosclerosis, are 
crossed with CD1d-/- mice which lack iNKT cells, there is a significant reduction in the extent 
of atherosclerosis compared to apoE-/- controls [459-461]. Similarly, CD1d-/- mice fed an 
atherogenic diet developed smaller lesions compared to wild type mice fed the same diet 
[459]. Interestingly however, adoptive transfer of wild type iNKT cells to RAG1-/-LDLR-/- mice, 
where cells are unable to phagocytose oxLDL, resulted in the development of plaque, 
inferring that iNKT cells themselves are pro-atherogenic in nature – even in the absence of 
exogenous lipids [462]. This suggests that cytokines or endogenous lipid antigens may play 
a larger role in plaque progression than previously thought.   
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Jα18-/- mice, which specifically lack type I (and not type II) NKT cells, have been used to 
clarify the importance of iNKT cells in atherosclerosis. Targeted deletion of the Jα18 gene 
in LDLR-/- mice was found to decrease both the extent of atherosclerosis in the aortic root 
and arch, as well as IFN-γ levels in both male and female mice [463].  In Vα14 LDLR-/- 
transgenic mice, where iNKT cells are expanded, macrophage accumulation was found to 
occur in adipose tissue, which may promote iNKT cell activation through presentation of lipid 
antigens [464]. Vα14 transgenic mice also have increased hyperlipidemia, insulin resistance 
and aortic atherosclerosis indicating a positive correlation between iNKT cell number and 
cardiovascular disease risk.  In addition, these studies also highlight the importance of 
targeting the type I or invariant (and not type II) NKT cells to prevent atherosclerosis.  
 
Interestingly, the characterization of murine iNKT cells by CD4+ and CD8+ subsets as 
previously described found the CD4+ iNKT cell subset as the most atherogenic [465]. This 
may be linked to the observation that the CD4+ subset expressed lower levels of the 
inhibitory NK cell receptor Ly49 and were stronger producers of IL-2, TNF-α and IFN-γ in 
response to α-GalCer stimulation than the other subsets [465].  Moreover, evidence 
suggests that these CD4+ iNKT cells contribute to atherosclerosis through production of 
perforin and granzyme B-mediated cell cytotoxicity [225].  This is in contrast to a study in 
humans where no differences were observed in the proportion of CD4+ and CD4- iNKT cells 
within the peripheral blood of healthy individuals versus patients who had suffered an acute 
MI [466].  
 
In addition, there is evidence to suggest that iNKT cells are capable of altering the content 
of atherosclerotic lesions. Nakai et al. demonstrated using apoE-/- mice that chronic α-
GalCer stimulation of iNKT cells could result in collagen depletion from atherosclerotic 
lesions and an increase in cellular content [459]. This suggests that iNKT cells display other 
effector functions in humans, which promote inflammation and liability of plaque to rupture.  
 
Importantly, iNKT cells may play a protective role in certain experimental conditions of 
atherosclerosis. Aslanian et al. demonstrated the effects of iNKT cells in atherogenesis to 
be more pronounced during early stages of disease, suggesting that iNKT cell involvement 
in atherosclerosis is transient [467]. This may explain why one study observed a  reduction 
in plaque size in LDLR-/- mice following treatment with α-GalCer indicating that iNKT cells 
may play an atheroprotective role in subclinical atherosclerosis [468]. Alternatively, Braun 
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et al. reasoned that this discrepancy could have been due to the measurement of different 
regions of the vasculature [469]. 
 
Data from animal models of atherosclerosis generally supports the theory that increased 
iNKT cell accumulation within plaque is a direct result of increased CD1d-mediated lipid 
presentation by antigen presenting cells. This is emphasized in a study by Strom et al. where 
mice lacking CD1d were found to have a 60% reduction in carotid plaque formation 
compared to wild type mice following carotid collar injury [470].  Furthermore, iNKT cell 
expansion occurred in the spleen and periadventitial space of the arteries in wild type mice, 
and was associated with increased carotid injury. On the whole, this suggests a pathogenic 
role for iNKT cells in atherosclerosis, although this could vary at different stages of disease 
and may not be representative of data from humans. 
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1.6 iNKT cells in SLE patients with atherosclerosis 
 
Whilst animal models have proved useful in clarifying the roles of iNKT cells in SLE and 
atherosclerosis, the two diseases have rarely been studied in combination, with very little 
data from human studies. This is particularly important in light of the differences in CD1d 
and lipid presentation between mice and humans, as has been described. Taking previous 
research into account, the role of iNKT cells in SLE patients with atherosclerosis appears 
extremely confusing due to their conflicting roles in both diseases. In SLE, iNKT cells have 
a defect in cell number and function, resulting in a defective iNKT cell pool, and loss of 
immunoregulation. This is in stark contrast to atherosclerosis, which appears to be mediated 
through increased presentation of glycolipids and iNKT cell activation, resulting in a 
proinflammatory response. As a consequence, this dichotomy exists whereby iNKT cells are 
viewed as protective against autoimmunity, but pathogenic in the context of atherosclerosis 
(Figure 1.18). 
 
It is possible however, that the concept of iNKT cells playing dual roles in both diseases may 
not be too farfetched. Evidence from a study on CD4+ T cells by Major et al suggests that T 
cells are able to convert phenotype upon transfer from a mouse model of SLE to 
atherosclerosis [198]. Despite this, it is unknown whether this would also true for iNKT cells, 
and whether this plasticity would be true in vivo in humans for SLE patients who later develop 
atherosclerosis. What is clear is that iNKT cell phenotype in SLE patients with 
atherosclerosis likely depends on numerous factors including disease activity, stage of 
atherosclerosis, smoking, age, medication and lipid profile. This conundrum therefore 
presents a challenge to understanding the mechanistics of plaque development in SLE 
patients, as well as the possibility of indirectly targeting iNKT cells in order to protect against 
both atherosclerosis and SLE.    
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Figure 1.18 The role of iNKT cells in autoimmunity and atherosclerosis 
iNKT cells mediate a balance between activation and tolerance under normal homeostatic 
conditions and a disturbance in this contributes to a number of immunopathologies 
associated with either increased or decreased iNKT cell function.  
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1.7 Hypothesis and aims 
 
Hypothesis: iNKT cell phenotype and function are defective in SLE patients due to altered 
lipid metabolism, and this contributes to the increased cardiovascular risk observed in these 
patients. 
 
Outline of PhD project:  
Using a cohort of 100 SLE patients who were scanned to determine the presence of 
preclinical atherosclerosis my aims were to: 
 Assess iNKT cell frequency, phenotype (surface markers) and function (cytokine profile) 
in patients with and without plaque. 
 Investigate whether serum lipids and metabolites were different in SLE patients and 
whether they affected iNKT cell function. 
 Explore the role of lipid biosynthesis and CD1d-mediated lipid antigen presentation in 
SLE patients and its influence on iNKT cell function. 
 Understand how altered iNKT cell function in SLE patients may contribute to 
atherosclerosis through transactivation of other immune cell types.    
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Materials and Methods 
 
2.1 Patients and controls 
 
650 SLE patients who met the 2004 revised criteria for SLE set out the America College of 
Rheumatology were assessed for disease activity and a personal history of cardiovascular 
as part of their routine visits to University College London Hospital (UCLH) [10, 38]. Of these, 
100 SLE patients who had not previously suffered a cardiovascular event were randomly 
selected for ultrasound scan by collaborators Dr. Sara Croca and Prof. Anisur Rahman at 
UCLH. Ultrasound scans were performed by Prof Andrew Nicolaides, Dr Maura Griffin and 
Dr Sara Croca, as follows: 
Vascular ultrasound of the common carotid artery (CCA), carotid bulb, carotid bifurcation, 
common femoral artery (CFA) and femoral bifurcation were performed bilaterally using the 
Philips IU22 ultrasound computer and the L9-3 MHz probe. IMT was measured using QLAB 
Advanced Quantification Software® version 7.1 (Philips Ultrasound, Bothell, USA), in order 
to provide an indication on the stage of atherosclerosis. A longitudinal section of the mid-
CCA was obtained and a 2 cm segment of the posterior wall was measured with at least 
97% accuracy. IMT was also measured in a transverse view of the mid-CCA using manual 
callipers with variability <1% compared with the longitudinal view. The mean IMT value was 
obtained from combining the bilateral measurements. Measurements were taken from the 
carotid and femoral arteries to quantify intima-media thickness and plaque presence, as well 
as calcium content, which is a key determinant of plaque stability [471].   
 
Regardless of their location, all the plaques which were identified were included in the 
analysis. When plaque was present, colour and Power Doppler images were obtained to 
ensure that the outline of the plaque was accurately determined. Plaque thickness was 
measured at the point of maximum thickness using manual callipers on longitudinal and 
transverse views and the mean value was obtained (variability <1%). Plaque echogenicity 
was characterized qualitatively by two trained observers independently (variability<10%) 
using a visual scale [472], and analysed for ultrasonic arterial wall changes and 
atherosclerotic plaques using “The Plaque Texture Analysis” software version 4.5 (LifeQ 
Ltd).  
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Plaque echogenicity measured by the later method was expressed numerically by Grey 
Scale Median (GSM) [202, 216, 473-475], which has been shown to reflect visual 
assessment of plaque using the Grey Weale classification [476]. Plaque area was measured 
using the same automated plaque texture analysis software using a method previously 
described [217, 218, 473]. Lipid rich, soft and unstable plaques were characterised by an 
area >95mm2 and GSM of <25 [477]; high GSM values were indicative of hard plaque, which 
is characterised by calcification [478]. Very few patients had lipid rich or unstable plaques or 
lipid cores of a quantifiable size.  
 
Plaque presence and size was characterised using a previously described arterial 
ultrasound score (AUS), which ranges from 0-8 for each artery [479, 480]. AUS was 
allocated to each arterial site according to both IMT measurements and assessment of 
plaque morphology (Table 2.1), using a classification system based on the one described 
by the American Heart Association [481]. Examples of class I, II and III lesions can be seen 
in Figure 2.1. This scoring system has previously been shown to predict cardiovascular 
event rate in a 6 year follow-up study where cardiovascular events were observed only in 
subjects with class II, III and IV lesions, with patient deaths occurring only in subjects with 
class III or IV lesions [480]. Participants’ total AUS was quantified by adding scores from the 
four individual sites to give a combined score ranging from 0-32. Class III and IV lesions 
were indicative of plaque, which enabled patients to be grouped according to whether or not 
they had plaque (SLE-P or SLE-NP) as well as the number of sites with plaque (Table 2.2).   
Supine blood pressure (BP) was measured in the left upper arm using an automated BP 
reader (Omron M6 HEM-700-E). Three measurements were taken and the first discarded. 
The average systolic and diastolic BP value was calculated using the second and third 
readings. Pulse pressure was calculated as the difference between systolic and diastolic 
BP, Mean BP value was calculated for each patient using:  
Mean BP= Diastolic BP + 1/3(systolic BP – diastolic BP). 
Blood samples were collected at the time of the scan and at regular time points following the 
scan, according to patients’ routine appointments, which on average were scheduled every 
3 months or sooner depending on clinical need. Routine blood was taken from patients at 
the time of each appointment to measure serum lipids, homocysteine, CRP and vitamin D. 
Research blood was also taken from SLE patients identified as having suffered a 
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cardiovascular event (stroke or MI), and healthy donors; both of which did not receive 
ultrasound scans. All participants completed a cardiovascular risk factor questionnaire at the 
time of blood donation to evaluate individual risk factors including medication, smoking and 
family history of cardiovascular disease. Basic characteristics of all participants can be seen 
in Figure 2.2, with more detailed analysis throughout Results sections 1&2.  
For all SLE patients, disease activity calculated using the British Isles Lupus Assessment 
Group (BILAG) index on every visit [38]. Those who had recently underwent rituximab 
therapy were excluded from the main analysis due to the known influence of B cell depletion 
on iNKT cell frequency [233, 482].  
The study had research ethics committee (06/Q0505/79) and National Health Service 
approval.  Ultrasound scans and blood donation were carried out subject to informed 
consent, which was obtained from all participants, under the guidelines of UCLH.  
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Class  Ultrasound morphology Arterial 
Ultrasound 
Score 
0 Normal: Intima-media thickness (<1mm) with no gaps or acoustic 
holes, which correspond to fatty streaks. 
0 
I Fatty streaks: Three ultrasonic layers (intima-media, adventitia, 
and periadventitia) clearly separated. No disruption of lumen-
intima interface for at least 3.0 cm, and/or initial alterations 
(lumen-intima interface disruption at intervals of <0.5 cm). 
2 
II Intima-media granulation or thickened intima-media: Granular 
echogenicity of deep, normally unechoic intimal-medial layer 
and/or increased intima-media thickness (>1 mm). 
4 
III Small plaque without hemodynamic disturbance†: Localized wall 
thickening and increased density involving all ultrasonic layers. 
Intima-media thickness >2 mm. 
6 
IV Large or stenotic plaque: As in III, but with hemodynamic stenosis 
on duplex scanning (sample volume in the center of the lumen), 
indicating stenosis >50%.‡ 
8 
 
Table 2.1: Ultrasound Arterial Morphology Classification  
Each artery was scored based on the above classification criteria, as previously described 
by Belcaro et al [480]. Class V (AUS of 10) refers to symptomatic plaques, regardless of 
size and is not included since none of the patients had suffered a cardiovascular event at 
the time of the scan. Scores for all four arteries were combined to give a total score for 
each patient.   
†Hemodynamic disturbance is defined as moderate spectral broadening (downstroke 
of systole); systolic window present; diastolic window reduced and/or absent. Ratio 
a−b/a<0.5, where a is the peak systolic velocity and b, the first peak end-systolic 
velocity. 
‡Peak frequency >4 kHz and spectral broadening throughout systole; no systolic 
window. Ratio a−b/a<5. 
Table obtained from Belcaro et al, 1996 [480]. 
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Figure 2.1: Representative Images of Ultrasound scans from patients in this 
study 
Examples of ultrasound images from scanned SLE patients, and their classification 
according to AUS score. Very few patients had lipid cores which could be 
quantified for size.  
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 Healthy 
donors 
(n=50) 
SLE-NP (n=64): 
0 sites with 
plaque 
SLE-P (n=36): 
1-4 sites with 
plaque 
SLE-CV (n=11) ANOVA or T test 
(as applicable) 
Mean Age (range) 39 (22-67) 40 (20-66) 54 (27-69) 50 (20-78) aHC vs SLEP 
p<0.001c 
aSLENP vs SLEP 
p<0.001 c 
Years since diagnosis  
(range) 
NA 13 (2-32) 21 (2-46) 18 (1-34) aP=0.0008 c 
Sex: female: male 47:3 62:2 33:3 9:2 aNS 
Ethnicity: C/A/AC/O (%) 40/4/6/0 
(80: 7: 13: 
0) 
33/9/17/5 
(51.6/14.1/26.6/
7.8) 
24/2/7/3 
(66.6/5.5/19.4/
4.7) 
8/1/1/1 
(73/9/9/9) 
aH vs SLE-NP 
p<0.05 c 
aH vs SLE-P p<0.05 c 
Personal history of CVD (%) 0 0 0 11 N/A 
Mean RT CCA IMT (range) ND 0.051 (0.04-
0.08) 
0.057 (0.04-
0.08) 
ND b0.002** 
Mean RT BULB MIT (range) ND 0.080 (0.05-
0.12) 
0.178 (0.07-
0.42) 
ND b<0.0001*** 
Mean LT CCA (range) ND 0.061 (0.04-
0.06) 
0.061 (0.05-
0.10) 
ND b<0.0001*** 
Mean LT BULB (range) ND 0.078 (0.05-
0.13) 
0.196 (0.07-
0.35) 
ND b<0.0001*** 
Mean total arterial score 
(range) 
ND 3.59 (2-8) 16.97 (8-26) ND b<0.0001*** 
      
 
Table 2.2: Basic characteristics of all study participants 
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2.2 Peripheral blood mononuclear cell (PBMC) isolation, storage and 
thawing 
 
Density gradient centrifugation was used to isolate PBMCs from heparinised blood. Blood 
was diluted 1:1 in RPMI-1640 medium (Sigma), before gently layering onto 15ml Ficoll-
paque (GE Healthcare) in 50ml falcon tubes.  Samples were then centrifuged at 800g for 30 
minutes at 21°C with minimum acceleration and brake settings to separate blood into layers 
(Figure 2.2). The white buffy coat layer was carefully removed and diluted 1:1 with RPMI-
1640 medium, then centrifuged at 400g for 10 minutes at 4°C. The supernatant was 
discarded and the pellet resuspended in 10ml RPMI. 
Cell concentration was determined by diluting 1:10 in trypan blue and counting cells using a 
haemocytometer under a light microscope. Lastly, cells were centrifuged using the same 
settings aliquotted into cryovials, at a concentration of 1x107 PBMCs/ml freezing medium 
containing fetal calf serum (FCS) and 10% dimethyl sulfoxide (DMSO). Vials were placed 
into Nalgene™ Mr Frosty freezing containers containing isopropanol in order to achieve a 
freezing rate of -1°C/minute before transfer to -80°C freezer for storage. For long-term 
storage samples were transferred to liquid nitrogen storage (-180°C).   
For each experiment cells were thawed by pre-warming 20ml complete RPMI (RPMI-1640 
medium; 10% FCS, 1% penicillin/streptomycin [Pen/Strep]) per sample to 37°C in a water 
bath. A sterile Pasteur pipette was used to thaw each vial individually before diluting in pre-
warmed complete RPMI, and washed to remove traces of DMSO.  
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Figure 2.2 Isolation of PBMCs using Ficoll-Paque Plus density gradient 
centrifugation 
 Illustration of the layering of blood before and after centrifugation. 
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2.3 Surface staining for FACS 
 
Multi-parameter flow cytometry was used to carry out immunophenotyping of iNKT cells and 
APCs. Cell staining was carried out in a 96 well plate at a concentration of 1-2x10⁶ PBMCs 
per well. Cells were stained with Live/dead violet or yellow (50µl/well diluted 1:200 in PBS) 
for 20 minutes at 4⁰C before washing in PBS.  Cells were then washed and stained with 
either a surface marker or intracellular panel using the antibodies indicated in Table 2.3 and 
Table 2.4. Panels were designed for use on BD LSR Fortessa and all antibodies were titrated 
for optimal dilution. 
For the surface marker panel, staining was carried out in 50μl cold FACS buffer containing 
1x phosphate buffered saline (PBS), 1% FCS, 0.01% NaN₃; 0.5%  Ethylenediaminetetra-
acetic acid (EDTA). A mix was prepared containing the following antibodies, which were 
diluted accordingly. iTCR-PE (1:10) and CD3-APC/efluor780 (1:50) were used to identify 
iNKT cells, with subsets CD4-BV605 (1:1000) and CD8-BV705 (1:100). Other markers 
stained for included activation markers CD25-alexafluor700 (1:25), CD69-APC (1:25) and 
PD-1-PE/Cy7 (1:25), as well as NK cell marker CD161-BV421 (1:25), and chemokine 
receptor CCR6-FITC (1:25). Cells were incubated at 4°C in the dark for 20 minutes to enable 
binding. Cells were then washed in 100ml MACS buffer and centrifuged at 2500rpm for 2 
minutes at 4°C, before fixing with 70μl 2% paraformaldehyde (PFA) and incubating in the 
dark at RT for 15 minutes. Finally, cells were washed and resuspended in 200μl FACS buffer 
ready for analysis.  For each sample, 1-5x10⁶ cells were acquired by flow cytometry using 
BD LSR Fortessa, and analysed using FlowJo version X (TreeStar).    
Staining for APCs was carried out with 1x10⁶ cells/well in 50μl MACS buffer as previously 
described. All antibodies were diluted 1:50 in FACS buffer with separate panels for 
monocytes, B cells and pDCs, which were labelled with CD14, CD19 and CD303 
respectively. APCs were stained for CD1d followed by lipid rafts (Section 2.5), or 
alternatively for scavenger receptors CD36, LOX-1 and LDLR. Monocyte subsets were 
stained for using CD14, CD16, CD68, CCR2, CD206 and CX3CR1. Cells were washed and 
fixed as above before acquisition of >3x105 cells by flow BD LSR Fortessa. Samples were 
analysed using FlowJo version X (TreeStar).    
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Table 2.3 Cell surface antibodies and markers used 
Surface 
marker 
Fluorochrome Clone Isotype Company Concentration 
in FACS 
Buffer 
Invariant T cell 
receptor 
(Vα24Jα18) 
PE 6B11 Mouse IgG1 BD Bioscience 3:50 
Invariant T cell 
receptor 
(Vα24Jα18) 
PE/Cy7 6B11 Mouse IgG1 eBioscience 3:50 
CD1d PE 51.1 Mouse IgG1 eBioscience 1:50 
CD3 APC/efluor780 SK7 Mouse IgG1 eBioscience 1:50 
CD4 Alexa488 OKT4 Mouse IgG2b BioLegend 1:50 
CD4 BV605 OKT4 Mouse IgG1 BioLegend 1:100 
CD8 BV711 RPA-T8 Mouse IgG1 BioLegend 1:100 
CD14 BV510 M5E2 Mouse IgG2a BioLegend 1:50 
CD14 efluor450 61D3 Mouse IgG1 eBioscience 1:50 
CD16 alexafluor700 3G8 Mouse IgG1 BioLegend 1:50 
CD19 alexafluor700 HIB19 Mouse IgG1 BioLegend 1:50 
CD25 Alexa700 BC96 Mouse IgG1 BioLegend 1:50 
CD25 APC BC96 Mouse IgG1 BioLegend 1:50 
CD36 FITC NL07 Mouse IgM eBioscience 1:25 
CD40L APC 24-31 Mouse IgG1 BioLegend 1:50 
CD68 PE/Cy7 Y1/82A Mouse IgG2b BioLegend 1:50 
CD69 APC FN50 Mouse IgG1 eBioscience 1:50 
CD161 BV421 HP-3G10 Mouse IgG1 BioLegend 1:50 
CCR2 (CD192) PerCP/Cy5.5 K036C2 Mouse IgG2a BioLegend 1:50 
CCR6 (CD196) FITC R6H1 Mouse IgG1 eBioscience 1:50 
CD206  PE 15-2 Mouse IgG1 BioLegend 1:50 
CD209 FITC DCN47.5 Mouse IgG1 Miltenyi Biotec 1:50 
PD-1 (CD279) PE/Cy7 EH12.2H7 Mouse IgG1 BioLegend 1:50 
CD303 APC 201A Mouse IgG1 BioLegend 1:50 
CX3CR1 FITC 2A9-1 Rat IgG2b BioLegend 1:50 
ICOS PE C398.4A Hamster IgG BioLegend 1:50 
LOX-1 PE 331212 Mouse IgG2b R&D Systems 1:25 
LDLR APC 472413 Mouse IgG1 R&D Systems 1:25 
Cholera Toxin 
subunit B 
(CTB) 
FITC N/A N/A Sigma 1:100 
Filipin Emission at 
470nm 
N/A N/A Sigma 1:200 
ANE Emission at 
~465/635nm 
N/A N/A Life 
Technologies 
4 mM 
Live/dead Yellow 
(emission at 
405nm) 
 N/A  N/A Life 
Technologies 
1:200 (PBS) 
Live/dead Aqua (emission 
at 405nm) 
N/A N/A Life 
Technologies 
1:200 (PBS) 
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2.4 Intracellular FACS staining 
 
For the intracellular panel, PBMCs were cultured for 4 hours in complete RPMI containing 
50ng/ml PMA, 250ng/ml ionomycin and 1:1000 Golgiplug (all from Sigma). PBMCs were 
washed and stained for iTCR, CD3, CD4 and CD8 as before. Cells were then washed and 
resuspended in 70μl Fix/Perm buffer (1:4) using the diluent provided (eBiosciences) before 
incubating for 20 minutes at 4°C in the dark and washing twice with PermWash buffer 1:10 
dH₂O (eBiosciences). Cells were resuspended, then stained for a maximum of three 
intracellular cytokines (2μl/well undiluted) and incubated at 4°C in the dark for 20 minutes. 
Samples were washed using Perm/Wash buffer as previously, then resuspended in MACS 
buffer for analysis. For each sample, 1-5x10⁶ cells were acquired by flow cytometry using 
BD LSR Fortessa, and analysed using FlowJo version X (TreeStar). 
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Table 2.4 Antibodies for Intracellular molecules  
Intracellular 
marker 
Fluorochrome Clone Isotype Company Concentration 
IFN-γ efluor450 4S.BS Mouse 
IgG1 
eBioscience 1:25 
IL-4 APC MP4-25D2 Mouse 
IgG1 
BioLegend 1:10 
IL-10 APC JES3-19F1 Rat IgG BD Bioscience 3:50 
CD1d PE 51.1 Mouse 
IgG1 
eBiosciences 1:50 
EEA1 FITC 14/EEA1 
(RUO) 
Mouse 
IgG1 
BD 
Biosciences 
1:100 
LAMP-1 
(CD107a) 
PerCP/Cy5.5 H4A3 Mouse 
IgG1 
BioLegend 1:50 
Ki67 PE B56 Mouse 
IgG1 
BD 
Pharminogen 
1:20 
Ki67 (isotype 
control) 
PE MOPC-21 Mouse 
IgG1 
BD 
Pharminogen 
1: 20 
TCR zeta 
(CD247) 
Alexa488 K25-407.69 Mouse 
IgG2A 
BD Phosflow 1:50 
ERK1/2 Alexa647 20A Mouse 
IgG1 
BD Phosflow 1:50 
T-bet PerCP/Cy5.5 4B10 Mouse 
IgG1 
BioLegend 1:50 
GATA-3 Alexa647 I6E10A23 Mouse 
IgG2b 
BioLegend 1:50 
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2.5 Lipid detection 
 
Staining for lipid rafts was carried out following staining for B cells, monocytes and pDCs 
and CD1d using surrogate glycosphingolipid marker CTB [380]. 50μl CTB-FITC (1:100 
FACS buffer) was added following re-suspension of PBMCs before incubating at 4°C in the 
dark for 30 minutes. Cells were then washed and fixed in 2% PFA, then analysed by flow 
cytometry as described in section 2.3. 
 
Filipin staining was carried out after staining for CD14+ monocytes, CD19+ B cells and lipid 
rafts. Cells were fixed with 2% PFA for 1 hour at room temperature, before washing in FACS 
buffer and staining with 50μg/ml filipin for 2 hours at room temperature in the dark. Cells 
were washed and resuspended in FACS buffer before proceeding to analysis as previously 
described. 
 
B cells and monocytes from healthy and SLE patients were stained with the membrane order 
probe di-4-ANEPPDHQ (ANE) [483]. PBMCs were stained for CD14 and CD19 (both 1:50 
FACS buffer), and incubated in the dark at 4°C for 20-30 minutes. Cells were washed in 
200µl MACS buffer before resuspending in 100µl of 4µM ANE and incubating at 37°C for 30 
minutes in the dark. Samples were resuspended in FACS buffer and read immediately on 
the LSR II using PerCP and PE for ANE. 
 
To calculate membrane order using MFI, the following equation was used:  
 
 
                                     
 
 
 
 
Alternatively, samples were analysed according to population by low, intermediate and high 
order (Figure 2.3).   
I500-580   - I620-750
I500-580  + I620-750
GP =
120 
 
 
 
 
Figure 2.3 FACS plots showing cells populations of high, medium and low 
membrane order as determined by di-4-ANEPPDHQ (ANE) 
 
 
 
 
 
 
  
PE
P
e
rC
P
Membrane Order
low
medium
high
1.74
54.8
42.8
121 
 
2.6 B cell and Monocyte Isolation  
 
50x10⁶ PBMCs from a healthy individual were stained for CD14-BV510 and CD19-alexafluor 
700 (both from BioLegend) in MACS buffer (1x PBS, 1% FCS, 0.5% EDTA). Cells were 
sorted using BD FACS Aria II according to CD14 and CD19 expression. Monocytes (CD14+), 
B cells (CD19+) and cells negative for both markers (mainly T cells) were collected for use 
in co-culture experiments.  Alternatively, B cells and monocytes were negatively isolated 
using magnegic bead isolation kits (EasySep kits, StemCell) according to manufacturer’s 
instructions. B cell and monocyte purification can be seen in Figure 2.4. 
 
Isolated B cells and monocytes were each cultured with RPMI containing 10% human serum 
from a healthy control, SLE plaque or SLE no plaque patient. Meanwhile, double negative 
cells were cultured with RPMI containing 10% pooled human serum (1% Pen/Strep). 
Following 3 hours incubation at 37°C (5% CO₂), B cells and monocytes were washed and 
co-cultured with the double negative cells. Cells were incubated for 1 and 2 days at 37°C 
(5% CO₂). Subsequent staining for iNKT cells, CD4 and CD8 expression and intracellular 
cytokines was carried out as previously described.     
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Figure 2.4 B cell and monocyte purification using StemCell EasySep kits 
Lymphocytes or monocyte populations were gated according to forward and side scatter, 
before assessing expression of CD14 (monocytes) or CD19 (B cell expression). 
Representative plots showing before and after purification using EasySep kits. 
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2.7 ImageStream analysis of CD1d recycling and lipid raft 
colocalisation 
 
Cells were stained for B cells (CD19), monocytes (CD14), CD1d and lipid rafts (CTB) as 
previously described. To induce clustering of CTB, cells were washed in PBS (0.5%BSA) 
and stained with goat α-human CTB at 1/125 dilution in PBS (0.1% BSA). Cells were 
incubated in the dark for 20 minutes at 4°C, before transferring to an incubator at 37°C (5% 
CO₂) for 20 minutes to induce antibody clustering. Finally, cells were washed twice in ice 
cold PBS, then fixed in 2% PFA.  
To measure differences in lipid processing via the lysosomes and endosomes, cells were 
surface stained for CD14 and CD19, followed by an intracellular stain for CD1d, lysosome 
marker CD107a and early endosome marker EEA1. Cells were cultured, stained and fixed 
as previously described, with endosome and lysosome stains carried out according to the 
manufacturer’s instructions. CD45RA and lipid rafts (CTB) were used as a negative 
colocalisation control.    
Acquisition of data was carried out using Amnis® ImageStreamX Mk II, where 1x10⁵ single 
cells were collected for each sample, based on object diameter and aspect ratio. Data was 
analysed using Amnis IDEAS software version 6.0.  Focused cells were gated according to 
gradient RMS, and single cells or conjugates were gated according to area and aspect ratio. 
The inbuilt feature finder wizard was used to determine the appropriate feature and mask 
combination to quantify each variable.  These were as follows: 
 Endosome count – Spot Count_Peak (M02, Channel 2, Bright 9.5) 
 Lysosome count – Spot Count_Spot (M05, Channel 5, Bright 12.5) 
 CD1d-endosome co-localisation – Bright Detail Similarity R3_MC_Ch02, Ch03 
 CD1d and lipid raft co-localisation - Bright Detail Similarity R3_Dilate(M01, 6) And 
Not Erode(M01, 3)_Ch02_Ch03 
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2.8 Lipid extraction from PBMCs 
 
10x10⁶ B cells or monocytes from healthy donors, SLE-NP and SLE-P patients were isolated 
by FACs sorting and washed in PBS to remove traces of serum. Cells were mixed with 250ul 
PBS and frozen/thawed three times to disrupt the cells before carrying out lipid isolation by 
chloroform: methanol extraction [484]. Pellets were then and mixed with 1.2ml methanol and 
chloroform (2:1 concentration) for 30 minutes at room temperature. Samples were 
centrifuged at 3500g for 5 minutes, before removing the supernatant, which was kept on ice. 
This was repeated to ensure total lipid extraction. Chloroform and PBS (1:1) were added to 
the lipid extract before centrifuging at 1000g for 5 minutes. The lower layer (Layer 1) but not 
the upper layer (Layer 2) was dried under a nitrogen stream. Both layers were stored 
separately at -80°C.        
 
To isolate lipid subgroups 1ml SupelCo Superclean LC-NH2 columns (Sigma) were pre-
treated with 2ml hexane (Sigma). Dried lipid Layer 1 lipid pellets were combined with Layer 
2 and dryed under nitrogen followed by reconstitution in 500μl chloroform, before adding to 
columns. Individual lipid fractions were then eluted using different elution buffers as 
indicated in Table 2.5. Fractions were dried under nitrogen stream and reconstituted in 50µl 
DMSO prior to use in cell culture experiments. Samples were stored at -80°C. 
 
Alternatively, total lipids isolated from PBMCs were sent off for HPLC analysis of 
glycosphingolipid content by Dr Dominic Alonzi in the Glycobiology Department at Oxford 
University. 
 
Fraction Lipid group(s) Elution buffer 
1 Cholesterol, di- and tri-glycerides 2ml diethyl-ether 
2 Ceramides and monoglycerides 1.6ml chloroform:methanol (23:1) 
3 Free fatty acids and free hydroxyl fatty 
acids 
1.8ml di-isopropylether acid: acetic 
acid (98:4) 
4 Neutral glycolipids and sphingoid 
bases 
2ml acetone: methanol (9:1.2 ) 
5 Neural phospholipids, PC, PE and 
sphingomyelin 
2ml chloroform: methanol (2:1) 
6 Gangliosides 2ml 0.2M ammonium acetone in 
methanol 
Table 2.5 Isolation of lipid fractions by chloroform: methanol extraction 
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2.9 PBMC culture  
 
α-GalCer culture: 
PBMCs from healthy donors, SLE-NP and SLE-P patients were cultured at a concentration 
of 1-2x10⁶ PBMCs/well for 7 days at 37°C (5% CO₂) in the presence of RPMI containing 
10% pooled human serum (Lonza), 1% Pen/Strep, 100ng/ml α-GalCer and 200IU/ml rhIL-
2. At 7 days cells were stained with live/dead, CD3 and iTCR (to detect iNKT cells) followed 
by either Ki67 (to assess proliferation) or costimulatory molecules CD40L and ICOS. 
Samples were analysed by flow cytometry as previously described.   
 
Healthy and patient serum: 
PBMCs from non-autologous healthy individuals were cultured at a concentration of 1-2x10⁶ 
PBMCs/well for 1, 2, 4 and 7 days at 37°C (5% CO₂) in the presence of healthy or SLE 
serum. Complete RPMI medium was prepared as previously described, but containing 50% 
human serum from either a healthy control or SLE patient, with the addition of 200IU/ml rhIL-
2.  A positive control sample was also prepared containing RPMI with pooled human serum 
(Lonza) and 100ng/ml α-GalCer. In some experiments, 10μg/ml purified CD1d blocking 
antibody (51.1) or isotype control antibody were also added to the culture medium. At each 
time point staining for iNKT cell surface markers, intracellular cytokines or CD1d and lipid 
rafts on APCs was carried out as previously described. Samples were analysed by flow 
cytometry. 
 
Cellular lipids: 
PBMCs from healthy individuals were cultured at a concentration of 1-2x10⁶ PBMCs/well for 
4 or 7 days at 37°C (5% CO₂) in the presence of RPMI containing 10% pooled human serum 
(Lonza), 200IU/ml rhIL-2 and 1:100 healthy, SLE-NP and SLEP B cell or monocytic lipid 
fractions isolated through chloroform: methanol extraction (Section 2.8). An equivalent 
concentration of vehicle (DMSO) was used a negative control in place of the lipid fractions. 
At each time point, staining for iNKT cell surface markers and intracellular cytokines was 
carried out as previously described. Samples were analysed by flow cytometry. 
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2.10 Generation of an iNKT cell line 
 
An iNKT cell line was produced using monocyte-derived dendritic cells (MDDCs) pulsed with 
α-GalCer to expand iNKT cells over the course of 7 days.  MDDCs were generated as 
follows, using a method based on a publication by Zhou and Tedder [197], and expanded 
by culture with iNKT cells using a method optimized by previous PhD student Anneleen 
Bosma. 
For each experiment monocytes were isolated from freshly obtained PBMCs by negative 
selection using the EasySep CD14 Enrichment Kit, which was followed according to the 
manufacturer’s instructions. Following purification, monocytes were resuspended at 1x106 
cells/ml in complete RPMI containing 10% human serum (Lonza), 1% Pen/Strep, 1000IU/ml 
granulocyte macrophage-colony stimulating factor (GM-CSF; PeproTech), and 500IU/ml 
recombinant human IL-4 (R&D Systems). Monocytes were incubated 1ml/well in a 12 well 
tissue culture plate for 4 days, before adding 100ng/ml LPS (Sigma) and 100ng/ml α-GalCer 
(Alexis Biochemicals) directly to the culture. On day 5, non-adherent MDDC cells were 
harvested and directly transferred to a separate well. At each step a small sample (200µl) 
was removed to assess monocyte purity and the presence of dendritic cells by staining for 
CD14-efluor 450 and CD209 (DC-SIGN)-FITC. Samples were acquired using BD LSR 
Fortessa II and data were analysed by Flowjo (Treestar). Purity can be seen in Figure 2.5.  
At day 5, 2x107 PBMCs from a healthy donor were thawed as previously described. Cells 
were then resuspended at approximately 3x106 cells/ml of complete RPMI containing 10% 
human serum (Lonza), 1% Pen/Strep, and 400IU/ml recombinant human IL-2 (R&D 
Systems). 1ml of PBMCs in complete medium was then added to each of the wells 
containing the non-adherent MDDCs. Cells were then incubated for 7 days at 37°C (5% 
CO2) to enable iNKT cell expansion. iNKT cells were assessed for expansion at day 7 by 
staining for CD3-APCefluor780 and iTCR-PE. Results can be seen in Figure 2.6.  
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Figure 2.5 Generation of Monocyte derived DCs by monocyte culture 
Sample was gated on monocytes according to FSC-A and SSC-A, followed by analysis of 
CD14 and CD209 (DC-SIGN) expression 
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Figure 2.6 Expansion of iNKT cell line   
The expanded iNKT cell line was assessed for iNKT cells by staining for Live/dead, CD3 and iTCR.  
(A) Samples were gated on total PBMCs (according to FSC/SSC) and live cells before (B) quantifying 
the percentage of CD3+iTCR+ iNKT cells both before and after culture with α-GalCer and IL-2. 
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2.11 Stimulation of APCs with LXR agonist GW3965 and PPARγ 
agonist Rosiglitazone 
 
2x106 PBMCs were cultured in the presence of either LXR agonist GW3965 (Sigma, 1µM) 
or PPARγ agonist Rosiglitazone (2.5 µM, Tocris Biosciences) resuspended in 200µl 
complete medium (1640 RPMI, 10%pooled human serum, 1% Pen/Strep). An equivalent 
volume of DMSO was used in place of GW3965 or PPARγ as a vehicle control.  At 4h, 24h 
and 48h cells were washed in FACS buffer and stained for CD14, CD19, CD1d, CTB and 
filiipin.  Flow cytometry was used to analyse expression of CD1d, lipid raft (CTB) and 
cholesterol (filipin) on B cells and monocytes post stimulation.  Alternatively, B cells and 
monocytes were isolated by negative selection using CD14+ and CD19+ enrichment kits 
(Stemcell Technologies) then co-cultured with the iNKT cell line shown in figure 2.5. iNKT 
cell phenotyping was carried out according to method in section 2.3.   
 
2.12 Conjugate formation experiments 
 
PBMCs were thawed as previously described and cultured with RPMI containing 10% 
pooled human serum, 1% Pen/Strep and α-GalCer. Cells were incubated at a concentration 
of 1x107 cells/ml for 2 hours at 37°C (5% CO₂) to enable uptake of lipids. Following 
incubation cells were stained for CD14 and CD19, before being sorted using BD FACS Aria. 
Purified populations of B cells and monocytes were washed in MACS buffer and 
resuspended in complete medium containing 10% pooled human serum and 1% Pen/Strep 
at a concentration of at 1x106/ml and placed on ice ready for use. 
 
Meanwhile, the iNKT cell line culture was harvested at day7 and washed in MACS buffer at 
500g for 10 minutes at 4C. Cells were stained using CD3-APCefluor780 and iTCR-PE at a 
concentration of 1µl/1x106 cells for 20 minutes at 4°C in the dark before washing. Cells were 
passed through a filter cap lip into 5ml polystyrene tubes for sorting using BD FACS Aria. 
iNKT cells (CD3+ and iTCR+) and T cells (CD3+ and iTCR-)  were collected. 
Sorted iNKT cell and T cell populations were rested for 2 hours at 37°C (5% CO2) in complete 
medium containing 10% human serum and 1% Pen/Strep. iNKT cells were then prepared in 
a suspension of 5x105/ml before being plated 50ul/well. A similar concentration of T cells 
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was used as a control. Control wells were also prepared containing single cell types; either 
B cells, monocytes, iNKT cells or T cells alone. 
To induce conjugate formation, purified B cells or monocytes were added to the appropriate 
wells and incubated at 37°C (5%CO2) for 5, 10 or 15 minutes. At each time point, 2 x 
Fixation/ Permeabilisation Buffer was added to the appropriate wells to stop the reaction. 
Samples were finally incubated in the dark at 4°C for 20 minutes before staining for cell 
signalling molecules. 
Samples were centrifuged at 800g for 3 minutes before intracellular staining for TCRζ-FITC 
and ERK1/2-alexa647, as described previously. Cells were resuspended in 200μl FACS 
buffer prior to analysis using LSR Fortessa II.    
 
2.13 Cytometric bead array  
 
Healthy and SLE patient serum samples, as well as supernatants from culture experiments 
were assessed for cytokines using BD cytometric bead array Flex kits. Cytokines analysed 
included IFNα, IFNγ, TNFα, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13 and IL-17. Standards were 
prepared according to the manufacturer’s instructions. To make the top standard, the 
lyophilised standard spheres for each cytokine were pooled and reconstituted in 4ml of 
assay diluent, before gently mixing and leaving to stand at room temperature for 15 minutes. 
500µl of assay diluent was then added to eight test tubes, and a serial dilution was performed 
by transferring 500µl of top standard into the first tube, mixing and transferring to the next. 
This process was repeated for all eight tubes to produce dilutions of 1:2, 1:4, 1:8, 1:16, 1:32, 
1:64, 1:128, and 1:256.  
Serum samples and supernatants were diluted 1:3 in assay diluent, before adding 25µl per 
well for each test. A solution containing capture beads for each cytokine was prepared by 
combining 0.5µl of each bead (IFNα, IFNγ, TNFα, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13 and IL-
17) and diluting in 25µl capture bead diluent, multiplied by the number of tests. 25µl was 
then added to each well before incubating in the dark at room temperature for 2 hours. 
Detection beads were prepared in a similar way to the capture beads, with 25µl added to 
each well before incubating at room temperature for 1 hour. Finally, wells were washed in 
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100µl wash buffer and resuspended in 150µl wash buffer for acquisition and analysis using 
BD FACS Array.  
2.14 THP-1 cells 
 
The human monocytic cell line THP-1 was maintained in complete culture medium (RMPI 
1640 containing L-glutamine (Sigma), 10% fetal bovine serum and 20ug/mL gentamycin 
(Sigma)) at 37°C and 5% CO2. To differentiate into macrophages, cells were plated at 
400,000 cells/mL in a 6 well plate in complete medium containing 5ng/mL phorbol-12-
myrisate 13-acetate (PMA) (Sigma) for 72 hours, washed twice with phosphate buffered 
saline (PBS), and allowed to rest for 24 hours in complete medium.  
 
For the co-culture experiment, PBMCs from a healthy donor were incubated for 4 days with 
serum from either healthy control donors, SLE patients without plaque or SLE patients with 
plaque (n=3/group). Subsequently CD3+ T cells (that included iNKT cells) were positively 
selected using the EasySep magnetic isolation following the manufacturer’s protocol (Stem 
Cell) and 1.5x106 T cells were added to each well of THP-1 macrophages. After 40 hours 
medium and T cells were removed and THP-1 cells were washed once with PBS before 
being lysed in TRIzol (Invitrogen) for RNA extraction.  
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2.15 RNA Isolation and qPCR 
 
Following culture of monocytes or THP-1 cells, wells were washed with ice cold MACS 
buffer, before centrifugation at 1500g, followed by lysis with TRIzol (Invitrogen). After 
addition of chloroform and phase separation (as per the manufacturer’s instruction) the 
aqueous phase was mixed 1:1 with 70% ethanol (Sigma) and the RNeasy Micro Kit (Qiagen) 
used for extraction of RNA. RNA was quantified using a Nanodrop Spectrophotometer. All 
260/280 and 260/230 ratios were >1.9. 1000ng of RNA were used to make cDNA using the 
AffinityScript QPCR cDNA Synthesis Kit (Agilent Technologies).  
 
qPCR was performed on the Stratagene Mx3005P qPCR system (Agilent Technologies) 
using Brilliant III SYBR Green Mastermix (Agilent Technologies). Intron spanning or flanking 
primer pairs were designed using Primer 3 [485, 486]. Primers were ordered from Sigma 
Aldrich (Table 2.6), and validated in house to assess the efficiency of amplification and check 
for primer dimer formation. Primers were used at a concentration of 100nM.  
 
Data analysis was performed using MxPro software. Gene expression was calculated using 
the relative standard curve method (Bookout AL and Mangelsdorf DJ, 2003), and normalised 
to the endogenous reference gene cyclophilin A.  
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Table 2.6 Primers used to amplify RNA for Cyclophilin A, CD206 and 
CD200R1 
 
 
  
Gene 
name 
PubMed ID Forward Primer Reverse Primer Amplico
n 
Length 
Cyclophilin 
A 
NM_021130 GCATACGGGTCCTGGCAT
CTTGTCC 
ATGGTGATCTTCTTGC
TGGTCTTGC 
201 
CD206 NM_002438 AATGAACGTGTGTGGATC
GC 
ATCAGCAGCCCAGTTA
GTGT 
99 
CD200R1 NM_138806 TGAAAGTCAATGGCTGCA
GA 
TCTGTGTAGCTGGCAT
AGGG 
97 
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2.16 Metabolomics Analysis 
 
Metabolomics analysis on patient and healthy serum samples was performed by Prof. Mika 
Ala-Korpela by Brainshake at the University of Eastern Finland using a biomarker analysis 
platform [196]. The metabolite quantification was performed using hydrogen nuclear 
magnetic resonance (HNMR) using two spectral windows LIPO and LMWV to give 
information on lipoprotein subclass distribution and low molecular weight metabolites 
including systemic amino acids, urea and creatinine. Models were cross-validated against 
NMR-independent lipoprotein and lipid data, and verified to lie within a 10% limit of the 
training data set or else were rejected from lipoprotein subclass analysis [487]. 
 
2.17 Data Analysis 
 
iNKT cell absolute numbers were calculated for SLE patients by multiplying the percentage 
of CD3+iTCR+ PBMCs by patient lymphocyte counts obtained at the time of blood donation. 
For healthy donors iNKT cell frequency was multiplied by 2.5x109 cells/litre, which was used 
as an average lymphocyte count according to UCLH reference guidelines.    
GraphPad Prism software (La Jolla, USA) was used for statistical analysis of data. Data was 
tested for normal distribution using the Kolmogorov-Smirnov test and parameteric or non-
parametric staitiscal tests used accordingly. Data was analysed by one-way ANOVA was 
used, followed by a Tukey T- test for significance or by students or paired T tests as 
appropriate. Linear regression was also performed. A 95% confidence interval was used to 
calculate significance. A bonferroni correction was additionally used for the metabolomics 
data to determine the threshold for significance. 
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CHAPTER III: 
Results 1 
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Results 1 – iNKT cell phenotype in SLE patients with atherosclerosis 
 
3.1 Introduction and Aims for this chapter 
 
SLE patients have a significantly increased risk of cardiovascular disease compared to the 
general population; however the mechanisms underpinning the development of 
atherosclerosis in these patients remain uncertain. Both SLE and atherosclerosis are 
immune mediated disorders characterised by lipid abnormalities in terms of altered cellular 
lipids and dyslipidaemia [143, 367, 488]. Furthermore, lipid recognition by iNKT cells has 
previously been shown to be defective and could therefore play an important role in the 
pathogenesis of both diseases [234]. 
 
Previous studies have shown that iNKT cells protect against the development of 
autoimmune disease, where they are decreased in number and fail to respond to stimuli 
such as α-GalCer treatment [233, 436]. This has led many to believe that iNKT cells play an 
immunoregulatory role under normal homeostatic conditions, which is lost in the context of 
autoimmune diseases such as SLE [409]. In contrast, iNKT cells are reported to be 
increased in atherosclerosis, where they play a pathogenic role in atherosclerotic plaque 
development [459]. However most of the data on atherosclerosis is based on animal models, 
whilst there is a distinct lack of data on the role of iNKT cells in SLE patients who have 
subsequently developed plaques. I therefore compared the phenotype and functional 
characteristics of iNKT cells from SLE patients with preclinical plaque (SLE-P), SLE patients 
without plaque (SLE-NP) and healthy donors.  
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3.2 The presence of subclinical plaque in SLE patients was associated 
with traditional cardiovascular risk factors 
 
To assess the role of iNKT cells in the development of atherosclerosis in SLE patients, I 
examined a cohort of 100 SLE patients that had not previously suffered a cardiovascular 
event and had received ultrasound scans to determine the presence of preclinical 
atherosclerotic plaque in the right and left carotid and femoral arteries (methods section 
describes patient selection criteria and details of plaque analysis). SLE patients were 
characterised according to the number of plaque sites which was calculated by arterial 
ultrasound scores with an AUS score of 6 or more indicative of plaque at each site. 
 
Patients were categorised as having plaque (SLE-P) or no plaque (SLE-NP) based on data 
from ultrasound scans. Table 3.1 shows clinical, demographic, serological, therapy and 
disease activity characteristics of patients in the plaque and no plaque groups, which were 
compared by student’s t tests or one way ANOVAs where applicable.  
 
None of the patients or healthy donors were categorised as obese as determined by body 
mass index over 30, or had previously been diagnosed with diabetes. The only significant 
differences between groups were that patients with plaque were older, had longer disease 
duration and higher mean systolic blood pressure than those without plaque. In particular 
there were no associations between plaque and patient medication or any measure of 
disease activity including anti-dsDNA, C3 levels and BILAG score at the scan and on 
subsequent visits.  
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 Healthy donors 
(n=50) 
SLE-NP 
 (n=64) 
SLE-P 
(n=36) 
Statistical Analysis 
Mean Age (range) 39 (22-61) 40 (20-66) 54 (27-69) aHC vs SLEP p<0.001** 
aSLENP vs SLEP p<0.001** 
Years since diagnosis  (range) NA 13 (2-32) 21 (2-46) aP=0.0008*** 
Sex: female: male 3:47 62:2 33:3 aNS 
Ethicity: C/A/AC/O (%) 40/4/6/0 
(80: 7: 13: 0) 
33/9/17/5 
(51:14:27:8) 
24/2/7/3 
(67: 6: 19: 8) 
aH vs SLE-NP p<0.05* 
aH vs SLE-P p<0.05* 
Smoking (%) 10 (20) 5 (7.8) 6 (16.7) aNS 
Personal history of CVD (%) 0 0 0 aNS 
Systolic blood pressure/mmHg 
(range) 
ND 122.9 (94-166) 132.3 (108-168) bp=0.0045** 
Diastolic blood 
pressure/mmHg (range) 
ND 76.1 (57-109) 75.1 (55-96) bp=0.651 
Pulse Pressure/mmHg (range) ND 46.8 (25-72) 57.1 (30-81) bp<0.0001*** 
Mean blood pressure/mmHg 
(range) 
ND 91.7 (70-125) 94.1 (77-115) bp=0.288 
Diabetes 0 0 0 NA 
Obesity (BMI>30) 0 0 0 NA 
Statins (%) 0 (0) 6 (9.4) 7 (18.9) bp=0.394 
ACE Inhibitor (%) 0 (0) 23 (35.9) 12 (33.3) bp=0.830 
Aspirin (%) 0 (0) 7 (10.9) 7 (19.4) bp=0.483 
Hydroxychloroquine (%) NA 42 (65.6) 23 (63.8) bp=0.863 
Pred ≥10mg/day (%) NA 9 (14.1) 5 (13.9) bp=0.991 
Pred <10mg/day (%) NA 33 (51.5) 17 (47.2) bp=0.885 
HCQ + disease modifying 
agents (%) 
NA 22 (34.2) 6 (16.7) bp=0.060 
Pred + disease modifying 
agents (%) 
NA 26 (40.6) 13 (36.1) bp=0.707 
Rituximab (%) NA 18 (28.1) 9 (25.0) bP=0.737 
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Global BILAG score at time of 
scan (range) 
NA 4.46 (0 – 17) 3.94 (0 – 32) bp=0.655 
Persistently active (%) NA 26 (40.6) 22 (61.1) bP=0.112 
Median anti-dsDNA antibodies 
(range) 
NA 89.97 (1-688) 109.0 (1-712) bp=0.192 
Median C3 (range) g/L NA 0.99 (0.49-1.42) 1.026 (0.69-1.46) bp=0.643 
 
Table 3.1: SLE patient and healthy donor characteristics: 
 100 SLE patients fulfilling the revised classification criteria for SLE [36] from the University College Hospital London SLE clinic and 
who had not previously suffered a cardiovascular event were scanned to determine the presence of plaque. At the time of the scan 
patients were assessed for smoking, blood pressure, medication and serum concentrations of anti-dsDNA antibodies and complement 
protein C3. Disease activity was assessed using the BILAG index, which distinguishes activity in 9 organs/systems [38]. Patients with 
active SLE disease had a BILAG global score >6. Patients with persistently active disease were identified as having a Global BILAG 
score >5 in at least two consecutive visits from the last four visits. Data expressed as mean except for anti-ds-DNA antibody and C3 
levels. 50 healthy donors were also recruited to the study. Healthy donors were not scanned for plaque but demographic information 
was collected. Data were analysed using either a One-way ANOVAa or Mann Whitney testb for significance using a 95% confidence 
interval. *** and ** denote significant results.  
 
BILAG - British Isles Lupus Assessment Group;  dsDNA – double stranded DNA;  NA – not applicable; ND – not determined; NS – not 
significant; SLE-NP – SLE patients without plaque; SLE-P – SLE patients with plaque; Pred – prednisolone  
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3.3 Characteristics of healthy donors  
 
Healthy donors (who were not scanned) were matched to SLE-NP patients according to 
gender and age. Similar to both SLE-NP and SLE-P patient groups healthy donors had 
not previously suffered a cardiovascular event. A cardiovascular risk factor questionnaire 
was used to assess smoking status, the use of anti-hypertensive medication or statins 
as well as personal and family history of cardiovascular disease (i.e. MI or stroke) 
(Appendix), calculation criteria described in Figure 3.1. SLE-CV patients who had 
suffered a cardiovascular event were not included in the ana 
 
Healthy donors included in the study were more similar to SLE-NP patients in terms of 
the frequency of cardiovascular risk factors reported, suggesting that they were unlikely 
to have plaque (Table 3.1 and Figure 3.1). For SLE-P patients the most reported risk 
factors were age>50, hypertension, current or past smoker and a family history of 
cardiovascular disease. 
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Figure 3.1 Differences in the cardiovascular risk factor profiles of healthy 
controls and SLE patients with and without plaque. 
 
100 patients from the SLE clinic at University College London Hospital underwent 
ultrasound scans to determine the presence of carotid and femoral plaque. Patients were 
given a score, according to the level of thickening at the different sites, with a score >6 
being indicative of the presence of plaque at one or more sites.  (A) Cardiovascular risk 
questionnaire scores from healthy controls (n=50) and SLE patients with (n=28) or 
without plaque (n=34). For each subject, one point was given for each reported risk factor 
including age (over 55), sex (male), ethnicity (African/Caribbean or Asian), statins, anti-
hypertensive medication, smoking (current or past smoker), past cardiovascular event 
and family history of cardiovascular disease. One way ANOVA **p=<0.01, NS - not 
significant; HC – healthy controls; SLE-NP – SLE patients without plaque; SLE-P – SLE 
patients with plaque (B) The most frequently reported risk factors amongst SLE patients 
with plaque (n=28) as analysed by questionnaire.      
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3.4 SLE patients with plaque have increased numbers of iNKT 
cells compared to SLE patients without plaque. 
 
Peripheral blood iNKT cell expression levels were assessed by flow cytometry, according 
to the gating strategy shown in Figure 3.2A. Previous data showing that SLE patients 
had reduced iNKT cell numbers compared to healthy donors was confirmed in SLE 
patients without plaque (SLE-NP) [233], however, this significant reduction was lost in 
SLE patients with plaque (SLE-P) (Figure 3.2B and C).  
 
In order to determine whether the increase in iNKT cells in SLE-P compared to SLE-NP 
patients was attributable to factors other than the presence of plaque, iNKT cell absolute 
numbers were correlated with age, disease duration, systolic blood pressure, patient 
medication and BILAG (disease activity) score. Despite the observation of a significant 
negative correlation between age and iNKT cell frequency in healthy individuals 
(p=0.001), which was in accordance with the literature [489], the discrepancy between 
iNKT-cell frequency in patients with and without plaque was not explained by age (one 
of the major differences between SLE-NP and SLE-P patients) (Figure 3.3A&B). In 
addition, no association was found between iNKT cell frequency and disease duration or 
systolic blood pressure (Figure 3.3B). A similar trend of increased iNKT cell numbers in 
SLE-P patients compared to SLE-NP patients was observed when patients were 
stratified according to patient medication (Figure 3.3C). No significant differences were 
observed between SLE patients with active (BILAG>5) and inactive (BILAG≤5) disease 
when separated into SLE-NP and SLE-P groups (Figure 3.3D).   
 
To investigate whether the increased iNKT cell numbers in SLE-P patients remained 
consistent over time healthy donors, SLE-NP and SLE-P patients were assessed for 
iNKT cell frequency on multiple visits. Despite clearly being variable between individuals, 
iNKT cell frequency remained stable for most individuals in the months following 
ultrasound scans of the patients, with similar observations for healthy donors (Figure 
3.4).  
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Figure 3.2 Increased iNKT cell frequency in SLE patients with plaque.  
PBMC from healthy donors (n=52), SLE-NP (n=30) and SLE-P (n=29) patients were 
assessed for iNKT cell frequency using antibodies to CD3 and invariant T cell receptor 
(iTCR). Gating strategy for iNKT cells (A) showing gating on total PBMCs, followed by 
single cells as determined by forward scatter height and area, then live cells which were 
negative for DAPI. iNKT cell population size was quantified by cells which were positive 
for both CD3 and the iTCR. CD3+iTCR+ populations were gated according to fluorescent 
minus one (FMO) controls. Representative flow cytometry dot plots (B) and cumulative 
data (C) showing iNKT cell frequency (absolute numbers and mean percentage) in 
healthy (n=52), SLE-NP (n=40) and SLE-P (n=34) populations. One-Way ANOVA and 
Tukey’s multiple comparison post-test; **p=<0.001, *p=<0.05, NS=not significant. HC – 
healthy controls; SLE-NP – SLE patients without plaque; SLE-P – SLE patients with 
plaque 
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Figure 3.3 Correlation of iNKT cell numbers with age, disease duration, 
systolic blood pressure, patient medication and disease activity 
PBMC from healthy donors (n=52), SLE-NP (n=30) and SLE-P (n=29) patients were 
assessed for iNKT cell frequency using antibodies to CD3 and iTCR before correlating 
with age. iNKT cells were analysed according to disease duration, systolic blood 
pressure, medication and BILAG score (to measure disease activity) in SLE patients. (A) 
Correlation in healthy donors, SLE-NP and SLE-P patients between iNKT cell absolute 
number and age. (B)  Correlation between iNKT cell absolute number and disease 
duration and systolic blood pressure in SLE-P (n=22-27) and SLE-NP (n=26-37) patients. 
Pearson’s correlation r= -0.391, p=0.001. (C) Graphs showing the influence of patient 
medication on absolute iNKT cell numbers including hydroxychloroquine, prednisolone 
and immunosuppressants. Mean ± SE. Students T test *p=<0.05. (D) Stratification of 
patients according to BILAG score and subsequent analysis of iNKT cell frequency in 
disease active (BILAG>5) and inactive (BILAG≤5) SLE-NP and SLE-P patients Mean, 
Students T test *p=<0.05. SLE-NP – SLE patients without plaque; SLE-P – SLE patients 
with plaque 
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Figure 3.4 Analysis of iNKT cell frequency over time 
iNKT cell frequency was assessed in PBMCs collected at different time points in healthy 
donors or SLE patients after the original scan. Graphs showing longitudinal differences 
in the frequency of iNKT cells in 4 representative healthy doors, SLE patients with plaque 
(SLE-P) and SLE patients without plaque (SLE-NP). Dotted line indicates the mean iNKT 
cell frequency of healthy donors.  
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3.5 iNKT cells from SLE-P patients are characterised by increased 
CD4 expression and a more activated phenotype compared to 
healthy controls   
 
As CD4+ iNKT cells have previously been shown to play a pro-atherogenic role in mouse 
models of atherosclerosis [465], I decided to investigate whether iNKT cell phenotype is 
altered in SLE patients with preclinical plaque. CD4+ and CD8+ iNKT cell populations 
were gated using the distribution of these subsets in CD3+iTCR- T cells. SLE-P patients 
had a distinct phenotype characterised by a switch towards CD4 positivity and a 
significant decrease in double negative (CD4-CD8-) iNKT cells compared to SLE-NP 
patients and healthy donors (Figure 3.5A&B).  
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Figure 3.5 iNKT cells from SLE-P patients show increased CD4 expression 
compared to healthy controls 
Analysis of iNKT cell phenotype was performed using polychromatic flow cytometry in 
healthy (n=13), SLE-NP (n=18) and SLE-P (n=19) populations. CD3, iTCR, CD4 and 
CD8 labelling was used to identify iNKT cell subsets. (A) Representative dot plots and 
(B) cumulative data. One-Way ANOVA and Tukey’s multiple comparison post-test; 
*p=<0.05. HC – healthy controls; SLE-NP – SLE patients without plaque; SLE-P – SLE 
patients with plaque 
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3.6 iNKT cells from SLE-P patients have a distinct phenotype 
compared to healthy individuals and SLE-NP patients  
 
In order to assess whether iNKT cells are differentially activated or are functionally 
altered in SLE patients with preclinical plaque, I investigated the expression of several 
surface markers on iNKT cells by flow cytometry by staining for CD25, CD69, CD161, 
PD-1 and CCR6. Gates were set on healthy donor CD3+iTCR- T cells with reference to 
fluorescence minus one (FMO) controls. Interestingly SLE-P patients had an altered 
phenotype compared to SLE-NP patients. Analysis by mean fluorescence intensity 
revealed a significant reduction in PD-1 expression on iNKT cells from SLE-P patients 
compared to SLE-NP patients. Subsequent quantification of the percentage of iNKT cells 
positive for each marker showed that iNKT cells from SLE-P patients had significantly 
elevated levels of CD69 and reduced expression levels of CD161 (NK marker) and PD-
1 (Programmed cell death protein 1, CD279) compared to SLE-NP patients and healthy 
controls while CD25 and CCR6 expression levels were elevated in iNKT cells from both 
SLE-P and SLE-NP patients compared to healthy donors (Figure 3.6).  
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Figure 3.6 iNKT cells from SLE patients with plaque show differential 
activation marker expression.  
iNKT cell phenotype was examined on PBMCs from healthy donors (n=21), SLE-NP 
(n=29) and SLE-P (n=26) patients, which were stained for CD3, iTCR, CD69, CD25, PD-
1, CCR6 and CD161. Representative histograms and cumulative data for MFI (mean 
fluorescence intensity) and percentage positive expression of CD69, CD25, PD-1, CCR6 
and CD161 in iNKT cells are shown. One-Way ANOVA and Tukey’s multiple comparison 
post-test; ***p=0.0001; **p=<0.001, *p=<0.05***. FMO= fluorescence minus one control. 
HC – healthy controls; SLE-NP – SLE patients without plaque; SLE-P – SLE patients 
with plaque 
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3.7 The iNKT cell phenotype observed in SLE-P patients is not 
observed in conventional CD4+ and CD8+ T cells, and is not 
explained by differences in expression within CD4 and CD8 iNKT 
cell populations 
 
In order to investigate whether the phenotype observed in plaque positive iNKT cells was 
specific to iNKT cells, I investigated the expression of the same surface markers (CD25, 
CD69, CD161, PD-1 and CCR6) in iTCR- CD4+ and CD8+ T cells. Importantly many of 
the surface markers were expressed at much lower levels in CD4+ and CD8+ T cells 
compared to iNKT cells indicating that they were of lesser importance in conventional T 
cell subsets. Comparison of healthy and patient groups by one-way ANOVA showed that 
the iNKT cell phenotype observed in figure 3.6 was unique and not recapitulated in 
conventional CD3+CD4+ or CD3+CD8+ cells (Figure 3.7). However, increased expression 
of CD25 and PD-1 and CCR6 in CD4+ conventional T cells from SLE-P patients indicated 
that conventional T cells as well as iNKT cells were more activated in patients with 
preclinical plaque.  
Investigation of CD4+ and CD8+ iNKT cells showed no differences in surface marker 
expression (CD25, CD69, CD161, PD-1 and CCR6) between SLE-NP and SLE-P 
patients when ANOVA was performed (Figure 3.8). Interestingly however, some 
differences were observed between iNKT cells from healthy donors and SLE patients. 
This was particularly evident for CCR6 expression which was significantly elevated in 
SLE-P compared to healthy donors within all CD4 and CD8 populations analysed. Other 
differences were mainly confined to the CD4+ iNKT cells, and included an increase in 
expression of the activation markers CD25 and CD69. The differences in CD161 
expression observed in Figure 3.6 could in part be explained by the CD8+ iNKT cells 
where CD161 levels were significantly lower in the SLE-P patients compared to healthy 
donors. 
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Figure 3.7 Activation marker expression is unaltered on conventional T 
cells from SLE patients with plaque  
CD4+ and CD8+ T cell phenotype was examined on PBMCs from healthy donors (n=21), 
SLE-NP (n=29) and SLE-P (n=26) patients, which were stained for CD3, iTCR, CD69, 
CD25, PD-1, CCR6 and CD161. Cumulative data showing the percentage of cells 
positive for CD69, CD25, PD-1, CCR6 and CD161 on CD3+iTCR- CD4+ and CD8+ T cells 
are shown. One-Way ANOVA and Tukey’s multiple comparison post-test; *p=<0.05. HC 
– healthy controls; SLE-NP – SLE patients without plaque; SLE-P – SLE patients with 
plaque 
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Figure 3.8 Expression of surface markers within CD4+ and CD8+ iNKT cell 
subsets show no difference between SLE-NP and SLE-P patients  
Surface marker expression was examined on CD4+ and CD8+ iNKT cell subsets from 
healthy donors (n=21), SLE-NP (n=29) and SLE-P (n=26) patients, which were stained 
for CD3, iTCR, CD4, CD8, CD69, CD25, PD-1, CCR6 and CD161. Cumulative data 
showing the percentage of cells positive for CD69, CD25, PD-1, CCR6 and CD161 on 
CD4-CD8- CD4+CD8- and CD4-CD8+ iNKT cells. One-Way ANOVA and Tukey’s multiple 
comparison post-test; *p=<0.05. HC – healthy controls; SLE-NP – SLE patients without 
plaque; SLE-P – SLE patients with plaque 
Gated on CD3+iTCR+ cells
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3.8 Low CD161 expression on iNKT cells from SLE patients with 
preclinical plaque is associated with decreased iNKT cell 
activation marker expression  
 
CD161 expression is associated with a number of T cell and NK cell functions, most 
notably activation [222, 490-492], however its role in iNKT cell populations remains 
uncertain. I questioned whether decreased expression of CD161 in SLE-P patients was 
associated with decreased expression of activation markers CD25, CD69 and PD-1. I 
therefore performed correlations between CD161 and other activation markers in healthy 
individuals, SLE-NP and SLE-P patients (Figure 3.9). Positive correlations were 
observed between CD161 and PD-1, CD69 and CD25 in SLE-P patients, which were 
found to be significant, suggesting an association between low CD161 expression on 
iNKT cells from SLE-P patients and reduced iNKT cell activation. 
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Figure 3.9 CD161 expression is positively correlated with activated 
increased iNKT cell activation marker expression in SLE-P patients.  
PBMCs were assessed for iNKT cell phenotype as described in Figure 3.2-5. Correlation 
plots relating iNKT cell expression of CD161 with expression of activation markers CD69, 
PD-1 and CD25 on iNKT cells from healthy donors (n=20), SLE-NP (n=30) and SLE-P 
(n=27) patients. Pearson’s correlation significant only in SLE-P patients; CD69 *p=0.038, 
r=0.478; PD-1: *p=0.002, r=0.603; CD25 *p=0.01, r=0.587. SLE-NP – SLE patients 
without plaque; SLE-P – SLE patients with plaque 
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3.9 iNKT cells from SLE-P patients show increased proliferative 
capacity compared to SLE-NP patients 
 
I questioned whether the increase in iNKT cell frequency and altered activation marker 
expression observed in SLE-P patients compared to SLE-NP patients could be 
associated with functional differences in iNKT cells such as proliferation.  To test this, 
PBMCs from healthy donors, SLE-NP and SLE-P patients were stimulated for 7ds with 
100ng/ml α-GalCer (a potent iNKT cell agonist) and 400IU/ml IL-2. At d7 cells were 
stained for CD3 and the iTCR as well as Ki67 (a marker of cell proliferation) and 
costimulatory molecules ICOS and CD40L. Cells were also stained for CD4, CD25 and 
CD127 to identify Tregs.  
 
iNKT cells from healthy donors and SLE-P patients showed increased proliferation as 
measured by Ki67 expression compared to SLE-NP patients (Figure 3.10A-C) in 
response to 7 day α-GalCer/IL-2 stimulation. Similar trends were observed when both 
the MFI of Ki67 expression (Figure 3.10A) and the percentage of Ki67 positive cells 
(Figure 3.10B) were analysed, although whether there was an increase in proliferation in 
healthy and SLE-P iNKT cells at day 7 compared to day 0 or whether it simply remained 
stable is to be determined. Furthermore, at day 7 the significant decrease in Ki67 in SLE-
NP iNKT cells compared to SLE-P iNKT cells was associated with proliferative 
responsiveness, which was found to be low in SLE-NP patients as has previously been 
reported [233] (Figure 3.10D&E). Analysis of co-stimulatory molecules revealed that 
ICOS expression on iNKT cells was increased in SLE-P compared to SLE-NP patients, 
but this wasn’t the case for CD40L (Figure 3.10F). No difference was observed in Tregs 
between SLE-NP and SLE-P patients suggesting that differences in Treg frequency were 
not responsible for the increased iNKT cell expansion observed in SLE-P patients (Figure 
3.10G). 
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Figure 3.10 iNKT cells from SLE-P patients but not SLE-NP patients 
undergo proliferation in response to α-GalCer stimulation 
PBMC from 5 HC, 7 SLE-NP and 7 SLE-P patients were cultured for 7ds with α-GalCer 
and IL-2 and assessed for the surface expression of CD3, iTCR and intracellularly for Ki-
67 to detect iNKT cell proliferation. iNKT cells were also stained for costimulatory 
molecules ICOS and CD40L, with a separate panel for CD4, CD25 and CD127 to identify 
CD4+CD25+CD127- Tregs. Cumulative data showing (A) mean fluorescence intensity 
(MFI) of Ki67 and (B) percentage of Ki67+ iNKT cells at d0 and 7d culture. (C) 
Representative plots are shown for day 7. Paired T test; *p=<0.05. (D) iNKT cell Ki67 
expression mean fluorescence intensity (MFI) at d7. Mean ± SE. One-way ANOVA and 
Tukey’s multiple comparison post-test; *p=<0.05. (E) Fold change in iNKT cell 
expression levels at d7 compared to d0. Mean ± SE. One-way ANOVA and Tukey’s 
multiple comparison post-test; *p=<0.05. (F) Percentage of cells positive for ICOS and 
CD40L expression at d7. (G) Percentage of CD4+CD25+CD127- Tregs at d7. Students 
T test *p=<0.05. HC – healthy controls; SLE-NP – SLE patients without plaque; SLE-P – 
SLE patients with plaque  
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3.10 iNKT cells from SLE-P patients show increased IL-4 
production compared to SLE-NP patients  
 
Intracellular cytokine staining was carried out to assess iNKT cell function in SLE-P 
patients compared to SLE-NP patients and healthy controls. Whilst little change in IFN-
γ was observed between patient groups, IL-4 was significantly elevated in iNKT cells 
from SLE-P patients compared to both SLE-NP patients and healthy donors (Figure 
3.11A). Similarly IL-10 was increased in iNKT cells from SLE-P (but not SLE-NP patients) 
compared to healthy controls (Figure 3.11B), suggesting an immune-regulatory or Th2 
cytokine profile. Further analysis of IFN-γ: IL-4 ratio showed that SLE-P patients were 
skewed towards an IL-4 response (Figure 3.11C). 
 
To determine whether the increased IL-4 production by iNKT cells from SLE-P patients 
was associated with a Th2 phenotype, PBMC were stained intracellularly for Th1-
associated transcription factor T-Bet and the Th2-associated transcription factor GATA-
3. Analysis according to percentage positive expression showed increased expression 
of GATA-3 compared to T-Bet in SLE-P patients (Figure 3.12). This indicated that iNKT 
cells from SLE-P patients had a Th2-like phenotype and supported the previous 
observation of increased IL-4 expression in iNKT cells from these patients (Figure 3.11). 
 
Due to my earlier finding of an increase in CD4+ iNKT cells in SLE-P patients, I 
questioned whether CD4+ iNKT cells were responsible for the Th2 cytokine profile 
observed in SLE-P patients. Comparison of CD4+ iNKT cells from SLE-NP and SLE-P 
patients revealed that CD4+ iNKT cells from SLE-P patients produced more IL-4 (but not 
IFN- γ and IL-10) compared to CD4+ iNKT cells from SLE-NP patients (Figure 3.13A).  
 
To assess whether CD4+ or CD8+ iNKT cells were responsible for the Th2 cytokine profile 
observed in SLE-P patients, expression of intracellular cytokines IFN-γ, IL-4 and IL-10 
were analysed in CD4+ and CD8+ subpopulations of iNKT cells. Data showed that whilst 
CD4+ iNKT cells were responsible for IFN-γ and IL-10 production, both CD4+ and CD8+ 
subsets are responsible for IL-4 production in SLE-P patients (Figure 3.13B). 
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Figure 3.11 SLE-P iNKT cells produce more IL-4 compared to SLE-NP and 
healthy donors  
Ex vivo PBMC from 21 SLE-NP and 21 SLE-P patients were cultured for 4 hours with 
PMA, ionomycin and Golgi plug then surface stained for CD3, iTCR and intracellularly 
for IFN-γ, IL-4 and IL-10 expression. (A) Cumulative data showing number (%) of iNKT 
cells positive for intracellular IFN-γ, IL-4 and IL-10 in healthy, SLE-NP and SLE-P 
patients. One-way ANOVA and Tukey’s multiple comparisons post-test. *p=<0.05; 
**p=<0.001. Representative dot plots showing number (%) of iNKT cells positive for 
intracellular (B) IL-4 and (C) IL-10 in healthy, SLE-NP and SLE-P patients gated 
according to FMO controls. (C) Ratio of iNKT cells producing IFN-γ compared to IL-4. 
Mean ± SE. One-way ANOVA and Tukey’s multiple comparison post-test; *p=<0.05; 
**p=<0.001. HC – healthy controls; SLE-NP – SLE patients without plaque; SLE-P – SLE 
patients with plaque; FMO – fluorescence minus one control. 
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Figure 3.12 SLE-P patients have a decreased T-bet: GATA-3 ratio 
PBMCs from 5 healthy donors, 5 SLE-P and 5 SLE-NP patients were surface stained 
with antibodies against CD3, iTCR and intracellularly with either T-Bet or GATA-3. (A) 
Representative histograms illustrating the differences in T-bet and GATA-3 expression 
between SLE-NP and SLE-P patients. Cumulative data showing (B) Intracellular 
expression of T-bet and GATA-3 in healthy, SLE-NP and SLE-P patients. Mean ± SE. 
One-way ANOVA and Tukey’s multiple comparison post-test; ***p<0.001. (C) T-bet: 
GATA-3 ratio. Mean ±SE, Students T test *p=<0.05. FMO – fluorescence minus one 
control; HC – healthy controls; SLE-NP – SLE patients without plaque; SLE-P – SLE 
patients with plaque 
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Figure 3.13 Expression of intracellular cytokines in CD4+ and CD8+ iNKT 
cells in SLE-P patients 
Ex vivo PBMC from 22 SLE-NP and 21 SLE-P patients were cultured for 4 hours with 
PMA, ionomycin and Golgi plug then surface stained for CD3, iTCR, CD4, CD8 and 
intracellularly for IFN-γ, IL-4 and IL-10 expression. (A) Graphs showing percentage (%) 
of CD4+ iNKT cells positive for intracellular IFN-γ, IL-4 or IL-10. (B) Comparison of CD4+ 
and CD8+ iNKT cells from SLE-P patients according to percentage positive expression 
of intracellular IFN-γ, IL-4 and IL-10. Mean ± SE. Students T test *p=<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IFN-γ
C
D
4+
C
D
8+
0
25
50
75
100
IL-4
C
D
4+
C
D
8+
IL-10
C
D
4+
C
D
8+
* *
0
25
50
75
100
0
25
50
75
100
IL
-4
+
 i
N
K
T
 c
e
lls
 (
%
)
IL
-1
0
+
 i
N
K
T
 c
e
lls
 (
%
)
IF
N
-γ
+
 i
N
K
T
 c
e
lls
 (
%
)
B
SL
E-
N
P
S
LE
-P
0
25
50
75
100
S
LE
-N
P
S
LE
-P
0
25
50
75
100
S
LE
-N
P
S
LE
-P
0
25
50
75
100
*
IFN-γ IL-4 IL-10
IF
N
-γ
+
 C
D
4
+
 i
N
K
T
 c
e
lls
 (
%
)
IL
-4
+
 C
D
4
+
 i
N
K
T
 c
e
lls
 (
%
)
IL
-1
0
+
 C
D
4
+
 i
N
K
T
 c
e
lls
 (
%
)
A
161 
 
3.11 SLE patients who have suffered a cardiovascular event are 
characterised by decreased iNKT cells and decreased intracellular 
IFN- γ and IL-4 expression compared to SLE-P patients     
 
The finding that iNKT cells from SLE-P patients were characterised by IL-4 phenotype 
led me to hypothesise that iNKT cells could be playing a protective role in the early or 
preclinical stages of atherosclerosis in SLE patients. To investigate whether iNKT cell 
phenotype was altered in the later stages of atherosclerosis, I divided SLE patients 
according to the number of sites with plaque as determined by ultrasound scan. In 
addition, I examined a group of SLE patients who had been identified as having 
previously suffered a cardiovascular event (SLE-CV) (Table 3.2). iNKT cell phenotyping 
was carried out on all patients as before to assess iNKT cell frequency, absolute iNKT 
cell number, CD4, CD8 and CD69 expression and the intracellular cytokines IFN-γ, and 
IL-4. 
  
Stratification according to the number of sites with plaque revealed that SLE patients 
with 3 or 4 plaque sites had significantly fewer iNKT cells compared to patients with 1 or 
2 plaque sites, suggesting that the increase in iNKT cells in SLE patients was associated 
with early plaque development only. Analysis of SLE-CV patients confirmed this 
hypothesis as indicated by the significant reduction in iNKT cells compared to patients 
with 1-2 sites with plaque (Figure 3.14A&B). Interestingly iNKT cells from SLE-CV 
patients also had a reduction in CD69 as well as increases in CD8+CD4- iNKT cells 
suggesting differences in iNKT cell activation in SLE-CV patients (Figure 3.14C-E). 
Interestingy however, no differences were observed in CD4+CD8- iNKT cells when 
analysed according to plaque sites, suggesting that CD4+ iNKT cells remain similar at 
different stages of atherosclerosis (Figure 3.14E). 
 
Furthermore, the finding that iNKT cells from SLE-CV patients expressed significantly 
lower intracellular IL-4 compared to patients with 1-2 sites with plaque, suggested that 
the Th2 response in SLE-P patients was associated with pre-clinical plaque and not more 
advanced lesions (Figure 3.15A&B). A reduction in IFN-γ+ iNKT cells in SLE-CV patients 
may suggest that iNKT cells in the peripheral blood of these patients have already been 
activated and are no longer efficient at producing cytokines (Figure 3.15A&B). 
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When absolute iNKT cell numbers were calculated using patients’ lymphocyte counts 
was there a significant increase in iNKT cells between SLE-NP and SLE-P patients. 
Furthermore, iNKT cell frequency was significantly inversely correlated with Grey Scale 
Median (GSM) (Figure 3.16, and methods section for description of GSM measurement), 
which is quantified according to plaque echogenicity and has been shown to relate to 
plaque stability, whereby low GSM values are indicative of a propensity to rupture [493]. 
No relationship however was found with other plaque measures (plaque thickness and 
total plaque area). Thus patients with more echolucent (unstable and lipid rich) plaque 
formation had increased iNKT cell frequency suggesting increased iNKT cell activation 
[241].  
 
I questioned whether IL-4 production by iNKT cells was associated with different types 
of plaque in SLE-P patients.  Grey scale median (GSM), plaque thickness and plaque 
area were each correlated with the percentage of iNKT cells positive for intracellular IL-
4 staining. Interestingly, a significant positive correlation (p<0.05) was observed for 
GSM, whilst trends towards a negative association between iNKT cell IL-4 and plaque 
area and thickness were observed (Figure 3.16A and C). 
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  SLE-CV 
patients 
(n=11) 
Mean Age (range) 50 (20-78) 
Years since SLE diagnosis  (range) 18 (1-34) 
Sex: female: male (%)  9: 2 (82/18) 
Ethicity: C/A/AC/O (%) 8/1/1/1 
(73/9/9/9) 
Smoking (%) 1 (9.09) 
Statins (%) 3 (27.27) 
Anti-hypertensives (%) 6 (54.54) 
Aspirin (%) 1 (9.09) 
Hydroxychloroquine (%) 5 (45.45) 
Pred ≥10mg/day (%) 1 (9.09) 
Pred <10mg/day (%) 7 (63.63) 
HCQ + disease modifying agents (%) 3 (27.27) 
Pred + disease modifying agents (%) 7 (63.63) 
Rituximab (%) 0 (0) 
Global BILAG score (range) 4.17 (0-10) 
Mean Total Cholesterol mmol/L (range) NR<5.2 4.50 (3.6-5.2) 
Mean Triglycerides mmol/L (range) NR<2.2 1.56 (0.4-2.6) 
Mean HDL mmol/L (range) NR >1.0 1.43 (0.7-2.1) 
Mean LDL mmol/L (range) NR <2.0 2.37 (1.7-3.1) 
Cholesterol: HDL ratio (range) NR <3.5 3.43 (2.4-5.1) 
  
 
Table 3.2 SLE cardiovascular event (SLE-CV) patient clinical 
characteristics 
SLE patients who had previously suffered a cardiovascular event were identified from a 
cohort of over 500 SLE patients at the University College Hospital London SLE clinic 
who fulfilled the revised classification criteria for SLE [36]. Patients donated blood at the 
time of the visit where they were assessed for smoking, medication, serum lipids and 
disease activity, which was measured by British Isles Lupus Assessment Group index 
(BILAG) score, which accounts for disease activity in 9 organs/systems. Patients with 
active SLE disease have a BILAG global score >6. Unlike SLE-NP and SLE-P patients, 
SLE-CV patients were not scanned for plaque.   
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Figure 3.14 SLE patients who have suffered a cardiovascular event have a 
different iNKT cell phenotype compared to SLE-NP and SLE-P patients  
Ex vivo PBMC from 46 SLE-NP, 27 SLE-P patients (stratified according to plaque sites) 
and 11 SLE-CV patients who had previously suffered a cardiovascular event were 
surface stained for CD3, iTCR, CD4, CD8 and CD69 expression. (A) Representative dot 
plots and (B) cumulative data showing iNKT cell frequency and absolute number in SLE 
patients with 0, 1-2 and 3-4 sites with plaque and SLE-CV patients. (C) Representative 
histograms and (D) cumulative data showing percentage of iNKT cells positive of CD69 
in SLE patients with 0, 1-2 and 3-4 sites with plaque and SLE-CV patients. (E) Frequency 
of CD4-CD8-, CD4+CD8- and CD8+CD4- iNKT cells in SLE patients with 0, 1-2 and 3-4 
plaque sites and SLE-CV patients. Mean± SE, One way ANOVA and Tukey’s multiple 
comparisons post-test.  **p<0.01, *p<0.05 HC – healthy controls; SLE-NP – SLE patients 
without plaque; SLE-P – SLE patients with plaque 
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Figure 3.15 SLE patients who have suffered a cardiovascular event have a 
different iNKT cell cytokine profile compared to SLE-NP and SLE-P 
patients  
Ex vivo PBMC from 46 SLE-NP, 27 SLE-P patients (stratified according to plaque sites) 
and 11 SLE-CV patients who had previously suffered a cardiovascular event were 
cultured for 4 hours with PMA, ionomycin and Golgi plug then surface stained for CD3 
and iTCR, then stained intracellularly for IFN-γ and IL-4 expression. (A) Representative 
dot plots and (B) cumulative data showing intracellular IFN-γ and IL-4 expression in the 
different patient groups. Mean± SE, One way ANOVA and Tukey’s multiple comparisons 
post-test. **p<0.01, *p<0.05 HC – healthy controls; SLE-NP – SLE patients without 
plaque; SLE-P – SLE patients with plaque 
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Figure 3.16 Correlations between different plaque measures and iNKT cell 
frequency or IL-4+ iNKT cells 
Ex vivo PBMC from 25 SLE-P patients were cultured for 4 hours with PMA, ionomycin 
and Golgi plug then surface stained for CD3 and iTCR, then intracellularly for IL-4. 
Patients were stratified according to the number of sites with plaque: 1-2 (n=15) or 3-4 
(n=10). Correlations of (A) iNKT cell numbers and (B) intracellular IL-4 with grey scale 
median (GSM), total plaque area and plaque thickness. Linear regression was carried 
out to assess correlation strength. (C) Pearson’s correlation coefficient (r) and p-value 
of correlations between GSM and iNKT cell absolute number or intracellular IL-4. 
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CHAPTER IV: 
Results 2 
 
  
168 
 
Results 2 – The role of serum lipids in SLE patients with 
atherosclerosis 
 
4.1 Introduction and aims for this chapter 
 
Previous studies have demonstrated that SLE patients are characterized by altered lipid 
metabolism, although whether patients are dyslipidaemic is a contentious issue. 
Evidence suggests that the presence of dyslipidemia in SLE patients ranges from 36% 
at diagnosis to 60% after 3 years, although this can vary by definition and may depend 
on patients’ disease activity [114]. Whilst not all patients fulfill the criteria for 
dyslipidaemia there is evidence to suggest that serum lipids are altered in SLE patients, 
which are characterised by increased VLDL and triglycerides and decreased HDL 
compared to healthy donors [127]. Since iNKT cells are activated by lipid presentation, I 
decided to explore the role of serum lipids in SLE patients with and without plaque.  
 
Dyslipidaemia has previously been associated with significantly decreased numbers of 
iNKT cells in a study by Nakou et al. who showed that treatment with simvastatin lead to 
an increase in iNKT cells in these patients in addition to a normalised lipid profile [494]. 
Furthermore, animal models have shown that dyslipidaemia is associated with increased 
iNKT cell anergy characterised by reduced iNKT cell responsiveness to α-GalCer and a 
reduction in both IFN-γ and IL-4  [495]. However, the role of serum lipids in SLE and how 
they may influence iNKT cell function remains largely unknown.  
 
I therefore hypothesised that altered serum lipids could be contributing to defective iNKT 
cell responses in SLE patients as well as the distinct iNKT cell phenotype observed in 
SLE patients with preclinical plaque. In addition to measuring serum lipids at the time of 
the scan using the standard methods at UCLH, metabolomics analysis was carried out 
to investigate the serum lipid profile in more detail. I correlated my results with the iNKT 
cell phenotyping data from Chapter 3, and cultured healthy PBMCs with patient serum 
in an attempt to recapitulate the iNKT cell phenotypes observed in SLE-NP and SLE-P 
patients.   
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4.2 SLE-NP and SLE-P patients show minimal differences in 
traditional measures of serum lipids and other biomarkers 
 
I first decided to investigate differences in lipids and other biomarkers of inflammation by 
comparing the clinical measures from SLE-NP and SLE-P patient serum, taken at UCLH 
at the time of the scan.  Mean levels of total cholesterol, triglycerides, LDL and HDL 
(including cholesterol: HDL ratio) as well as C-reactive protein, vitamin D and 
homocysteine were within the normal clinical ranges used by UCLH to monitor patients’ 
lipids (Table 4.1). Furthermore, out of total cholesterol, triglycerides, HDL, LDL and 
Cholesterol: HDL ratio, only 9.4% of SLE-NP and 33.3% of SLE-P patients had 3 or more 
lipid measures outside of normal range with only 9.4% of SLE-NP and 18.9% of SLE-P 
patients being prescribed statins at the time of the scan (Table 3.1). Both groups of 
patients in this study would therefore not typically be classified as dyslipidemic since 
mean levels of cholesterol, HDL, LDL and triglycerides are far lower compared to studies 
involving patients with hypercholesterolemia [496-498]. Whilst lipid abnormalities were 
more common in SLE-P patients, analysis of the two groups of patients by student’s t 
tests found very few differences between SLE-NP and SLE-P patients groups in serum 
lipid measurements. Only triglyceride levels and total cholesterol: HDL ratios were 
significantly elevated in SLE-P patients compared to those without plaque (Table 4.1).  
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Table 4.1: SLE patient serum lipids and biomarkers  
 SLE–NP (n=64) SLE–P (n=36) P value 
Mean CRP mg/dL (range)  
NR <5 
6 (0.6-7.7) 3.44 (0-15.5) p=0.261 
Mean Homocysteine μmol/L (range)  
NR 6-15 
13.98 (9-17.5) 16.92 (9-38) p=0.055 
Mean Creatinine μmol/L (range)  
NR 53-115 
71.28 (42-227) 55.79 (40-184)  p=0.311 
Mean Vitamin D nmol/L (range)  
NR 25-137 
63.06 (14-228) 55.79 (7-114) p=0.619 
Mean Total Cholesterol mmol/L (range)  
NR<5.2 
4.67 (2.5 – 7.3) 5.04 (2.9 – 6.5) p=0.067 
Mean Triglycerides mmol/L (range)  
NR<2.2 
1.01 (0.4 – 2.3) 1.31 (0.6 – 2.8) p=0.002a  
Mean HDL mmol/L (range)  
NR >1.0 
1.71 (0.8 – 2.7) 1.60 (0.8 – 3.0) p=0.289 
Mean LDL mmol/L (range)  
NR <2.0 
2.49 (0.8 – 4.8) 2.84 (1.2 – 4.2) p=0.084 
Cholesterol: HDL ratio (range)  
NR <3.5 
2.87 (1.6 – 5.2)  3.38 (1.8 – 5.6) p=0.008a 
 
Table 4.1 SLE patient serum lipids and biomarkers  
Patient blood samples from the time of the scan were assessed for a range of 
biomarkers including C reactive protein (CRP), homocysteine, creatinine, vitamin D and 
serum lipids.  For creatinine, only 11 patients (5/64 SLE-NP and 6/36 SLE-P) had 
creatinine levels outside the normal range for UCLH. Data were analysed by a two-
tailed T test for significance using a 95% confidence interval. a denotes significant 
results. SLE-P – SLE patients with plaque; SLE-NP – SLE patients without plaque. NR 
– normal range. 
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4.3 SLE patients have altered serum metabolites compared to 
healthy individuals 
 
To better characterise differences in serum lipids and other biomarkers in SLE patients 
compared to healthy donors proton nuclear magnetic resonance spectroscopy was 
carried out on serum [499]. This enabled the characterisation of 233 metabolic variables 
including the size, density and composition of lipoprotein classes as well as other 
information on the types of lipids and amino acids present. Data were analysed by 
multiple student’s t tests and threshold for significance was adjusted using a Bonferroni 
correction. The most significant differences were observed for measures of very low 
density lipoprotein (VLDL), small high density lipoprotein (S-HDL), glutamine and acetate 
(Figure 4.1A). In particular, differences in lipoprotein content was observed whereby the 
total cholesterol content of medium and large VLDL and small HDL was increased in 
SLE patients compared to healthy controls (Figure 4.2B and C). 
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Figure 4.1 SLE patients are characterised by altered serum metabolites 
compared to healthy donors 
Serum from 10 healthy donors and 86 SLE patients was analysed by proton nuclear 
magnetic resonance spectroscopy to characterize serum lipids and metabolites. Results 
from healthy individuals and SLE patients were compared using unpaired students t tests 
and carrying out a logarithmic transformation of the p values to facilitate graphical 
presentation. (A) Histogram showing the metabolites most significantly different between 
the two groups, including a Bonferroni correction (y=3.66) to account for the number of 
comparisons. (B) Heat map depicting most significant comparisons in terms of VLDL, 
IDL, LDL and HDL particle size and composition, with higher log-10 p values (red colour) 
representing greater differences between metabolites in healthy donors compared to 
SLE patients. (C) Comparison of lipoprotein concentration between healthy individuals 
and SLE patients including VLDL, IDL, LDL and HDL as well as acetate and glutamine, 
which were also significantly altered. Student’s t test: *p<0.05, ** p<0.01, ***p<0.001. 
VLDL; very large density lipoprotein, IDL; intermediate density lipoprotein, LDL; low 
density lipoprotein, HDL; high density lipoprotein. 
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4.4 SLE patients with preclinical plaque have an altered serum 
metabolite profile compared to SLE patients without plaque 
 
Data from SLE patients were also analysed to identify differences between SLE-NP and 
SLE-P patients by carrying out multiple student’s t tests and using a Bonferroni correction 
to calculate the level for significance. Whilst none of the metabolites reached significance 
according to the Bonferroni correction, several differences were observed between SLE-
NP and SLE-P patients with a significance of p<0.05 (Figure 4.2A, 4.3A and Table 4.2). 
Analysis of lipoprotein groups showed that most of the differences were in VLDL, in 
particular the free cholesterol and phospholipid content of VLDL (Figure 4.2B). 
Furthermore SLE-P had consistently higher concentrations of all forms of VLDL 
compared to SLE-NP patients, which was not observed for other lipoprotein classes 
including IDL, LDL and HDL particles (Figure 4.3B).  
 
Since triglycerides were previously identified as being increased in SLE-P patients 
compared to SLE-NP patients, I correlated patients’ clinical measures of triglycerides 
with the metabolites which were identified as most significant between SLE-NP and 
SLE-P patients (Figure 4.4). However, only triglyceride: phosphoglyceride ratio and 
glycoprotein aceytls were identified as being significantly correlated with triglycerides. 
This suggests that the level of triglycerides is not associated with differences in VLDL 
concentration and composition, suggesting that they should be regarded as 
independent measures.  
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Table 4.2 Serum metabolomics analysis in SLE patients with and without 
plaque  
Serum samples taken at the time of femoral and carotid ultrasound scan from 33 SLE 
patients with carotid or femoral plaque (SLE-P) and 53 patients with no plaque (SLE-NP) 
were assessed for lipid distribution in lipoprotein subclasses by proton nuclear magnetic 
resonance (NMR) spectroscopy. Proportions of total serum cholesterol, phospholipids 
and triglycerides carried by each lipoprotein subclass were determined [499]. Table lists 
the markers showing significant differences between SLE patients with and without 
plaque using Students T test a 95% confidence interval (no significance was seen using 
the Bonferoni correction). HDL, high density lipoprotein; LDL, low density lipoprotein; IDL 
intermediate density lipoprotein; VLDL, very low density lipoprotein; SLE-P, SLE patients 
with plaque; SLE-NP, SLE patients without plaque.  
 
 
 
Metabolite 
 
 
SLE-NP mean 
(range) 
 
SLE-P mean 
(range) 
p value 
Free cholesterol to total lipids ratio in medium VLDL  10.89 
(7.61-13.38) 
11.61 
(9.18-13.67) 
0.00113 
Glycine 0.297 (0.196-0.438) 0.265 (0.198-0.347) 0.0027 
Free cholesterol to total lipids ratio in large VLDL  9.82 
(1.54-15.98) 
12.01 
(2.72-17.58) 
0.00231 
Phospholipids to total lipids ratio in chylomicrons and 
extremely large VLDL  
9.31 
(2.96-12.12) 
10.87 
(6.48-22.33) 
0.00403 
Triglycerides to total lipids ratio in very small VLDL  17.37 
(7.75-25.29) 
19.44 
(12.96-29.48) 
0.0103 
Mean diameter for LDL particles 24.06 
(23.55-25.13) 
23.89 
(23.47-24.46) 
0.0129 
Ratio of omega-6 fatty acids to total fatty acids 33.65 
(26.17-41.2) 
32.15 
(26.49-38.67) 
0.0162 
Triglycerides to total lipids ratio in IDL  17.37 
(5.22-18.73) 
12.24 
(7.61-24.59) 
0.0165 
Ratio of triglycerides to phosphoglycerides 0.51 
(0.25-1.21) 
0.61 
(0.32-1.27) 
0.0183 
Ratio of 22:6 docosahexaenoic acid to total fatty acids 1.24 
(0.54-1.97) 
1.42 
(0.49-2.54) 
0.0217 
Glycoprotein acetyls (mainly a1-acid glycoprotein) 0.074 (0.039-0.1332) 1.52 
(1.09-2.43) 
0.029 
Ratio of monounsaturated fatty acids to total fatty 
acids 
22.9 
(17.92-30.05) 
24.2 
(17.9-29.3) 
0.0307 
Triglycerides to total lipids ratio in large LDL  9.54 
(5.18-19.92) 
11.23 
(7.25-26.01) 
0.0317 
Cholesterol esters to total lipids ratio in IDL 46.66 
(38.18-62.11) 
44.54 
(21.71-49.66) 
0.0338 
Cholesterol esters to total lipids ratio in very small 
VLDL 
43.6 
(33.5-61.0) 
41.4 
(21.5-51.7) 
0.0358 
Citrate 1.42 
(1.02-2.01) 
0.05 (0.036-0.103) 0.045 
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Figure 4.2 SLE-P patients are characterised by altered serum metabolites 
compared to SLE-NP patients  
 
Serum from 30 SLE-P and 56 SLE-NP patients were analysed by proton nuclear 
magnetic resonance spectroscopy for 233 serum lipid metabolites. Results were 
compared using unpaired Students T tests and carrying out a logarithmic transformation 
of the p values for plotting. (A) Histogram showing the most significant metabolites 
between the two patient groups, including a Bonferroni correction (y=3.66) to account for 
the number of comparisons. (B) Heat map depicting most significant comparisons in 
terms of VLDL, IDL, LDL and HDL particle size and composition, with higher log-10 p 
values (red colour) representing greater differences between metabolites in SLE-NP 
compared to SLE-P patients.  
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Figure 4.3: Serum metabolomics analysis in SLE patients with and without 
plaque.  
Serum samples taken at the time of femoral and carotid ultrasound scan from 36 SLE 
patients with carotid or femoral plaque (SLE-P) and 64 patients with no plaque (SLE-
NP) were assessed by proton nuclear magnetic resonance spectroscopy for 332 serum 
lipid metabolites. (A) Box and whisker plot showing the markers with significant 
differences between SLE patients with and without plaque using multiple Students T 
tests, a 95% confidence interval (no significance was seen using the Bonferoni 
correction). (B) Proportions of total serum cholesterol, phospholipids and triglycerides 
carried by each lipoprotein subclass were determined [499] HDL, high density 
lipoprotein; LDL, low density lipoprotein; IDL intermediate density lipoprotein; VLDL, 
very low density lipoprotein; SLE-P, SLE patients with plaque; SLE-NP, SLE patients 
without plaque. TG, triglycerides; FA, fatty acid; PL, phospholipid; CE, cholesterol 
esters; FC, free cholesterol; MUFA, monounsaturated FA. Mann Whitney test, 
*p=<0.05, **p=<0.001. 
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Figure 4.4: Triglycerides are positively associated with phosphoglycerides 
and glycoprotein acetyls in SLE-P patients   
Serum samples taken at the time of femoral and carotid ultrasound scan from 36 SLE 
patients with carotid or femoral plaque (SLE-P) and 64 patients with no plaque (SLE-
NP) were assessed by proton nuclear magnetic resonance spectroscopy for 332 serum 
lipid metabolites. Significant metabolites were correlated against SLE-P patient serum 
metabolites and linear regression was carried out to determine any relationship. 
***p<0.001, ** p<0.01 
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4.5 The iNKT cell phenotype in SLE-P patients is associated with 
altered serum lipids, in particular with VLDL. 
 
Whilst triglycerides represent a good diagnostic measure for dyslipidemia, more specific 
analysis more specific analysis of metabolites could prove useful in determining the 
relationship between serum lipids and iNKT cell function. In light of the differences 
observed between serum metabolites (e.g. VLDL content) in SLE-NP compared to SLE-
P patients, I questioned whether they were associated with the differential iNKT cell 
phenotype described in Results 1. The most significant variables reported in Table 4.2 
were correlated with iNKT cell frequency, CD69, CD161 and intracellular IL-4 expression. 
In all cases, correlations were found to be significant for SLE-P patients only, with most 
correlations for iNKT cell frequency, followed by CD161 then IL-4. In particular, these 
correlations mostly involved VLDL particle composition, including phospholipid and free 
cholesterol content (Figure 4.5 and Table 4.3). Other metabolic markers found to 
correlate with iNKT cell markers included mono-unsaturated fatty acids, omega 6 fatty 
acids and docosahexaenoic acid (DHA) (Figure 4.5 and Table 4.3) 
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Table 4.3 Serum metabolomics analysis in SLE patients with and without 
plaque 
Serum samples taken at the time of femoral and carotid ultrasound scan from 36 SLE 
patients with carotid or femoral plaque (SLE-P) and 64 patients with no plaque (SLE-NP) 
were assessed for lipid distribution in lipoprotein subclasses by proton nuclear magnetic 
resonance (NMR) spectroscopy as carried out by Kettunen et al. [499]. Proportions of 
total serum cholesterol, phospholipids and triglycerides carried by each lipoprotein 
subclass were determined. Table lists the markers identified as most significant between 
SLE patients with and without plaque using student’s t test a 95% confidence interval (no 
significance was seen using the Bonferoni correction). Serum metabolite expression was 
correlated with iNKT cell frequency and percentage of iNKT cells positive for CD161 and 
intracellular IL-4 expression using Pearson’s correlation coefficient (r), significance was 
determined using a 95% confidence interval. * denotes significant correlations between 
iNKT cell frequency and serum metabolites.  
 
Metabolite Correlation with iNKT 
cell absolute number: 
Pearson’s correlation 
coefficient 
 (r) and (p value) 
Correlation with CD161+ 
iNKT cells: Pearson’s 
correlation coefficient (r) 
and (p value) 
Correlation with iNKT 
cell 
intracellular IL-4:  
Pearson’s correlation 
coefficient 
(r) and (p value) 
SLE-NP  SLE-P SLE-NP SLE-P SLE-NP SLE-P 
Free cholesterol to total 
lipids ratio in medium VLDL  
0.0729 
(0.7350) 
-0.4950 
(0.0087)** 
-0.006318 
(0.9745) 
0.2819 
(0.2285) 
-0.3646 
(0.1502) 
0.1873 
(0.4039) 
Glycine 0.2747 
(0.1940) 
-0.1742 
(0.3660) 
-0.1135 
(0.6150) 
0.04907 
(0.8467) 
-0.1342 
(0.5956) 
-0.2539 
(0.2543) 
Free cholesterol to total 
lipids ratio in large VLDL  
-0.1169 
(0.5684) 
-0.5135 
(0.0350)* 
-0.0063 
(0.5384) 
0.6572 
(0.0016**) 
-0.05266 
(0.8356) 
0.3801     
(0.0810) 
Phospholipids to total lipds 
ratio in chylomicrons and 
extremely large VLDL  
-0.1275 
(0.5528) 
-0.5948 
(0.0092)** 
-0.1204 
(0.5417) 
0.4750 
(0.0398*) 
-0.1193 
(0.6485) 
-0.05080 
(0.8137) 
Triglycerides to total lipids 
ratio in very small VLDL  
0.01406 
(0.9480) 
-0.3285 
(0.1832) 
-0.05913 
(0.7650) 
-0.3180 
(0.1600) 
-0.2211 
(0.3779) 
-0.01551 
(0.9426) 
Mean diameter for LDL 
particles 
0.07357 
(0.7326) 
-0.2659 
(0.2862) 
0.06292 
(0.7504) 
0.05822 
(0.8021) 
0.2961 
(0.2328) 
-0.1291 
(0.5477) 
Ratio of omega-6 fatty acids 
to total fatty acids 
0.2004 
(0.3478) 
0.5610 
(0.0154)* 
0.1720 
(0.3814) 
0.1495 
(0.5177) 
0.1217 
(0.6305) 
-0.3340 
(0.1288) 
Triglycerides to total lipids 
ratio in IDL  
0.06820 
(0.7515) 
-0.2858 
(0.2661) 
0.06698 
(0.7349) 
-0.3025 
(0.2081) 
-0.3136 
(0.2051) 
-0.01551 
(0.9426) 
Ratio of triglycerides to 
phosphoglycerides 
-0.04249 
(0.8437) 
-0.3621 
(0.1398) 
-0.1377 
(0.4934) 
-0.2560 
(0.2759) 
-0.3255 
(0.2023) 
0.7954 
(<0.0001)* 
Ratio of 22:6 
docosahexaenoic acid to 
total fatty acids 
0.2976 
(0.1578) 
0.3857 
(0.1139) 
0.2889 
(0.1360) 
-0.2826 
(0.2146) 
-0.00268 
(0.9916) 
-0.5275 
(0.0116)* 
Glycoprotein acetyls (mainly 
a1-acid glycoprotein) 
-0.1798 
(0.4005) 
0.1861 
(0.3628) 
-0.08732 
(0.6920) 
-0.01568 
(0.9477) 
-0.0944 
(0.7095) 
0.3720 
(0.0734) 
Ratio of monounsaturated 
fatty acids to total fatty acids 
-0.03111 
(0.8853) 
-0.5570 
(0.0163)* 
0.06407 
(0.7460) 
0.4901 
(0.039*) 
-0.3282 
(0.1837) 
0.4555 
(0.0332)* 
Triglycerides to total lipids 
ratio in large LDL  
0.02350 
(0.9132) 
-0.2727 
(0.2896) 
0.03345 
(0.8658) 
-0.2433 
(0.3154) 
-0.3136 
(0.2051) 
-0.1364 
(0.5252) 
Cholesterol esters to total 
lipids ratio in IDL 
-0.1044 
(0.6274) 
0.005076 
(0.9841) 
-0.1361 
(0.4897) 
0.6572 
(0.0016**) 
0.3029 
(0.2373) 
0.2659 
(0.2092) 
Cholesterol esters to total 
lipids ratio in very small 
VLDL 
-0.04726 
(0.8264) 
-0.2168 
(0.3874) 
-0.01703 
(0.9315) 
0.1047 
(0.6514) 
0.3486 
(0.1562) 
0.3179 
(0.1393) 
Citrate 0.3126 
(0.1370) 
-0.0478 
(0.8054) 
-0.0279 
(0.8894) 
-0.2297 
(0.3300) 
-0.5179 
(0.0277)* 
-0.1229 
(0.5672) 
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Figure 4.5 The iNKT cell phenotype observed in SLE-P patients is 
associated with differences in serum metabolites including VLDL   
Serum from 30 SLE-P and 56 SLE-NP patients were analysed by proton nuclear 
magnetic resonance spectroscopy for 233 serum lipid metabolites. Results were 
compared using an unpaired Students T test and the most significant metabolites were 
correlated against iNKT cell frequency and the percentage of iNKT cells positive for 
CD69, CD161 and intracellular IL-4 as shown in Figure 3.5 and 3.9 respectively.  Volcano 
plots depicting Pearson’s correlation coefficient (r) against –log10 (p value) are shown 
for correlations between iNKT cell frequency, CD69, CD161 or IL-4 and all metabolites 
identified as significant between SLE-NP and SLE-P. HC – healthy controls; SLE-NP – 
SLE patients without plaque; SLE-P – SLE patients with plaque 
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4.6 The iNKT cell phenotype in SLE-P patients is not mediated by 
cytokines in the serum 
 
In addition to activation by CD1d-mediated lipid  antigen presentation, iNKT cells can 
also be activated by cytokines; IL-12 for example has been shown to activate iNKT cells 
directly [286]. To investigate whether there were differences in serum cytokines between 
healthy controls, SLE-NP and SLE-P patients a cytometric bead array was carried out 
for cytokines IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17a, IFN-α, IFN-γ and TNF-α (Figure 
4.4). However, no significant difference was observed for any of the cytokines, 
suggesting that differences in cytokines were not responsible for the altered iNKT cell 
phenotype in healthy donors, SLE-NP and SLE-P patients. Therefore I hypothesised that 
differences in the serum lipids were driving the altered iNKT cell phenotype in SLE-P 
patients.  
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Figure 4.6 Serum cytokine expression levels are similar in SLE patients 
with and without plaque.  
Serum from 10 healthy donors, 23 SLE-NP and 17 SLE-P patients taken at the time of 
the carotid/femoral ultrasound scan were analysed by Cytometric Bead Array (CBA, BD 
Bioscience) for the following cytokines: IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17a, IFN-
α, IFN-γ and TNF-α according to manufacturer’s instructions. No signal was detected for 
the presence of IL-4 using this method (data not shown). Scatterplot showing mean. No 
significant differences in cytokine expression levels were detected when all groups were 
compared using ANOVA, or when SLE-NP and SLE-P patients were compared using a 
Mann Whitney test. HC – healthy controls; SLE-NP – SLE patients without plaque; SLE-
P – SLE patients with plaque 
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4.7 Altered lipid presentation drives the iNKT cell phenotype 
associated with SLE-P patients  
 
To determine whether the differential iNKT cell phenotype observed between SLE-NP 
and SLE-P patients in “Results 1” was associated with serum factors, PBMCs from 
healthy donors were cultured with serum from non-autologous healthy controls, SLE-NP 
and SLE-P patients in an attempt to recapitulate the SLE-P phenotype in healthy PBMCs.  
Only serum from SLE-P patients induced increased iNKT cell expansion (Figure 4.5A-
C), which was associated with increased IL-4 production compared to SLE-NP serum in 
a similar way to the ex vivo iNKT cell phenotype seen in SLE-P patients (Figure 4.5E). 
The development of this phenotype was blocked by the addition of blocking anti-CD1d 
antibody (Figure 4.5F) indicating that CD1d-mediated lipid antigen presentation was 
required for the differential iNKT cell phenotype observed upon treatment with SLE-P 
serum. 
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Figure 4.7 Serum from SLE-P patients drives an altered iNKT cell 
phenotype  
PBMCs isolated from 4 different healthy donors were each cultured (5x106/well) for 7d 
in RPMI containing 50% serum from 3 different healthy donors, SLE-NP or SLE-P 
patients with the addition of anti-CD1d as a control. At d0, d4 and d7 PBMCs were 
labelled with CD3 and iTCR and stained intracellularly for IFN-γ and IL-4 before 
analysing by flow cytometry. (A) iNKT cell frequency over time as per gating strategy 
(Figure 3.2), showing results from 4 different healthy donors. (B) Representative plots at 
d7 and (C) cumulative data showing percentage change in iNKT cell frequency at d7 
compared to d0. (D) Percentage of iNKT cells positive for intracellular IL-4 at d7 culture. 
(E) iNKT cell percentage change at d4 and d7 from ex vivo PBMC frequency at day0 
upon treatment with SLE-NP and SLE-P serum, and the influence of blocking the iTCR 
using anti-CD1d (F) Cumulative data at d7, showing the effect of anti-CD1d blocking 
antibody. Mean ±SE. One-way ANOVA and Tukey’s multiple comparison post-test, 
**p=<0.001, *p=<0.01. HC – healthy controls; SLE-NP – SLE patients without plaque; 
SLE-P – SLE patients with plaque 
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CHAPTER V: 
Results 3 
 
 
 
 
 
 
 
 
 
 
 
 
  
186 
 
Results 3 – CD1d-mediated lipid presentation in SLE patients with 
atherosclerosis 
 
5.1 Introduction and aims for this chapter 
 
CD1d is an MHC-class I-like molecule expressed by antigen presenting cells 
including monocytes, macrophages, dendritic cells and B cells. It is necessary for 
presentation of lipid antigens to iNKT cells via binding to the iTCR and was first 
characterised by its ability to bind the marine sponge-derived iNKT cell agonist 
α-GalCer [268].  
 
In addition, the plasma membrane distribution of CD1d with lipid microdomains 
(so called lipid rafts) can also influence iNKT cell responses, and can direct iNKT 
cell function [377]. In particular, a study by Im et al showed that co-localisation 
between CD1d and lipid rafts in a JAWS II cell line resulted in a Th1 cytokine 
response, whereas CD1d exclusion from lipid rafts induced in a Th2 response.  
Lipid rafts are defective in B and T cells from SLE patients [367, 368], however 
the role of CD1d-lipid raft interactions on iNKT cell function is humans has not 
been previously investigated, and such experiments are extremely difficult to 
carry out since modulating CD1d-lipid raft interactions would likely interfere with 
lipid metabolism in general.   
 
The aim of this chapter was to investigate whether CD1d expression and its 
association with lipid rafts was altered in SLE patients with and without plaque 
and whether this could be due to differences in CD1d recycling, which is required 
for the loading of different lipids for CD1d-mediated antigen presentation to iNKT 
cells. Furthermore, I explored whether altered antigen presenting cells in SLE 
patients could induce differences in conjugate formation with iNKT cells in 
response to α-GalCer and the effect on signalling downstream of the iTCR.  
 
 
187 
 
5.2 CD1d and lipid raft expression on B cells is altered in SLE 
patients compared to healthy controls 
 
CD1d expression on B cells, monocytes and pDCs was characterised by flow 
cytometry. Whilst no significant differences were observed for monocytes and 
pDCs, B cells from both SLE-NP and SLE-P patients were found to have 
significantly decreased CD1d expression compared to healthy controls in line with 
data previously published by Bosma et al [233] (Figure 5.1A, C and D).  
 
Since membrane lipids are thought to play a role in CD1d-mediated antigen 
presentation I decided to investigate expression of lipid rafts on B cells, 
monocytes and pDCs using CTB which has previously been shown to be a 
surrogate marker for glycosphingolipids, a major component of lipid rafts [380]. 
Analysis of flow cytometry data revealed increased lipid raft expression in B cells 
from both SLE-NP and SLE-P patients compared to healthy controls. Whilst no 
significant differences were detected in monocytes (Figure 5.1A&B), there was a 
trend towards increased lipid raft expression on pDCs (Figure 5.1D).  
 
Correlations between the MFI of CD1d and lipid rafts (CTB) were performed for 
B cells and monocytes. Healthy donors were compared to both SLE-NP and SLE-
P patients. Interestingly, I observed significant strong positive correlations in 
healthy individuals for B cells but not monocytes, which was lost in both SLE-NP 
and SLE-P patients (Figure 5.2A). Thus the results indicated that while significant 
differences in CD1d and lipid raft expression were observed in B cells from SLE 
patients compared to healthy donors, this was not associated with the presence 
of preclinical plaque.  
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Figure 5.1 B cells and monocyte CD1d and lipid raft expression in healthy 
donors, SLE-NP and SLE-P patients 
106 PBMCs from 14 healthy donors, 10-32 SLE-NP and 10-23 SLE-P patients 
were surface stained ex vivo for CD14, CD19, CD303, CD1d and Cholera toxin 
B (lipid rafts). Data were analysed by flow cytometry.  (A) Representative 
histograms showing lipid raft and CD1d expression in B cells and monocytes from 
healthy donors, SLE-NP and SLE-P patients. (B) Cumulative data showing mean 
fluorescence intensity (MFI) of lipid raft and (C) CD1d expression on B cells and 
monocytes from healthy donors, SLE-NP and SLE-P patients. (D) CD1d and lipid 
raft expression on pDCs. Mean ± SE. One-way ANOVA and Tukeys multiple 
comparisons test. *p=<0.05, **p<0.01 (E) Correlation between CD1d and CTB 
(lipid raft) expression in B cells and monocytes from healthy donors and SLE 
patients. Linear regression was used to determine the strength of correlation 
given. *p=<0.05, r=0.6892; HC – healthy controls; SLE-NP – SLE patients without 
plaque; SLE-P – SLE patients with plaque 
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5.3 SLE patients show differences in CD1d and lipid raft co-
localisation   
 
Differences in the level of CD1d expression alone, perhaps due to increased recycling 
may influence iNKT cell proliferation [233]. Whilst this may contribute to the reduced 
numbers of iNKT cells observed in SLE patients in general, CD1d expression alone 
cannot account for differences in the iNKT cell cytokine profile observed between SLE-
NP and SLE-P patients.  
 
CD1d association with lipid rafts has previously been shown to influce iNKT cytokines 
responses, whereby CD1d incorporation into lipid rafts promoted an NKT1 response and 
CD1d exclusion from lipid rafts promted an NKT2 response [377]. However, such work 
has been carried out using cell lines and may not represent the situation in human cells. 
 
Due to the pathogenic role of lipid defects in SLE and based on work by Im et al [377], I 
decided to investigate whether differences in CD1d and lipid raft colocalisation could 
influence iNKT cell responses in healthy, SLE-NP and SLE-P patients. Specifically, I 
questioned whether differences in CD1d and lipid raft co-localisation could be 
responsible for the Th2 iNKT cell phenotype observed in iNKT cells from SLE patients 
with preclinical plaque (Figure 3.10). ImageStream cytometry was used to quantify co-
localisation between CD1d and lipid rafts, by means of the similarity feature in IDEAS 
analysis software for ImageStream (Amnis). Importantly, monocytes were found to have 
more CD1d and lipid raft co-localisation compared to B cells, as can be seen from the 
representative images (Figure 5.2A); a finding which was proved significant upon 
analysis using the similarity feature, which compares the fluorescence of CD1d and CTB 
across different regions of each cell. Importantly, B cells but not monocytes from SLE 
patients were also found to have significantly increased CD1d-CTB co-localisation 
(Figure 5.2B), with no difference between SLE-NP and SLE-P patients. These results 
were confirmed by confocal microscopy performed by a graduate student in the Jury Lab 
(data not shown). 
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Figure 5.2  B cells and monocytes show differences in colocalisation 
between CD1d and lipid rafts in SLE patients compared to healthy donors. 
106 PBMCs from 5 healthy donors, 5 SLE-NP and 6 SLE-P patients were surface 
stained ex vivo for CD14, CD19, CD1d and CTB (lipid rafts). Data were acquired 
by imaging flow cytometry and analysed using IDEAS software for ImageStream 
to quantify CD1d and CTB co-localisation. Briefly cells were gated on focused 
and single cells, then either CD14+ or CD19+ populations before applying the 
similarity feature to measure co-localisation between CD1d and CTB. (A) 
Representative plots showing expression of lipid rafts [CTB] (green) and CD1d 
(red) on monocytes (purple) and B cells (pink) as well as CD1d-lipid raft co-
localisation (merged image) for healthy, SLE-NP and SLE-P patients.(B) 
Cumulative data showing the level of co-localisation in B cells and monocytes 
from healthy donors, SLE-NP and SLE-P patients. Mean± SE. One-way ANOVA 
*p=<0.05 
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5.4 Serum from SLE patients contributes to the decrease in CD1d 
expression observed on B cells from SLE patients 
 
Since B cells from SLE patients were found to have reduced CD1d expression and 
increased lipid raft expression compared to healthy individuals [233, 368], I questioned 
whether serum factors (potentially lipids) could be driving this response by culturing 
healthy PBMCs with patient serum in an attempt to recapitulate the antigen presenting 
cell phenotype observed in SLE-NP and SLE-P patients. Interestingly, there was a 
reduction in CD1d on B cells from SLE patients, which was found to be significant for 
SLE-NP patients compared to healthy controls after 4 days of culture (Figure 5.3A). 
Whilst no difference was observed for B cell lipid raft expression, there was a trend 
towards increased lipid raft expression on SLE-NP monocytes (Figure 5.3B). 
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Figure 5.3 CD1d and lipid raft expression in healthy B cells and 
monocytes in response to 4 day culture with serum from healthy donors, 
SLE-NP and SLE-P patients  
PBMCs isolated from 4 different healthy donors were each cultured (5x106/well) for 7d 
in RPMI containing 50% serum from healthy donors (n=3), SLE-NP (n=3) or SLE-P (n=3) 
patients. At d0, d4 and d7 PBMCs were stained for CD14+ monocytes, CD19+ B cells, 
CD1d and CTB (lipid rafts), before analysing by flow cytometry. MFI of (A) CD1d Lipid 
raft and (B) CTB expression on B cells and monocytes after 4 days of culture Mean± SE. 
One-way ANOVA *p=<0.05. HC – healthy controls; SLE-NP – SLE patients without 
plaque; SLE-P – SLE patients with plaque 
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5.4 SLE-NP patients have increased endosome expression 
compared to SLE-P patients and healthy individuals 
 
Internalisation and CD1d recycling is necessary for CD1d-mediated lipid antigen 
presentation to iNKT cells. CD1d internalisation occurs via sorting endosomes, which 
fuse to lysosomes where the loading of either endogenous or exogenous lipids takes 
place. 
 
Since endosomes and lysosomes are important in this process, I quantified the numbers 
of B cell and monocyte endosomes and lysosomes in healthy donors, SLE-NP and SLE-
P patients using early endosomal marker EEA-1 and lysosomal marker LAMP-1. 
ImageStream cytometry was used to acquire data, which were analysed using the spot 
count feature in IDEAS analysis software (Amnis) to identify and count the “spots” with 
greatest intensity for EEA-1 and LAMP-1. 
 
Lysosome numbers were found to be similar B cells and monocytes in healthy donors 
and patients with SLE (Figure 5.4A). However, monocytes from healthy donors had 
significantly increased endosome numbers compared to B cells, (Figure 5.4B). 
Interestingly, SLE-NP patients had significantly increased numbers of monocyte 
endosomes compared to both healthy controls and SLE-P patients. However, analysis 
of CD1d-endosome and CD1d–lysosome co-localisation using the similarity feature 
showed no difference between SLE-NP and SLE-P patients, despite finding more co-
localisation in monocytes compared to B cells (Figure 5.4C). Whether differences in 
endosome function between SLE-NP and SLE-P monocytes contribute to the differential 
iNKT cell phenotype observed remains to be seen.  
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Figure 5.4 Differences in endosome and lysosome expression in SLE 
patients compared to healthy donors. 
2x106 fresh PBMCs from 4 healthy donors, 5 SLE-NP and 5 SLE-P patients were 
stained for CD14, CD19, CD1d, early endosome marker EEA-1, and lysosome 
marker LAMP-1. Cells were acquired by ImageStream cytometry (Amnis) and 
analysed using IDEAS software to quantify endosome and lysosome frequency 
and co-localisation with CD1d. (A) Cumulative data for endosome and lysosome 
spot counts in B cells and monocytes from healthy donors, SLE-NP and SLE-P 
patients. (B) Representative images for endosome and lysosome frequency 
showing EEA1 (green), CD1d (red) LAMP-1 (yellow), monocytes (purple) and B 
cells (pink) and merged images for CD1d co-localisation with endosomes and 
lysosomes. (C) CD1d co-localisation with endosomes and lysosomes in healthy 
and SLE patients as determined by the bright detail similarity feature. Mean± SE. 
One-way ANOVA *p=<0.05 
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5.5 B cells form fewer stable conjugates with iNKT cells compared 
to monocytes in healthy donors, SLE-NP and SLE-P patients  
 
I questioned whether differences in lipid raft and CD1d expression in B cells and 
monocytes were associated with differences in immune synapse formation with iNKT 
cells and changes in subsequent signalling via iTCR activation. To investigate this, an 
iNKT cell line was grown using monocyte-derived dendritic cells (MDDCs) as described 
in Methods section 2.10. Meanwhile, freshly isolated PBMCs from healthy donors, SLE-
NP or SLE-P patients were pre-treated with α-GalCer overnight and FACS-sorted to 
obtain purified B cells and monocytes. These were then co-cultured with purified iNKT 
cells for 5, 10 and 15 minutes before assessing conjugate formation by flow cytometry. 
Methods were carried out by Natalya Ellis, a medical student who I supervised.  
 
At all time-points, a greater percentage of iNKT-cells formed conjugates with monocytes 
compared to B cells (Figure 5.5A-C). B cell-iNKT cell conjugate formation was relatively 
consistent over time with a trend towards fewer conjugates formed in B cells from SLE-
NP and SLE-P patients compared to healthy donors (Figure 5.5A-C). iNKT cell-monocyte 
interactions were more varied; monocytes from SLE-P patients  formed more conjugates 
with iNKT cells at 5 minutes compared to 15 minutes, in contrast to monocytes from 
healthy controls where the numbers of conjugates increased over time (Figure 5.5).  
 
These results suggested that iNKT cells formed more transient interactions with B cells 
compared to monocytes. This observation was investigated further using imaging 
cytometry to visualise conjugates, which confirmed that monocytes formed more 
conjugates with iNKT cells compared to B cells (Figure 5.5D). 
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Figure 5.5 Frequency of iNKT cells forming conjugates with healthy, SLE-
NP and SLE-P B cells and monocytes in response to α-GalCer. 
PBMCs from healthy (n=8), SLE-NP (n=8) and SLE-P (n=10) donors were pre-
treated with α-GalCer before staining for CD14+ monocytes and CD19+ B cells, 
which were isolated by FACS sorting. Meanwhile PBMCs from healthy individuals 
were stained for live/dead, CD3 and iTCR before isolating iNKT cell by FACS 
sorting. Isolated B cells or monocytes were subsequently co-cultured with iNKT 
cells from healthy individuals for 5, 10 and 15 minutes before 
fixing/permeabilising and staining with antibodies to phosphorylated ERK and 
pTCRζ. The percentage of iNKT cells forming conjugates with healthy, SLE-NP 
or SLE-P B cells and monocytes at 5 and 15 was calculated. (A) Line graphs and 
(B) cumulative data showing the kinetics of B cell- and monocyte-iNKT cell 
conjugate formation at 5 and 15 minutes. Mean± SE. One-way ANOVA *p=<0.05 
(C) Representative FACS plots showing the percentage of monocytes from 
healthy donors, SLE-NP and SLE-P patients forming conjugates with 
heterologous healthy iNKT cells at 5 and 15 minutes. Imaging cytometry was 
used to confirm the presence of conjugates in experiments (D) Representative 
images of B cell-iNKT cell and monocyte-iNKT cell conjugates showing iTCR 
(yellow), monocytes (purple), CD3 (red) and B cells (pink). 
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5.6 B cells and monocytes from healthy donors and SLE patients 
with and without plaque induce differential iNKT cell signalling  
 
Next I investigated whether changes in B cell and monocyte interactions with iNKT cells 
were associated with differential signalling via the iTCR.  iNKT cells forming conjugates 
were analysed for pTCRζ and pERK1/2 expression by flow cytometry. As expected iNKT 
cells forming conjugates with either B cells or monocytes from healthy donors had higher 
levels of pTCRζ and pERK1/2 compared to unconjugated iNKT cells (Figure 5.6A).  
Methods here were performed by Natalya Ellis, an iBSc student under my supervision.  
 
Interestingly, in healthy donors despite forming fewer and potentially more transient 
interactions with B cells compared to monocytes, both TCRζ  and ERK1/2 
phosphorylation was increased compared to that seen in monocyte/iNKT cell conjugates 
(Figure 5.6B-E). Further analysis of B cell-iNKT cell conjugates showed that B cells from 
SLE-NP (but not SLE-P) patients induced stronger pERK upon conjugation with healthy 
iNKT cells, compared to B cells from healthy donors (Figure 5.6B&C). However, no 
differences in TCRζ phosphorylation were observed in iNKT cell conjugates with B cells 
from healthy donors or either SLE groups.  
 
When I considered iTCR signalling in the monocyte-iNKT cell conjugates, monocytes 
from SLE-NP patients were found to induce lower ERK1/2 and TCRζ phosphorylation 
compared to monocytes from healthy donors and SLE-P patients (Figure 5.6D&E), which 
reached significance for TCRζ expression between SLE-NP monocyte- and SLE-P 
monocyte-iNKT cell conjugates. 
 
Overall, these results show that B cells and monocytes interact differently with iNKT cells 
in healthy individuals and that this is associated with differences in the activation of iTCR-
associated signalling molecules. In B cells and monocytes from SLE patients altered 
patterns of iTCR signalling are triggered compared to healthy donors, which could be 
related to changes in lipid raft and CD1d expression driving abnormal iNKT cell 
activation.  
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Figure 5.6 ERK and TCR zeta signalling in iNKT cells forming conjugates 
with B cells and monocytes from healthy, SLE-NP and SLE-P patients 
PBMCs from healthy (n=8) , SLE-NP (n=8)  and SLE-P (n=10) donors were pre-
treated with α-GalCer before staining for CD14+ monocytes and CD19+ B cells, 
which were isolated by FACS sorting. Meanwhile PBMCs from healthy individuals 
were stained for live/dead, CD3 and iTCR before isolating iNKT cell by FACS 
sorting. Isolated B cells or monocytes were subsequently co-cultured with iNKT 
cells from healthy individuals for 5, 10 and 15 minutes before 
fixing/permeabilising and staining with antibodies to phosphorylated ERK and 
pTCRζ. (A) Representative histograms showing pTCRζ and pERK1/2 expression 
in unconjugated healthy iNKT cells compared to those forming conjugates with 
healthy B cells and monocytes. (B) Representative histograms and (C) 
cumulative data showing mean fluorescence intensity of pTCRζ and pERK1/2 
expression in iNKT cell conjugates with B cells from healthy, SLE-NP and SLE-P 
patients at 15 minutes. (D) Representative histograms and (E) cumulative data 
showing mean fluorescence intensity of pTCRζ and pERK1/2 expression in iNKT 
cell conjugates with monocytes from healthy, SLE-NP and SLE-P patients at 15 
minutes. Mean± SE. One-way ANOVA and Tukey’s multiple comparison post-
test *p=<0.05 
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CHAPTER VI: 
Results 4 
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Results 4: Role of endogenous lipids in iNKT cell responses and 
monocyte transactivation 
 
6.1 Introduction and aims for this chapter 
 
The results described in Chapter 3 show that monocytes and B cells interact with iNKT 
cells in different ways. Furthermore the results suggest that only monocytes show 
differential effects on iNKT cell activation in SLE-P patients compared to SLE-NP 
patients and healthy donors.  
Little is known about the endogenous lipids which activate iNKT cells despite attempts 
to characterise them through their ability to bind CD1d. Lipids previously identified 
include LPC, β-GlcCer and Igb3 although their roles in humans and in the absence of 
infection remains contentious [310, 314, 315, 318]. Instead most studies have used α-
GalCer due to its potency to activate iNKT cells; however since it is derived from a marine 
sponge such culture experiments do not resemble the normal physiological situation in 
vivo [273].   
Therefore the first aim of this chapter was to investigate the ability of lipids isolated from 
B cells or monocytes from healthy, SLE-NP and SLE-P patients to activate iNKT cells 
from healthy donors. Lipids were isolated by chloroform: methanol extraction with further 
purification into several fractions based on their chemical composition 
 
Due to the importance of monocytes in the development of atherosclerosis, I went on to 
investigate whether monocytes had a different phenotype in SLE patients with pre-
clinical plaque, including the frequency of intermediate or CD14++CD16+ monocytes, 
which have been shown to be increased in atherosclerosis [168-170], as well as 
characterisation of monocytes based on CD68+CCR2+ and CD206+CX3CR1+ which have 
been described as M1-like and M2-like respectively by Fadini et al. who observed altered 
frequencies in dyslipidaemic patients [497]. Scavenger receptor expression was also 
determined due to their importance in the uptake of lipids, which I have shown to be 
different between SLE-NP and SLE-P patients shown in Results 3. 
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Finally, M2 macrophages are induced by IL-4 and play a protective role in 
atherosclerosis, where they promote tissue repair [188]. I therefore investigated whether 
iNKT cells or serum from SLE patients with preclinical plaque could also induce 
polarisation of M2 macrophages in order to support my previous finding of increased 
intracellular IL-4 in SLE-P patients shown in Results 1. 
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6.2 Phospholipids from SLE-P monocytes induce greater iNKT cell 
expansion compared to those from SLE-NP patients  
 
To determine whether altered endogenous lipids in healthy donors, SLE-NP and SLE-P 
patients could influence iNKT cell responses cellular lipids were extracted from purified 
ex vivo monocytes and B cells from healthy donors, SLE-NP and SLE-P patients using 
chloroform: methanol isolation and subsequent fractionation with amino propyl columns 
(Figure 6.1A for experimental plan). B cell and monocytic lipids (Fractions 1-6) from 
healthy donors, SLE-NP and SLE-P patients were then co-cultured with PBMCs isolated 
from healthy donors in the presence of pooled human serum and IL-2 to induce iNKT 
cell expansion. Initial experiments established that iNKT cells from healthy donors 
responded more robustly to the lipid fraction 5 (F5) containing phospholipids and 
sphingomyelin; this was regardless of whether lipids were B cell- or monocyte-derived 
(Figure 6.1B).   
 
F5 lipids purified from B cells and monocytes isolated from SLE-NP and SLE-P patients 
and healthy donors were then used to stimulate iNKT cells from healthy donors. Only 
monocytic F5 lipids isolated from SLE-P patients induced a significant increase in iNKT 
cell expansion (Figure 6.2 A-C). This was associated with a more anti-inflammatory 
cytokine environment, characterised by increased expression levels of IL-4, IL-13 and 
reduced IFN-γ in tissue culture supernatants compared to SLE-NP patients or healthy 
controls (Figure 6.2D-F). These responses were blocked by the addition of anti-CD1d 
antibody suggesting that CD1d-mediated presentation of F5 lipids to iNKT cells was 
required for iNKT cell expansion and the increase in IL-4 and IL-13 and decrease in IFN-
γ in response to Fraction 5 (Figure 6.2G and H).  
 
These results suggested that phospholipids and sphingomyelin from monocytes 
presented via CD1d in SLE-P patients were more effective at inducing iNKT cell 
expansion compared to those presented by SLE-NP patients, and that this triggered the 
production of anti-inflammatory and potentially athero-protective cytokines. Whilst 
cytokine secretion was blocked by anti-CD1d, whether iNKT cells are the source remains 
under question.  
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Figure 6.1 Isolation of B cell and monocyte lipid fractions from healthy 
donors, SLE-NP and SLE-P patients 
Cellular lipids from B cells or monocytes from 5 healthy donors were isolated by 
chloroform: methanol extraction, and separated into 6 different fractions using amino 
propyl columns before resuspending in 50µl DMSO. 5x106 PBMCs from healthy donors 
were then cultured with 2µl of each lipid fraction in complete RPMI supplemented with 
200IU/ml IL-2. iNKT cells were quantified by flow cytometry at d0, d4 and d7. (B) 
Cumulative data from 3-5 experiments showing iNKT cell expansion upon culture of lipid 
fractions from B cells or Monocytes with PBMCs from healthy donors. Mean ±SE. One-
Way ANOVA and Tukey’s multiple comparison post-test; *p=0.05. PC – 
phosphatidylcholine; PE - phosphatidylethanolamine 
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Figure 6.2 The effect of B cell and monocyte lipid fractions on iNKT cells 
from healthy donors  
Monocyte and B cell lipids were purified from 5 healthy donors, 6 SLE-NP and 6 SLE-P 
patients (107 cells/group) by chloroform/methanol isolation and fractionation using amino 
propyl columns. Fraction 5 (F5) lipids were re-suspended in DMSO and cultured with 
PBMCs from 3 healthy donors +IL-2 for 7ds. At d7 cell culture supernatants were 
collected and PBMCs were labelled with CD3 an iTCR. (A) Representative flow 
cytometry dot plots showing INKT cell frequency in response to monocyte derived F5 
lipids and cumulative data showing response to (B) monocyte derived and (C) B cell 
derived F5 lipids. Mean ±SE. One-way ANOVA and Tukey’s multiple comparison test, 
*p=<0.05. Cell culture supernatants from d7 cultures were assessed for expression of 
IL-4, IL-13 and IFN-γ by CBA. Cumulative data for (D) Monocytes and (E) B cells are 
shown as well as (F) representative overlays. Mean ±SE.  One-way ANOVA and Tukey’s 
multiple comparison post-test, *p=<0.05. The experiment was repeated ± blocking anti-
CD1d antibody or isotype control. (G) Representative flow cytometry dot plots showing 
iNKT cell frequency from cultures with SLE-P monocyte lipids for 7d and (H) cumulative 
CBA data of IL-4, IL-13 and IFN-γ expression in tissue culture supernatants. Mean ±SE. 
Students t test, **p=<0.01, *p=<0.05.CBA – cytometric bead array; SLE-NP – SLE 
patients without plaque; SLE-P – SLE patients with plaque   
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6.3 Expression of B cell and monocyte scavenger receptors is 
comparable in SLE-NP and SLE-P patients  
 
My observation that phospholipids from SLE-P monocytes could induce differences in 
iNKT cell expansion and cytokine response suggested that other differences in 
monocytes could contribute to atherosclerosis in SLE-P patients. I therefore examined 
monocyte phenotype and function in more detail. 
 
Due to the importance of scavenger receptors in lipid uptake, B cells and monocytes 
were assessed for CD36, LDLR and LOX-1 expression in healthy individuals, SLE-NP 
and SLE-P patients as well as a group of SLE patients who had previously suffered a 
cardiovascular event (Table 3.2). No significant differences were observed between 
healthy, SLE-NP and SLE-P patients (Figure 6.3), although trends were observed 
including an increase of CD36 and LDLR expression on B cells and a decrease in CD36 
expression on monocytes from SLE-P patients, which could represent changes in 
scavenger receptor expression in SLE patients with asymptomatic plaques. Interestingly, 
the major finding was an increase in LOX-1 expression on monocytes from SLE patients 
who had previously had a cardiovascular event, suggesting that alterations in LOX-1 
expression on monocytes occur at later stages of atherosclerosis.  
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Figure 6.3 Expression of CD36, LDLR and LOX-1 in Monocyte and B cell 
phenotype in healthy donors, SLE-NP, SLE-P and SLE-CV patients 
106 PBMCs from 6 healthy donors, 10 SLE-NP, 10 SLE-P and 8 SLE-CV patients were 
surface stained ex vivo for CD14, CD19 plus a combination of CD36, LDLR and LOX-1, 
or CD1d. Data were analysed by flow cytometry. Percentage of (A) B cells and (B) 
monocytes positive for CD36, LDLR and LOX-1 Mean, One-way ANOVA and Tukey’s 
multiple comparison post-test, **p=<0.01, ***p=<0.001. HC – healthy controls; SLE-NP – 
SLE patients without plaque; SLE-P – SLE patients with plaque; SLE-CV – SLE patients 
who have suffered a cardiovascular event 
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6.4 SLE-P patients are characterised by increased numbers of 
anti-inflammatory monocytes  
 
Ex vivo quantification of pro-inflammatory monocytes according to CD14 and CD16 
expression revealed that SLE-NP patients had a significantly greater percentage of 
CD14++CD16+ (so called ‘intermediate’) monocytes compared to healthy individuals and 
SLE-P patients (Figure 6.4A and B). Interestingly, analysis of SLE patients who had 
previously suffered a cardiovascular event had a higher frequency of intermediate 
monocytes in these patients compared to SLE-P patients and healthy controls, with 
numbers being more similar to SLE-NP patients.     
 
Further ex vivo characterisation of monocytes was carried out based on a gating strategy 
by Fadini et al. which identified M1- or M2-like monocytes ex vivo [497]. Analysis showed 
that both SLE-NP and SLE-P patients had an increase in frequency of the pro-
atherogenic or M1-like CD14+CD68+CCR2+ monocytes compared to healthy individuals 
(Figure 6.4C-F). In contrast, M2-like CD14+CD206+CX3CR1+ monocytes, which are 
thought to be anti-atherogenic, had a significantly increased frequency in SLE-P patients 
compared to SLE-NP patients (Figure 6.4C-F). 
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Figure 6.4 Monocyte phenotype in healthy individuals, SLE-NP patients 
and SLE-CV patients who had previously suffered a cardiovascular event.  
PBMCs from 8 healthy donors, 18 SLE-NP, 11 SLE-P and 8 SLE-CV patients were 
surface stained for CD14, CD16, CD206, CD68, CCR2 and CX3CR1. Monocyte 
populations were assessed by flow cytometry. (A) Representative dot plots and (B) 
cumulative data for CD14++CD16- classical monocyte, CD14++CD16+ intermediate 
monocyte and CD14+CD16+ non-classical monocyte frequency. Mean, One-way ANOVA 
and Tukey’s multiple comparison post-test, **p=<0.001, *p=<0.01. (C) Representative 
dot plots and cumulative data for M1-like (CD68+CCR2+) monocytes and (D) M2-like 
(CD206+CX3CR1+) monocytes. (E) M1:M2 ratio in healthy, SLE-NP and SLE-P patients. 
Mean ±SE. One-way ANOVA and Tukey’s multiple comparison post-test, **p=<0.01, 
*p=<0.05. HC – healthy controls; SLE-NP – SLE patients without plaque; SLE-P – SLE 
patients with plaque; SLE-CV – SLE patients who have suffered a cardiovascular event 
  
209 
 
6.5 iNKT cells are required for polarisation of M1/M2 
macrophages  
 
I questioned whether iNKT cells themselves could influence monocyte/macrophage 
polarisation, and therefore determine the immune response within the atherosclerotic 
plaque. To test this purified monocytes were co-cultured with T cells from healthy donors 
with serum from SLE-NP, SLE-P patients and healthy donors for 7d. SLE-P serum 
preferentially induced the differentiation of M2 macrophages detected by CD206 
(mannose receptor), which is regulated by IL-4 [188]. In monocyte only cultures there 
was no significant difference in M2 macrophage differentiation in cultures with healthy, 
SLE-NP and SLE-P serum (Figrue 6.5B&C). In monocyte and T cell co-cultures there 
was a greater amount of M2 macrophage differentiation, with nearly al the cells positive 
for CD206, although no differences were observed between healthy, SLE-NP and SLE-
P serum cultures (Figure 6.5D). The addition of anti-CD1d blocking antibody was able to 
inhibit M2 macrophage differentiation on each occasion (Figure 6.5D). 
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Figure 6.5 Macrophages fail to differentiate to M2 phenotype in the 
absence of iNKT cells 
(A) Experimental plan: Purified monocytes (105/well) either with or without T cells 
(7.5x105/well) from 4 healthy donors were co-cultured in the presence of 50% serum 
from six SLE-NP, SLE-P patients and heterologous healthy donors for 7ds. At d7 
adherent differentiated macrophages were recovered and surface stained for CD68 and 
CD206. (B) Gating strategy showing CD68+ gating, followed by representative plots for 
CD206. (C) Cumulative data from monocyte only cultures showing frequency and MFI of 
CD206 on CD68+ macrophages. Mean ±SE. One-way ANOVA and Tukey’s multiple 
comparison post-test, *p=0.05. (E) Cumulative data showing percentage of CD206+ 
macrophages from monocyte and T cell co-cutures. Mean ±SE. One-way ANOVA and 
Tukey’s multiple comparisons post-test. HC – healthy controls; SLE-NP – SLE patients 
without plaque; SLE-P – SLE patients with plaque; NS – not significant  
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6.6 iNKT cells from SLE-P patients influence monocyte and 
macrophage phenotype 
 
To establish the role of iNKT cells in driving monocyte and macrophage polarisation iNKT 
cells were differentiated with SLE-P and SLE-NP serum to induce the characteristic SLE-
NP or SLE-P iNKT cell phenotype. Pre-conditioned iNKT cells were then co-cultured with 
the human THP-1 macrophage cell line (in order to rule out differences between 
macrophages derived from healthy donor PBMCs). Expression of M1 and M2 
macrophage genes was then assessed by qPCR, which was carried out by Kirsty 
Waddington.  
Genes analysed were the M1-associated gene for Pro-platelet basic protein (PPBP) 
[500] and several M2-associated genes, namely CD163, CD206, CD200R and the 
Stabilin-1 (STAB-1) gene [501]. Such genes were chosen based on transcriptional profile 
analysis studies of GM-CSF- and M-CSF-differentiated macrophages, which led to the 
identification of several genes including PPBP, CD163, CD206, CD200R and STAB-1 
which could discriminate between M1 and M2 macrophages respectively [500, 502]. 
Furthermore, Roma-Lavisse et al. showed that M2 macrophage genes CD206, CD200R 
and STAB-1 were positively associated with plaque stability in atherosclerosis patients 
[502].    
Only iNKT cells exposed to SLE-P serum induced upregulation of the CD206 and 
CD200R genes associated with M2 macrophage polarisation [501] while no differential 
effect was observed with expression of PPBP an M1 macrophage-associated gene [500] 
(Figure 6.6A for experimental strategy, 6.6B and data not shown). 
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Figure 6.6 iNKT cells from SLE-P patients support M2 macrophage 
differentiation 
PBMCs from 2 healthy donors were each cultured with 50% serum from three different 
healthy donors, 3 SLE-NP and 3 SLE-P patients for 7ds to induce iNKT cell 
differentiation. (A) Experimental plan: CD3+ T cells were isolated and co-cultured 
(1.5x106/well) with differentiated THP-1 human macrophage cell line (1x106/well) for 
40hs. Macrophages were recovered and RNA analysed for expression of CD206 and 
CD200R gene expression by qPCR. (B) cumulative data showing CD206, CD200R, 
STAB1, CD163 and PPBP gene expression in THP-1 macrophages normalised to the 
level of cyclophilin [503]. Mean ±SE. One-way ANOVA and Tukey’s multiple comparison 
post-test *p=0.05. HC – healthy controls; SLE-NP – SLE patients without plaque; SLE-P 
– SLE patients with plaque  
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CHAPTER VII: 
Results 5 
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Results 5: Preliminary data - lipid metabolism in antigen 
presenting cells and its effect on iNKT cells 
 
7.1 Introduction and aims for this chapter 
 
The results presented in the previous chapters suggest that serum factors influence 
differential iNKT cell phenotypes in SLE patients with and without plaque and that this is 
associated with interactions with monocytes rather than B cells. However, previous work 
performed in the lab has shown that B cells also influence iNKT cell defects in patients 
with SLE.  
Lipid metabolism is important for many aspects of immune cell function. These include 
the formation of lipid rafts which are regulated through cholesterol biosynthesis, and the 
production of cytokines in order to modulate immune responses [374]. Previous work 
from the laboratory has shown that lipid biosynthesis is altered in SLE patients whereby 
T cells have increased expression of LXRβ, a gene which controls lipid biosynthesis 
[380]. This was subsequently found to contribute to the defects in lipid rafts in SLE 
patients, which could be corrected by normalising glycolipid metabolism [380]. Similar 
defects in lipid biosynthesis through LXR, as well as PPARγ have been described in 
cardiovascular disease [504, 505], which is of relevance to this study due to the 
increased cardiovascular risk in SLE patients. 
Furthermore, there is evidence that lipid biosynthesis can regulate CD1d-mediated lipid 
antigen presentation to iNKT cells. For example, in dendritic cells PPARγ stimulation has 
been shown to upregulate CD1d expression [383], whilst defective expression of both 
CD1d and PPARγ on adipocytes has been shown to contribute to the lack of iNKT cells 
observed in obesity [384]. It is unknown, however whether LXR also plays a role in this 
process.  
I therefore decided to investigate whether altering lipid biosynthesis through LXR and 
PPARγ could explain the differences in CD1d and lipid raft expression in B cells 
described in Chapter 5 that was observed in all SLE patients regardless of whether they 
had plaque.  
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7.2 Differences in lipid biosynthesis between healthy, SLE-NP and 
SLE-P patients 
 
To question whether there were differences in cholesterol biosynthesis between B cells 
and monocytes from healthy donors, SLE-NP and SLE-P patients FACS staining for 
filipin (cholesterol) and ANE (lipid order) was carried out with MSc student Shaheer El-
Bardisy [364]. I observed an increase in both lipid order and cholesterol expression in 
monocytes compared to B cells, indicative of increased plasma membrane stability 
(Figure 7.1A and B). Interestingly, cholesterol expression was increased in B cells and 
monocytes from SLE-NP, but not SLE-P patients compared to healthy individuals (Figure 
7.1B).    
Membrane lipids are regulated by several mechanisms including de novo lipid 
biosynthesis, uptake and recycling pathways and cholesterol efflux via channels such as 
ATP binding cassette A1 (ABCA1)[374]. Flow cytometry analysis of ABCA1 expression 
found increased ABCA1 on B cells compared to monocytes (Figure 7.1C), indicating 
differences in lipid metabolism. However, no significance was observed due to the low 
numbers of samples in each group. 
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Figure 7.1 Differences in membrane order, cholesterol and ABCA1 
transporter expression between healthy donors, SLE-NP and SLE-P 
patients 
106 PBMCs from 3-15 healthy donors, 3-15 SLE-NP and 3-15 SLE-P patients were 
surface stained ex vivo for CD14, CD19 plus filipin (cholesterol), ABCA1 or ANE (to 
measure membrane order). Data were analysed by flow cytometry. (A) Membrane order 
of B cells and monocytes, as determined by formula in methods section 2.5. (B) MFI of 
Filipin (cholesterol) expression on B cells and monocytes (C) MFI of ABCA1 channel 
expression on B cells and monocytes. Mean ± SE One-Way ANOVA was used to test 
for significance. *p<0.05; HC – healthy controls; SLE-NP – SLE patients without plaque; 
SLE-P – SLE patients with plaque; ABCA1- ATP Binding Casette A1; ANE- di-4-
ANEPPDHQ. 
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7.3 Liver X receptor agonist induces altered lipid biosynthesis in B 
cells from healthy individuals  
 
I then questioned whether the differences in CD1d and CTB expression observed from 
ex vivo staining of B cells and monocytes (Results Chapter 5) could be explained by 
altered lipid biosynthesis. To investigate how altered lipid biosynthesis could influence 
the expression of different glycosphingolipid species in B cells from healthy individuals, 
PBMCs from healthy donors were cultured for 24h with either 1µM LXR agonist GW3965 
or vehicle (DMSO). Whole PBMCs, rather than B cells were cultured with LXR agonist 
GW3965 in order to preserve B cell viability, whilst reflecting the situation in vivo. 
B cells were subsequently labelled with CD19 and sorted by FACS before pooling 1x107 
B cells for each condition.  Lipids were subsequently isolated from B cells by chloroform: 
methanol extraction before being assessed for glycosphingolipids by high performance 
liquid chromatography (HPLC), which was carried out by Dr Dominic Alonzi at the 
Glycobiology Institute, Department of Biochemistry University of Oxford. 
Interestingly, treatment of PBMCs with LXR agonist GW3965 resulted in the upregulation 
of several glycosphingolipid species in B cells in comparison to treatment with vehicle 
alone (DMSO). Namely, GW3965 treatment resulted in augmented GA2 expression as 
well as the induction of GD3, GD1a and GT3 (Figure 7.2). 
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Figure 7.2 The effect of LXR agonist on B cell glycosphingolipid species 
PBMCs from 3 healthy donors were cultured for 24h with1µM LXR agonist GW3965 or 
vehicle (DMSO). Cells were labelled with CD19 and B cells were isolated using FACS 
sorting before pooling healthy donors and carrying out chloroform: methanol extraction 
on 1x107 B cells. The total cellular GSL profile was analysed by HPLC following 
glycanase digestion to release the GSL sugar head groups. Data is represented as 
qualitative HPLC plots showing the position of known GSL standards and GSL species 
in B cells from healthy donors treated with vehicle (DMSO) or LXR agonist GW3695. 
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7.4 Glycolipid content in B cells and monocytes from SLE patients 
is similar to healthy controls 
 
Previous work from the laboratory has identified increased expression of certain 
glycosphingolipids in T cells from SLE patients compared to healthy donors, which were 
associated with defective T cell signalling and function [367, 380]. I therefore decided to 
investigate whether glycolipid expression was altered in antigen presenting cells from 
SLE patients with and without plaque by carrying out HPLC on lipids isolated from B cells 
and monocytes (Figure 7.3). Interestingly, GM3 was found to be absent in B cells from 
SLE-NP patients, although it is unknown whether this was due to poor sample quality. 
Analysis of monocytes showed a slight reduction in GM3 in SLE-NP monocytes, and 
potentially increased levels of GD3 in SLE-P monocytes. This work is part of an ongoing 
collaboration with Dr Alonzi, Glycobiology Inst. Oxford University.  
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Figure 7.3 Differences in glycolipid content in B cells and monocytes from 
healthy, SLE-NP and SLE-P patients 
1x107 B cells and monocytes from healthy (n=7), SLE-NP (n=6) and SLE-P (n=7) 
patients were labelled with CD14 and CD19 then isolated by FACS sorting before 
carrying out chloroform: methanol extraction. The total cellular GSL profile was analyzed 
by HPLC following glycanase digestion to release the GSL sugar head groups. Data is 
represented as qualitative HPLC plots showing the position of known GSL standards and 
GSL species in B cells and monocytes from healthy controls, SLE-NP and SLE-P 
patients. SLE-NP – SLE patients without plaque; SLE-P – SLE patients with plaque 
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7.5 Altered lipid metabolism in B cells and monocytes of SLE 
patients  
 
Previous work from the lab has shown that treatment of CD4+ T cells with LXR agonist  
induced increased CTB expression in cells from healthy donors and induce lipid raft-
associated defects similar to those identified in  in SLE patients [380]. I therefore sought 
to determine whether stimulation of lipid biosynthesis pathways (LXR or PPARγ) could 
influence B cells and monocyte membrane lipids as well as CD1d expression, and 
whether this had any subsequent influence on iNKT cells. To achieve this, freshly 
isolated PBMCs were cultured in vitro with LXR agonist (GW3965), PPARγ agonist 
(Rosiglitazone) or vehicle (DMSO) for 4, 24 and 96h, before staining for B cells (CD19), 
monocytes (CD14), CD1d, lipid rafts (CTB) and cholesterol (filipin). Experiments were 
performed by MSc student Shaheer El-Bardisy under my supervision.  
Whilst LXR and PPARγ agonist failed to influence CD1d expression in both B cells and 
monocytes when compared to vehicle-treated (data not shown), trends were observed 
for lipid raft expression whereby LXR agonist was found to increase lipid raft expression 
on B cells over time, whilst PPARγ agonist treatment was found to increase lipid raft 
expression on monocytes.  However, neither of these trends reached significance when 
paired t tests were used to compare vehicle with LXR or PPARγ treatments, although 
this was probably due to low sample numbers. 
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Figure 7.4 LXR agonist GW3965 and PPARγ agonist Rosiglitazone 
stimulation influences B cell and monocyte lipid raft expression  
PBMCs from healthy donors (n=3-4) were cultured in complete medium at a 
concentration of 107/ml in the presence of 1µM of LXR agonist GW3965, 2.5 µM PPARγ 
agonist Rosiglitazone or equivalent concentrations of DMSO (vehicle) for 4, 24 and 96h, 
At each time point cells were stained for CD14 (Monocytes), CD19 (B cells), and CTB 
(lipid rafts) and expression quantified by flow cytometry. Percentage change in MFI for 
CTB in (A) B cells and (B) monocytes for each treatment, calculated relative to ex vivo 
CTB expression from the same healthy donors.   
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7.6 Altered lipid biosynthesis in B cells (but not monocytes) 
influences iNKT cell expansion and cytokine responses 
 
To determine whether LXR or PPARγ agonist stimulation could influence iNKT cell 
responses, potentially via changes in CD1d and lipid raft expression, an iNKT cell line 
was generated over 7 days as described in methods section 2.10.  Meanwhile, PBMCs 
were cultured with 1μM LXR agonist (GW3965),  2.5μM PPARγ agonist (Rosiglitazone) 
or vehicle (DMSO) overnight before negatively isolating B cells or monocytes  and co-
culturing for 48h with the expanded iNKT cell line (CD3+ cells isolated by FACS sorting 
or by negative selection kits). Cells were subsequently surface stained for CD3 and 
iTCR, and intracellularly for IFN-γ, IL-4 and IL-10. iNKT cell phenotype was analysed by 
flow cytometry. Experiments were performed by Shaheer El Bardisy under my 
supervision. 
Data was plotted relative to unstimulated (vehicle/DMSO). Interestingly, iNKT cells were 
expanded when cultured with B cells which had been pre-treated with PPARγ agonist, 
whilst LXR agonist had the opposite effect (Figure 7.5A). Both these responses were 
inhibited with anti-CD1d antibody, demonstrating that this effect was due to alterations 
in CD1d-mediated antigen presentation. No effect however was observed for co-cultures 
with monocytes (Figure 7.5B). 
Analysis of cytokines by intracellular staining revealed that LXR (but not PPARγ)-
stimulated B cells could induce a Th1 cytokine response in iNKT cells, characterised by 
increased intracellular IFN-γ and decreased IL-4 (Figure 7.6A and B). This was inhibited 
in cultures with anti-CD1d antibody, suggesting that this was due to altered CD1d-
mediated antigen presentation. No effect was observed on intracellular IL-10 in co-
cultures with either LXR- or PPARγ-stimulated B cells (Figure 7.6C), whilst stimulation 
of monocytes with LXR or PPARγ agonist failed to have any effect on iNKT cell cytokine 
production (data not shown).   
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Figure 7.5 LXR and PPARγ stimulation of B cells but not monocytes 
influences CD1d-mediated presentation and subsequent activation of 
iNKT cells 
PBMCs from healthy donors (n=2-4) were cultured in complete medium at a 
concentration of 107/ml in the presence of 1µM of LXR agonist GW3965 or 2.5μM PPARγ 
agonist Rosiglitazone for 24h before isolating B cells or monocytes by negative selection. 
These were co-cultured for 48h with purified iNKT cells from a cell line expanded over 7 
days ±αCD1d antibody. Cells were stained for CD3 and iTCR before analysing by flow 
cytometry. Percentage change in iNKT cell frequency was calculated for (A) B cell and 
(B) monocyte co-cultures relative to unstimulated (DMSO) control. Data were analysed 
by student’s t test whereby each treatment was compared to anti-CD1d. *p<0.05 
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Figure 7.6 LXR stimulation of B cells induces a Th1 response upon 
subsequent co-culture with iNKT cells  
PBMCs from healthy donors (n=2-4) were cultured in complete medium at a 
concentration of 107/ml in the presence of 1µM of LXR agonist GW3965 or 2.5μM PPARγ 
agonist Rosiglitazone for 24h before isolating B cells by negative selection. These were 
co-cultured for 48h with purified iNKT cells from a cell line expanded over 7 days ±anti-
CD1d antibody. Cells were stained for CD3 and iTCR, then intracellularly for IFN-γ, IL-4 
and IL-10 before analysing by flow cytometry. Percentage change in expression of (A) 
IFN-γ, (B) IL-4 and (C) IL-10 relative to unstimulated (DMSO) control. Data were 
analysed by student’s t test whereby each treatment was compared to anti-CD1d. 
*p<0.05 
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Chapter 8: Discussion 
 
8.1 Conclusions  
 
I report a number of novel findings in relation to the role of iNKT cells in the development 
of atherosclerosis in SLE patients.  
 SLE-P patients had an increased iNKT cell frequency compared to SLE-NP 
patients and a unique iNKT cell phenotype characterised by differential 
expression of CD4, CD69, CD161 and PD-1, and increased IL-4 production 
compared to those without plaque and SLE patients who have suffered 
cardiovascular events. 
 Serum metabolomics analysis identified dyslidaemia in SLE patients compared 
to healthy donors and significant alterations in VLDL expression and lipid content 
between SLE-P compared to SLE-NP patients.  
 The unique SLE-P iNKT cell phenotype was not associated with differences in 
CD1d expression or the location of CD1d to lipid raft domains but was associated 
with more rapid interactions (conjugate formation) between monocytes and iNKT 
cells and increased signalling via the iTCR. 
 Phospholipids isolated from monocytes but not B cells from SLE-P patients were 
able to induce the SLE-P iNKT cell phenotype in healthy donor cells during in 
vitro culture.  
 iNKT cells from SLE-P patients  promoted M2-like macrophage polarisation, 
associated with anti-inflammatory responses in plaque. 
 
 
I hypothesise that altered serum VLDL contributes to the differential iNKT cell phenotype 
and cytokine responses observed between SLE-NP and SLE-P patients. The increased 
IL-4 production by iNKT cells from SLE-P patients consequentially results in polarisation 
of M2 “anti-inflammatory” macrophages, which may play an athero-protective role in 
patients with preclinical atherosclerosis. This protective response is probably 
overwhelmed in more advanced plaques where iNKT cells appear anergic. A diagram 
outlining the proposed mechanism of iNKT cell activation and responses during different 
stages of plaque development in SLE patients is shown in Figure 8.1. 
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Figure 8.1 Differences in serum VLDL drive an altered iNKT cell phenotype 
and an anti-inflammatory macrophage response in SLE patients with 
preclinical plaque 
In SLE-NP patients, serum lipids induce altered presentation of endogenous lipids to 
generate an iNKT cell phenotype characterised by low CD4 expression and CD69 
expression, and high CD161 and PD-1 expression associated with high IFN-γ and low 
IL-4 production. This drives an inflammatory M1 macrophage phenotype. In SLE-P 
patients, altered presentation of phospholipids drives iNKT cell expansion with high CD4 
and CD69 and low CD161 and PD-1 expression. This is associated with increased IL-4 
production with drives an M2 macrophage phenotype. In SLE-CV patients, I hypothesise 
that increased iNKT cell accumulation within the plaque, or M1 macrophage polatisation 
could promote a proinflammatory iNKT cell response characterised by high CD4 and 
CD8 expression, with low CD161, PD-1 and CD69. The lack of iNKT cell IL-4 could 
represent a subsequent failure to induce M2 macrophage differentiation. 
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8.2 iNKT cell frequency and atherosclerosis in SLE patients 
 
The importance of iNKT cells in the pathogenesis of both atherosclerosis and SLE is 
supported by my results describing a distinct iNKT cell phenotype in SLE patients with 
and without preclinical plaque. This included differences in iNKT cell frequency, CD4 and 
CD8 subsets, activation markers, cytokines and responsiveness to α-GalCer in SLE-NP 
and SLE-P patients compared to healthy donors (Table 8.1). 
 
The increased iNKT cell frequency in SLE-P compared to SLE-NP patients suggested 
that iNKT cell expansion could occur as a protective response during early plaque 
development. Very little is known about iNKT cell function in human health and disease; 
in particular their ability to orchestrate both pro-inflammatory and immunoregulatory 
responses and how this balance is maintained. The finding of decreased iNKT cells in 
SLE-NP patients compared to healthy donors is in support of previous studies  showing 
several iNKT cell defects in SLE, including reduced frequency [233, 436, 439]. Reduced 
iNKT cell frequency has been described in some animal models of atherosclerosis, 
where it is thought to be due to increased migration to inflamed tissues although these 
models typically resemble advanced atherosclerosis [219, 458]. In one of the few models 
of preclinical plaque, Major et al. observed that iNKT cell numbers were elevated in the 
spleen and liver of ApoE-/- mice (compared to plaque sites) during early lesion formation, 
a finding which was reversed during later stages of atherosclerosis [461].  
 
While few human studies have investigated iNKT cell frequency and function in 
asymptomatic atherosclerosis patients, several studies have observed increased iNKT 
cell numbers in atherosclerotic lesions, supporting a role for iNKT cells in plaque 
development [457, 458, 506]. However, in a study by Kyriakakis et al. fewer iNKT cells 
were detected in the circulation of individuals with asymptomatic plaque compared to 
healthy donors, which although was true in this study was not found to be significant. 
Kyriakakis et al. also reported that patients with symptomatic atherosclerosis had lower 
iNKT cell frequencies compared to asymptomatic individuals, which is also in line with 
my data showing that SLE patients who had suffered a cardiovascular event had 
significantly reduced iNKT cell frequencies compared to patients with preclinical plaque 
[458]. Importantly there were some differences between my study and Kyriakakis et al. 
which make comparison difficult, in particular the study population were from a previously 
healthy population with no previous history of autoimmune disease, and had differences 
in age and gender compared to my SLE patient groups. Overall, whilst my data suggest 
that iNKT cells are decreased in SLE patients compared to healthy individuals as a 
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consequence of the disease, differences in iNKT cell frequency during the various stages 
of atherosclerosis may be indicative of atherosclerosis progression with higher iNKT cell 
frequencies associated with preclinical plaque. One likely explanation for this would be 
due to differences in the localisation of iNKT cells within the tissues, whereby one may 
expect decreased iNKT cells in the peripheral blood of SLE-CV patients due to increased 
localisation into the plaque, which may not be as apparent during the earlier stages [458].  
 
Strikingly I found a significant positive correlation between iNKT cell number and plaque 
calcification (grey scale median) which suggested an association between iNKT cells 
and more stable plaque. This is supported by Rohm et al. who examined T cell markers 
in stable and unstable plaque specimens [507]. Fewer Tregs but increased T helper and 
CTLs were detected in the unstable compared to stable plaque specimens [507]. T cells 
within the plaque were also found to be more activated with increased expression of 
CD25 and CD69 [507]. 
 
I also investigated other plaque related factors including age, patient disease activity and 
medication, which could influence iNKT cell phenotype. iNKT cell frequency was 
negatively correlated with age in the healthy controls as described previously [489, 508], 
but this was lost in SLE patients. Ageing can also influence iNKT cell subset distribution 
and function with older individuals showing an increase in CD4 positivity [509] and 
reduced proliferative capacity in response to α-GalCer [508], with a shift from NKT1 to 
NKT2 type response [509]. Interestingly this could suggest that the iNKT cell phenotype 
of older individuals is similar to that of SLE patients, and raises the question of whether 
immunological ageing could be a consequence of SLE. This could be further addressed 
by assessing conventional T cells for characteristics associated with immunological 
ageing such as shortened telomere length, and defective responsiveness to antigen 
challenge i.e. increased Tregs and decreased memory T cell populations as observed in 
the skin [510]. It would be interesting to correlate such measures with iNKT cell function 
in SLE patients compared to older individuals.   
As reported by Bosma et al. [233] no significant differences in iNKT cell frequency 
between disease active and inactive patients when categorised according to BILAG at 
the time of the scan were observed. Similarly, patient medication had little effect on iNKT 
cell frequency, also reflecting data from Bosma et al. where the relationship between 
iNKT cell frequency in disease active vs. inactive patients remained the same when 
medication was taken into account [233]. However, an effect of medication on iNKT cells 
cannot be completely ruled out. Indeed, Zhao et al observed that treatment with 
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cyclophosphamide or mycophenolate mofetil resulted in an increase in iNKT cell 
numbers [511]. Furthermore, in a study on patients with early RA, iNKT cell numbers 
from naïve-treated patients were found to correlate with the inflammatory markers CRP 
and ESR [512]. This correlation was lost in patients taking immunosuppressants 
indicating that DMARD and steroid treatment can influence iNKT cells. 
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 SLE-NP SLE-P SLE-CV 
iNKT cell 
identification 
and subsets 
iNKT cell frequency ↓  - ↓ 
CD4 -  ↑  - 
CD8  -  - ↑↑ 
iNKT cell 
surface markers 
CCR6 ↑ ↑ ND 
CD25 ↑ ↑ ND 
CD69  - ↑↑  - 
CD161  - ↓↓ ↓↓ 
PD-1 ↑  - ↓ 
iNKT cell 
intracellular 
cytokines and 
proliferation 
Proliferation (Ki67 
expression) 
↓ ↑ ND 
IL-4 ↓ ↑ ↓ 
IFNγ ↑ ↑ ↓ 
 
Table 8.1 Surface marker expression relative to healthy individuals  
Summary to show differences in iNKT cell frequency, surface marker expression, 
cytokines and proliferation in response to 7 day stimulation with α-GalCer in SLE-NP, 
SLE-P and SLE-CV patients relative to healthy donors.  
 
SLE-NP – SLE patients without plaque; SLE-P – SLE patients with plaque; SLE-CV – 
SLE patients who have suffered a cardiovascular event. 
↑ denotes increased expression compared to healthy donors 
↓ denotes decreased expression compared to healthy donors 
-    denotes no change in expression compared to healthy donors 
ND denotes not determined 
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 8.3 iNKT cell phenotype and atherosclerosis in SLE patients 
 
I found that CD4+ and CD4+CD8+ iNKT cell subsets were elevated in SLE-P patients and 
CD8+ iNKT cells were increased in the SLE-CV patients compared to healthy controls 
mainly at the expense of the CD4-CD8- iNKT cell population. CD4+ iNKT cells have 
previously been shown to be more atherogenic compared to double negative iNKT cells 
in mice [465]. Adoptive transfer of CD4+ NKT cells into T and B cell-deficient mice in a 
study by Li et al. confirmed that NKT cells directly contribute to atherogenesis [225]. They 
found that the mechanisms employed by CD4+ NKT cells in atherosclerosis were perforin 
and granzyme-B dependent, and contributed to multiple characteristics of 
atherosclerosis including necrotic core formation and increased VCAM-1 expression 
[225]. In contrast, very little is known about CD8+ iNKT cells, although it thought that 
these cells may play a similar role to CD8+ T cells though their ability to mediate cytotoxic 
functions [513]. In addition, these cells produce IFN-γ but not IL-4 upon antigenic 
stimulation in mice [514], which supports my hypothesis of a pathogenic NKT1 response 
in SLE-CV patients where CD8+ iNKT cells are present. 
 
My hypothesis of differences in the distribution of iNKT cells in SLE patients is supported 
by the finding of increased CD8+ iNKT cells in SLE-CV patients. Since one would not 
expect any differences in iNKT cell subset development between SLE-P and SLE-CV 
patients, it is plausable that CD4+ iNKT cells preferentially localise to the plaque thus 
leading to an increase in CD8+ compared to CD4+ iNKT cells in the peripheral blood of 
SLE-CV compared to SLE-P patients, which would be in support of the proatherogenic 
role for CD4+ iNKT cells which has previously been described [465]. This could be further 
investigated by analysis of plaque specimens for CD4+ and CD8+ iNKT cells during 
different stages of atherosclerosis in mouse models of SLE. 
  
Furthermore, I also discovered changes in iNKT cell phenotype. CCR6 and CD25 
expression were elevated on iNKT cells from all SLE patients compared to healthy 
controls, regardless of whether they had plaque. Increased CCR6 expression has been 
described previously on iNKT cells from SLE patients with active disease [232] and is 
implicated in the homing of lymphocytes to sites such as the intima, where 
atherosclerotic plaque forms [515].  This is achieved through binding to its receptor 
CCL20, which is also expressed on human atherosclerotic plaques [516].  
  
CD25 (IL-2R) contributes to iNKT cell expansion and is thought to play a regulatory role. 
Similar to Tregs, CD25 is predominantly expressed on CD4+ iNKT cells [347], meaning 
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its expression on iNKT cells from SLE patients could simply be a result of increased 
CD4+ iNKT cell numbers.  In addition IL-2 enhances iNKT cell expansion, which could 
suggest that iNKT cells from SLE patients have increased functional potential [358]. One 
study found that constitutive expression of CD25 by iNKT cells in early life meant that 
they were primed to respond to lower doses of antigenic stimulation [517].  
 
Expression of CD69, an early activation marker, was raised on iNKT cells from SLE-P 
patients but not SLE-NP or SLE-CV patients compared to healthy donors. However, the 
role of CD69 in atherosclerosis remains unknown; whilst CD69 knockout mice are 
protected from atherosclerosis [518], enhanced expression of CD69 has been observed 
within unstable carotid plaque specimens in humans [507]. Similar conflicting 
observations have been seen in SLE where CD69 expression is associated with 
increased IFN-γ production by NK cells [519], whilst CD69 expression on CD8+ T cells 
was found to induce apoptosis of other immune cell types [520].  
 
Strikingly, CD161 expression was decreased on iNKT cells from SLE-P patients 
compared to SLE-NP patients and healthy donors. CD161 is present on both NK cells 
and Th17 cells, and functions as an inhibitory receptor for cytotoxicity by interacting with 
its ligand LLT1 [521]. Since there was no difference in IL-17 intracellular cytokine 
production between SLE-NP and SLE-P patients, it is possible that CD161 could be 
acting through a negative feedback mechanism to downregulate cytotoxicity in these 
patients.  
 
Furthermore, CD161 expression has been shown to relate to many functional aspects of 
iNKT cells. Interestingly, high CD161 expression on iNKT cells was associated with 
anergy as well as failure to proliferate, secrete cytokines and induce cytolytic activity 
[522], whereas in conventional T cells, high CD161 expression was found to be 
associated with IFN-γ production [222]. Both these studies reflect my observation for 
SLE-NP patients where high CD161 expression on iNKT cells was associated with 
increased IFN-γ production and poor proliferative responsiveness to α-GalCer. In 
contrast, the absence of CD161 on iNKT cells was associated with increased IL-4 
production in animal models  [223], which supports my data from SLE-P patients where 
CD161 expression correlated with intracellular IL-4. 
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CD161 may also act by altering the activation threshold of iNKT cells, based on my 
finding that CD161 expression is positively correlated with activation markers CD25, 
CD69 and PD-1 in SLE-P patients. This theory has previously been proposed in relation 
to MAIT cells whereby loss of CD161 during HIV infection was found to be associated 
with increased levels of MAIT cell activation [224]. Changes to the activation threshold 
have also been identified in plaque-derived iNKT cells, albeit assessed by 
responsiveness to α-GalCer, and not CD161 expression [458]. Interestingly, low 
expression of Ly49 in mice (homologous to CD161 in humans) is associated with 
atherosclerosis in ApoE deficient mice [465]. This supports my preliminary data showing 
that CD161 expression is decreased to a greater extent in SLE patients who had suffered 
a cardiovascular event. 
The finding of increased PD-1 in SLE-NP compared to healthy controls and SLE-P 
patients is supported by studies where PD-1 was shown to play an important role in the 
inhibition of T cell functions and induction of anergy in iNKT cells through recruitment of 
intracellular Src homology region 2 domain-containing phosphatase SHP-1 and SHP-2, 
which inhibits downstream signalling pathways [523, 524]. PD-1 expression may also be 
linked to cytokine polarisation, since the PD-1 pathway can substantially increase the 
amount of IFN-γ produced in response to Mycobacterium tuberculosis infection [523]. 
This is particularly relevant to iNKT cells from SLE-NP patients which I have shown 
predominantly produce IFN-γ.  Importantly, blocking PD-1 was found to protect NKT cells 
from apoptosis in annexin V+ IFN-γ+ cells but not annexin V+ IL-4+ cells [523], suggesting 
that the reduction in PD-1 seen in SLE-P patients may be associated with increased 
survival and maintenance of the iNKT cell population. 
Importantly, I have shown that the differences in iNKT cell phenotype observed are 
mostly iNKT cell-specific; although trends were observed in conventional T cells, these 
were to a much lesser extent and not significant. Whilst in support of my hypothesis that 
iNKT cells play a role in the development of atherosclerosis in SLE patients, it does raise 
the question on the contribution of iNKT cells to the overall immune response due to the 
fact that they are smaller in number compared to conventional T cells.  
Despite my findings, the phenotypic characterisation of iNKT cells in SLE patients is 
somewhat confusing due to the large degree of heterogeneity. Whilst I observed positive 
correlations between CD161 and several activation markers in SLE-P patients, their 
relevance remains under scrutiny since SLE-P patients have lower CD161 expression 
and higher CD69 expression compared to SLE-NP patients. Functional characterisation 
of CD25+, CD69+ and CD161+ iNKT cells has not previously been carried out, and 
236 
 
remains a challenge in SLE due to the lower frequency of iNKT cells compared to healthy 
individuals. This would provide greater insight into how CD161 may affect iNKT cell 
function. In light of this I decided to focus on iNKT cell function rather than phenotype, 
and how this may influence atherosclerosis progression. 
 
 
8.4 iNKT cell responsiveness and cytokine production in SLE 
patients with plaque 
 
My data has clearly shown differences in iNKT cell responsiveness between healthy, 
SLE-NP and SLE-P patients, whereby iNKT cells from SLE-NP patients failed to expand 
in response to α-GalCer. This is partially supported by data from Bosma et al, where 
iNKT cells from SLE patients were less responsive to α-GalCer [233]. Little is known 
however about the effect of α-GalCer on iNKT cells from atherosclerosis patients. 
Although Kyriakakis et al. showed that iNKT cells isolated from the plaque itself are more 
sensitive to α-GalCer compared to those from peripheral blood, they did not investigate 
iNKT cell expansion for patients with preclinical plaque [458]. I have therefore shown for 
the first time that SLE patients with preclinical plaque display altered responsiveness to 
α-GalCer, which is supported by the finding of increased proliferation (as measured by 
Ki67 expression) in iNKT cells from SLE-P patients after 7 days. Furthermore, elevated 
ICOS but not CD40L expression was observed on iNKT cells from SLE-P patients 
following culture with α-GalCer. It is tempting to speculate that this finding  indicates the 
increased iNKT cell activation in SLE-P patients is due to increased interactions with 
monocytes, rather than B cells which would also result in elevated CD40L expression as 
well [388].   
Whilst IFN-γ production by iNKT cells was increased in all SLE patients compared to 
healthy controls, the observation of a significant increase in IL-4 and IL-10 production by 
iNKT cells in SLE-P patients compared to healthy donors suggests that iNKT cells may 
play a protective role in SLE patients with preclinical plaque, which is lost in SLE-CV 
patients. This role for IL-4 in early atherosclerotic lesions is supported by Llorente-Cortés 
et al. who observed significantly increased IL-4 gene expression in PBMC from patients 
with subclinical femoral artery atherosclerosis [525]. Furthermore, decreased expression 
of transcription factor T-bet and increased GATA-3 in iNKT cells from SLE-P patients 
compared to SLE-NP patients could indicate that iNKT cells from SLE-P patients were 
NKT2 cells,  a functional iNKT cell subset  expressing high CD4, low T-bet and 
constitutive IL-4 production, with anti-inflammatory properties [265]. Importantly 
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differences in CD4 and CD8 subsets, in particular the CD4+ iNKT cell subset could 
explain the increase in IL-4 secretion in SLE-P patients since CD4+ iNKT cells have been 
shown to be associated with Th2 cytokine secretion in healthy donors and cancer 
patients [265, 526], which supports my data on SLE-P patients.   
My observation of increased IL-10 production by iNKT cells from SLE-P patients is 
supported by van Puijvelde and colleagues who described increased IL-10 production 
by iNKT cells during the initiation of atherosclerosis in mice, whilst Lehuen et al. have 
showed that IL-10 production by iNKT cells contributes to diabetes [468, 527]. A 
protective role for iNKT cell-derived IL-10 has also been shown in models of obesity, 
where IL-10 was able to induce a Treg response [251].  
 
However, there is no clear consensus on whether iNKT cells play a protective role in the 
initial stages of atherosclerosis since most evidence is contradictory. For example, IL-4 
knockout mice have been shown to have reduced atherosclerotic lesion size suggesting 
a pathogenic role for IL-4 in atherosclerosis [528], whilst CD1d knockout mouse models 
have concluded that iNKT cells contribute to the formation of the fatty streak in preclinical 
plaques [467]. One the contrary more recent studies have indeed demonstrated that 
iNKT cells can play an atheroprotective role in vivo during the initial stages of plaque 
development [468], which reflects their function under normal homeostatic conditions 
[243]. Due to the importance of iNKT cells in immune regulation, I propose that the IL-4 
and IL-10 response observed could be an attempt at the resolution of atherosclerosis by 
the iNKT cells themselves. This is supported by the fact that my work is from an 
autoimmune perspective where the presence of iNKT cells is thought to be beneficial 
[409]. 
 
Furthermore, analysis of SLE-CV patients who had previously suffered a cardiovascular 
event confirmed that this NKT2 response is specific to preclinical plaque. Specifically, 
SLE-CV patients had reduced IL-4 and IFN-γ iNKT cell production similar to  ApoE-/- mice 
with advanced plaques [459], supporting my hypothesis that  in the later stages of 
atherosclerosis iNKT cells become anergic and lose the ability to produce cytokines. 
However, due to low numbers of SLE-CV patients available I was unable to control for 
the length of time since the cardiovascular event, which has been shown to influence 
plaque stability and the immune environment [529, 530]. 
 
Finally, it is unknown whether iNKT cells within the plaque have a different phenotype 
and function compared to those within the blood. This is certainly the case in adipose 
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tissue from mice, where iNKT cells express lower CD4 and NK1.1, as well as a reduction 
in IFN-γ and IL-10 [199, 229], and this was attributed to altered gene expression; in 
particular a reduction in PLZF and an increase in both T-bet and GATA-3.  Moreover, 
parabiotic animal models confirmed that iNKT cells from adipose tissue are tissue 
resident [251], although it is unknown whether this could be the case for iNKT cells from 
atherosclerotic plaque.  
 
8.5 SLE patients with plaque have an altered serum metabolic 
profile 
 
Metabolomics analysis suggested a strong role for differences in serum lipids at driving 
altered iNKT cell responses, with differences in healthy donors compared to SLE 
patients, as well as between SLE-NP and SLE-P patients. Differences in small HDL were 
observed between healthy and SLE patients, but not between SLE-NP and SLE-P 
patients. The presence of small dense HDL in SLE patients is correlated with 
complement activation in terms of C3 and C4 titres, as well as the presence of subclinical 
atherosclerosis in one recent study [531]. Also, reduced circulating HDL levels have been 
associated with autoimmune diseases in animal models. For example, SR-BI deficient 
mice exhibit larger HDL particles with increased cholesterol content which are less 
effective at controlling immune responses [532]. As a result SR-BI null mice show 
increased B and T lymphocyte proliferation, as well as production of autoantibodies and 
deposition of immune complexes in the kidney similar to SLE [533]. This finding suggests 
that in addition to measuring the plasma levels of HDL to assess cardiovascular risk, the 
functional status of HDL should also be taken into account; a factor which is starting to 
receive more emphasis. Importantly, abnormal HDL is enriched in triglycerides and 
depleted in cholesteryl esters, which results in impaired anti-oxidative and anti-
inflammatory capacity [534, 535], as well as reduced ability to induce cholesterol efflux 
[536].   
Evidence suggests that HDL may also influence membrane lipids of cells, since HDL and 
apoA-I can promote cholesterol efflux from cells via ATP-binding cassette transporters 
ABCA1 and ABCG1 [537]. This is supported by the finding that mice with a combined 
ABCA1 sand ABCG1 deficiency have very low HDL levels, as well as severe 
inflammation and atherosclerosis [538]. A study by Rohatgi et al. showed that cholesterol 
efflux capacity was inversely related to the incidence of cardiovascular events in a cohort 
of 2924 individuals, and had a stronger influence on cardiovascular disease compared 
239 
 
to the HDL cholesterol level and particle concentration [539]. Such differences could 
therefore contribute to the altered lipid raft expression on T cells from SLE patients as 
previously reported [380], as well as differences in lipid rafts on B cells reported in this 
study. It is unknown whether altered HDL is a cause or consequence of altered immune 
responses in autoimmune diseases. However, it is clear that autoimmunity can be 
sustained through defects in circulating lipids, which contribute to impaired lipid 
metabolism and altered membrane lipid rafts, resulting in hyperactivation of T and B 
lymphocytes [540]. 
Many of the differences between SLE-NP and SLE-P patients were related to lipids, 
which I hypothesised had an anti-inflammatory role in SLE-P patients. For example, the 
observation of increased omega 6 fatty acids in SLE-P is supported by animal models 
where omega-6 fatty acids could prevent atherosclerotic plaque development [541]. 
Similarly, the increased 22:6 docosahexaenoic acid (DHA) seen in SLE-P patients 
supports its role as an anti-inflammatory marker due to the inverse correlation with 
markers of inflammation including IL-6 and CRP and association with lower 
cardiovascular disease incidence [542]. Interestingly, DHA supplementation has been 
shown to be atheroprotective in mice fed a high fat diet, through its ability to reduce 
cholesterol levels [543]. Likewise, the increase in monounsaturated fatty acids (MUFA) 
in SLE-P compared to SLE-NP patients is consistent with their protective role in 
cardiovascular disease [544], whilst a reduction in cholesterol esters in SLE-P patients 
is indicative of increased cholesterol catabolism and a reduction in foam cell formation, 
and thus may be protective against atherosclerosis [160]. 
The most striking findings between SLE-NP and SLE-P patients were the differences in 
VLDL (but not IDL, LDL or HDL) concentration as well as difference in its composition; 
total cholesterol was increased in all SLE patients compared to healthy donors, whilst 
free cholesterol and phospholipids were increased in SLE-P patients compared to SLE-
NP patients. These findings are supported by Chung et al. who observed a difference in 
the size of particles, whereby VLDL from SLE patients was larger compared to healthy 
controls [545]. They found that the size of the particles may be a better indicator of 
atherosclerosis in SLE, due to the association with inflammatory markers such as CRP. 
However, they observed no relationship between size of LDL and the development of 
atherosclerosis, again supported by my findings. This was also the case in a study by 
Olusi et al. which showed that patients with SLE had higher plasma concentrations of 
VLDL, triglycerides, LDL and ApoB, with lower HDL concentrations [546]. 
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Whilst it is clear that differences in lipoprotein subclasses can predict subclinical 
atherosclerosis in the general population [547], there is little information on lipoprotein 
subclasses in SLE patients. Chung et al. found no association between lipoprotein 
subclasses and coronary atherosclerosis [545], although this unexpected result could 
have been due to differences in disease activity or the drugs used to treat patients – an 
important conclusion, since little is known about the effect of corticosteroids on 
lipoprotein subclasses [545].  
One possible mechanism through which VLDL may be increased in SLE patients with 
preclinical atherosclerosis is through the adipokine resistin, which stimulates VLDL, apoB 
and lipid secretion by hepatocytes and is associated with cardiovascular disease [548]. 
Resistin can also influence expression of MTP, which is required for the processing of 
lipids for CD1d-mediated presentation [548]. This is particularly relevant to SLE patients 
where increased resistin levels correlate with coronary artery calcification levels [423]. 
Other molecules linked with VLDL levels in cardiovascular disease include irisin-1 and 
omentin-1, which are associated with lipoprotein metabolism and could prove important 
diagnostic biomarkers [549]. There is evidence to suggest that the increased 
phospholipid content of VLDL observed in SLE-P patients could be protective against 
atherosclerosis [550]. During lipid transport phospholipids are transferred from VLDL and 
LDL to HDL mediated by Apo-AI. The finding of increased phospholipids in chylomicrons 
from SLE-P patients suggests that lipid transport may be defective in SLE-P patients 
[551]. 
Interestingly a case-control study by Hua et al. showed that SLE patients with a history 
of cardiovascular disease (cases) had a significantly greater concentration of VLDL 
particles compared to SLE patients without cardiovascular disease (controls) [115]. 
Cases also showed significantly increased small dense LDL, with increased small HDL 
cholesterol in controls. The finding that VLDL differentiates between cases and controls 
is supportive of my data, despite the fact that this study involved patients with early 
atherosclerosis. It would therefore be interesting to carry out metabolomics analysis of 
serum from the SLE-CV patients in this study. 
In addition to lipids, metabolomics analysis identified several other factors in the serum 
that were associated with SLE and atherosclerosis. These included reduced glutamine 
levels in SLE patient serum compared to healthy individuals, which is supported in the 
literature, where is thought to play a role in cerebral disease activity [552]. The 
observation of increased acetate in SLE patients is indicative of alterations in the 
endogenous metabolism of glucose, fatty acids and amino acids in SLE patients 
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compared to healthy individuals [553]. However, the finding of lower concentrations of 
glycine in SLE-P compared to SLE-NP patient serum was not supportive of an anti-
atherogenic response in SLE-P patients due to reports of anti-inflammatory, 
immunomodulatory and cytoprotective functions for glycine, which protect against 
oxidative stress and protein glycation in the vasculature [554, 555]. However, whether 
such differences in biomarkers could influence immune cell function in SLE patients 
would require further investigation. 
In support of the differences in serum metabolites between SLE-NP and SLE-P patients 
and their relationship with iNKT cell frequency and IL-4 in SLE-P patients, I have shown 
that serum from SLE-NP and SLE-P patients can recapitulate the iNKT cell expansion 
and cytokine profile of SLE-NP and SLE-P iNKT cells in healthy PBMCs.  This effect was 
found to be CD1d-mediated, since it was blocked by culturing cells in the presence of 
anti-CD1d antibody. Similarly, the finding that culture of PBMCs from healthy donors with 
serum from SLE-NP and SLE-P patients could reduce B cell CD1d expression in vitro 
with a trend towards increased lipid raft expression suggests that factors in the serum 
can influence CD1d-mediated lipid presentation. Preliminary data suggest that this may 
occur through alterations in lipid biosynthesis, although this would require further 
investigation.   
 
No significant differences were seen in serum cytokines levels between SLE-NP and 
SLE-P patients and this may rule them out as having an influence on iNKT cell function 
in atherosclerosis. This is supported by findings in the general population where Chironi 
et al. showed little difference in serum cytokines when healthy individuals were stratified 
according to the reported frequency of cardiovascular risk factors [556].  Despite 
differences in iNKT cell-derived IL-4, my finding that it was undetectable in patient serum 
could suggest that IL-4 participates in a more localised immune response within the 
plaque itself as indicated by Kyriakakis et al [458]. Importantly, the observation of no 
difference in IL-12, a cytokine known to directly activate iNKT cells [286], suggests that 
the differences in iNKT cell activation between SLE-NP and SLE-P patients are due to 
altered lipids being presented, since I was also able to rule out interactions between 
CD1d and lipid rafts.   
 
To better understand the differences in serum lipids between healthy donors, SLE-NP 
and SLE-P patients results would need validating with more healthy donors, as well as 
taking samples from different time points due to the influence of SLE disease activity, as 
well as factors like diet and exercise on lipoprotein size, composition and concentration 
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and other serum metabolites. It also remains to be seen whether lipids from SLE-P 
patients are more similar to healthy donors or SLE-NP patients, which could be achieved 
by further statistical analysis.  
To determine whether differences in either the concentration or composition of serum 
VLDL contributes is responsible for the iNKT cell phenotype observed in SLE-P patients, 
I would carry out VLDL isolation from the serum of healthy, SLE-NP and SLE-P patients. 
I would then culture VLDL with PBMCs from healthy donors in an attempt to recapitulate 
the iNKT cell expansion and NKT2 response observed in SLE-P compared to SLE-NP 
patients.  
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8.6 Are CD1d and lipid rafts dysfunctional in SLE patients with 
atherosclerosis?  
 
Analysis of antigen presenting cell phenotype confirms previous work showing that CD1d 
expression is reduced on B cells (but not monocytes) from SLE patients, with no 
difference according to whether they had plaque or not [232, 233]. Reasons for this 
remain unknown although there are several possibilities including decreased activation 
by PPARγ and vitamin D [383, 387] as well as increased TLR9 stimulation on B cells, 
which regulates CD1d expression via miR155 and Ets1 [557].  My results were also in 
line with data from RA patients where no differences in CD1d expression are observed 
in monocytes [512], which suggests that CD1d-mediated presentation by B cells (and 
not monocytes) is dysfunctional in autoimmunity.  
The altered expression and relationship between CD1d and lipid rafts (CTB) in B cells 
could therefore be SLE specific rather than associated with the presence of 
atherosclerosis. This is supported by previous reports showing that membrane lipids are 
defective in B cells from SLE patients with implications on immune cell function [558]. 
The position of lipid rafts relative to CD1d was disrupted but only in B cells from SLE 
patients compared to healthy individuals, a finding which could have functional 
implications on the recognition of lipid antigen by iNKT cells.  C20:2 lipid analogues were 
shown to induce a Th2 response in the absence of CD1d-lipid raft co-localisation, 
meaning that one may have expected greater co-localisation for plaque-negative 
patients [296, 559]. However, this experiment involved murine CD1d and an antigen 
which may not be physiologically relevant to humans. Therefore, I would need to repeat 
these experiments using specific lipids identified from patient serum or more relevant 
lipid antigens. This would enhance our understanding of CD1d and lipid raft co-
localisation and its effect on iNKT cell function, as well as whether it could be manipulated 
by different lipid antigens. However, it remains to be seen whether the lipid being 
presented or the position of CD1d is more important in determining iNKT cell effector 
responses.  
Reduced B cell CD1d expression in SLE patients has previously been associated with 
increased internalisation and recycling to the plasma membrane [233]. However I did not 
identify differences in lysosome or endosome numbers in SLE B cells (only endosome 
numbers were increased in monocytes from SLE-NP patients) and no differences in 
CD1d-endosome or lysosome co-localisation were detected. Yet I cannot rule out 
differences in recycling since other factors such as the  pH of endosomal compartments 
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have been found to regulate the loading of Th1-biasing vs Th2-biasing forms of α-GalCer 
onto CD1d [377], whilst differences in the various chaperones which regulate CD1d 
recycling could play a role in the rate of CD1d recycling [279]. It is also possible that 
differences in other antigen presenting cells may be contributing to altered iNKT cell 
activation since I observed a trend towards increased lipid rafts in pDCs from SLE 
patients. This supports data from Menon et al. showing that pDCs are defective in SLE 
patients [560], but whether this is due to their effect on iNKT cells remains to be 
determined. 
 
8.7 iNKT cell signalling 
 
My results showing that B cells and monocytes interact differently with iNKT cells 
provides an insight into how lipid antigen presentation by different antigen presenting 
cells could differentially influence iNKT cell function.  No previous reports have 
investigated the dynamics of iNKT cell-APC interactions and it will be interesting to 
investigate the underlying mechanisms further using endogenous lipids rather than α-
GalCer as the stimulating lipid. Changes in conjugate formation were associated with 
altered iNKT cell intracellular signalling. Despite forming fewer and more transient 
conjugates with iNKT cells B cells induced stronger phosphorylation of iTCRζ and 
ERK1/2. This observation warrants further study as to the reasons behind this, and its 
consequence.  
In vitro, blockade of ERK has been shown to significantly decrease numbers of iNKT 
cells in mice with a concurrent increase in CD69 expression and IFN-γ secretion, in a 
similar fashion to iNKT cells in the SLE-NP patients [561, 562]. However, there were 
some differences in vivo; namely a reduction in CD69 expression and IFN-γ secretion 
[561], thus highlighting that the differences observed in ERK signalling in this study may 
not be representative of the signalling in vivo.  They also indicate a requirement of other 
pathways including NFκB and p38 MAPK signalling. 
Therapeutically, several molecules have been developed which interfere with ERK 
signalling, thus altering iNKT cell activation and function. These include DPPE-PEG350, 
which has been shown to attenuate allergen-induced airways hypersensitivity by binding 
to CD1d and inhibiting ERK phosphorylation [563]. This antagonist has also been shown 
to reduce atherosclerosis in mice in an iNKT cell-dependent manner and could play a 
role here [564]. 
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Lipids could therefore play more of a role in the formation of conjugates between CD1d 
and iNKT cells as well as the subsequent signal strength, so it would be interesting to 
repeat this experiment with cellular lipids isolated from B cells or monocytes from healthy, 
SLE-NP and SLE-P patients instead of α-GalCer – in particular, fraction 5 (neutral 
phospholipids, PC, PE and sphingomyelin), which I found could induce iNKT cell 
expansion in SLE-P patients. This was blocked by anti-CD1d antibody suggesting lipid 
antigen presentation to iNKT cells was responsible for this effect. Whilst fraction 5 from 
SLE-P monocytes appeared to induce IL-4 and IL-13 in the culture supernatants in 
cultures with healthy PBMCs and was blocked with anti-CD1d, intracellular cytokine 
staining would be useful in confirming cytokines to be iNKT cell-derived. 
 
8.8 Monocytes and iNKT cell activation 
 
Importantly, my results have showed a role for differences in monocytic lipids between 
healthy donors, SLE-NP and SLE-P patients contributing to altered iNKT cell activation, 
a result which warrants further study. In this study, phospholipids from SLE-P monocytes 
induced significant iNKT cell expansion compared to phospholipids from SLE-NP 
patients. This was associated with increased IL-4 and IL-13, and decreased IFN-γ 
concentrations suggesting that differences in phospholipids in SLE-P patients 
contributed to the iNKT cell expansion and NKT2 response observed. Phospholipids 
have been identified previously to activate iNKT cells [314]. For example LPC is 
upregulated during inflammation and serves as danger signals to activate iNKT cells 
[243, 565]. In addition to indicating differences in lipid metabolism between healthy 
donors, SLE-NP and SLE-P patients, these results also suggest that monocytes may 
play more of a role compared to B cells in the development of atherosclerosis. However, 
it remains to be determined whether monocytes were indeed responsible for the 
presentation of endogenous lipids in these experiments.  
 
This potential role for monocytes in atherosclerosis is supported by the finding of 
increased expression of scavenger receptors LOX-1, LDLR and CD36 on monocytes 
compared to B cells. Comparison of patient groups revealed a trend towards decreased 
CD36 expression on monocytes from SLE-P patients, which is supported by Syväranta 
et al, who found significantly reduced expression by qPCR in aortic valve stenosis (AVS) 
patients [566].  The reduction in CD36 expression could be seen as either 
downregulation due to activation or alternatively as an immunoregulatory mechanism in 
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an attempt to resolve inflammation within the plaque. As a result, further work is needed 
to look at responses associated with CD36 activation in SLE patients, and its known 
influence on CD86 and HLA-DR expression, which may contribute to atherosclerosis 
development [567].  The increase in LOX-1 expression seen in AVS was observed on 
monocytes from SLE patients who had suffered a cardiovascular event but not in SLE-P 
patients suggesting that increased LOX-1 expression is characteristic of later stages in 
atherosclerosis [566]. 
 
I observed increased numbers of intermediate CD14++CD16+ monocytes in the SLE-NP 
patients and SLE patients who had cardiovascular disease compared to healthy controls 
and SLE-P patients. The importance of CD14++CD16+ monocytes during later stages of 
atherosclerosis is highlighted by a study on haemodialysis patients where individuals 
with advanced carotid plaques had higher counts of classical and intermediate 
monocytes compared to individuals without advanced plaques [568]. Moreover, in obese 
patients with subclinical atherosclerosis CD16+ monocyte frequency is similar to the 
general population, but is decreased following bariatric surgery where intermediate 
monocyte frequency was associated with decreased intima media thickness [168]. 
Importantly, a study by Mikolajczyk et al. showed that increased CD14++CD16+ monocyte 
frequency was associated with IMT in SLE patients but not healthy individuals [569]. 
 
8.9 M1 and M2 macrophage polarisation 
 
In recent years, the balance between pro-inflammatory M1 and anti-atherogenic M2 
macrophages has been implicated in atherosclerosis progression, with M2 macrophages 
postulated to play a role during its early stages [190].  My results showing increased 
CD14+CD206+CX3CR1+ (M2-like) monocytes in SLE patients with preclinical 
atherosclerosis is in direct contrast to the study by Fadini et al. where patients with 
asymptomatic lesions had increased numbers of CD14+CD68+CCR2+  (M1-like) 
monocytes and decreased numbers of CD14+CD206+CX3CR1+ (M2-like) monocytes 
[497]. However, Fadini et al. studied patients with Familial and Non-familial hyper-
cholesterolaemia, which are characterised by a very severe form of dyslipidaemia with 
significantly elevated LDL and total cholesterol but normal HDL and triglyceride levels; 
in this study SLE patients were all within the standard normal ranges used in clinical 
practice and only triglycerides were found to be significantly different between SLE-NP 
and SLE-P patients. Furthermore, the cohort in the study by Fadini et al. had no previous 
history of autoimmune disease, and therefore didn’t have the same underlying immune 
247 
 
cell dysfunction observed in SLE patients. Importantly, the M1:M2 ratio observed for the 
healthy donors in my study was similar to that of Fadini et al. despite some differences 
in the size of M1 and M2 monocyte-macrophage populations, which could be explained 
by the finding that the donors in my study were much younger. However, it is important 
to note that no other groups have adopted this monocyte-macrophage gating strategy 
yet and despite being a recent publication, no functional data available on the roles of 
the M1 and M2 subsets, apart from their altered distribution in pre-diabetic and 
hypercholesteroleamic patients [497, 570]. The relevance of these markers to monocyte 
function therefore warrants further investigation.    
 
The finding of increased numbers of CD14+CD206+CX3CR1+ “M2-like” monocytes and 
a decreased M1: M2 monocyte ratio in SLE patients with preclinical plaque is in line with 
previous data supporting a role for M2 macrophages in early plaque development [571], 
and could therefore point to a protective anti-atherogenic immune response. 
 
Using the mannose receptor (CD206) as an M2 marker, M2 cells have been identified in 
areas surrounding the plaque while M1 cells were located in the lipid core [572, 573].  Whilst 
recent studies have shown that symptomatic carotid lesions exhibit increased lipid and 
inflammatory cell infiltration, with a greater proportion of M1-like pro-inflammatory 
macrophages over M2-like anti-inflammatory macrophages [574], both macrophage subsets 
have also been reported to be present in early lesions (fatty streaks)  as well as more 
advanced lesions [500]. Furthermore, Lee et al. studied plaque in patients with acute 
myocardial infarction compared to stable angina and revealed differences in 
macrophage phenotype [575], supporting disease specific variations in 
macrophage/monocyte polarisation meaning that macrophage polarisation may vary 
according to the type of plaque or cardiovascular event.  
 
In contrast, Oksala et al. found M2 macrophages to be associated with more unstable 
plaque [576], however this shown to be related to the expression of the cell adhesion 
molecule kindlin-3 (FERMT3). Another explanation would be the possibility that 
alternative M2 macrophage subsets (M2a, M2b, M2c and M2d) may be responsible for 
differential effects within the plaque since M2a are described as being involved in wound 
healing, M2b in immunoregulation, M2c in efferocytosis and M2d in tumour growth [577]. 
It is difficult to conclude precisely which macrophage/monocyte subsets predominate at 
different stages of plaque development; alterations in the plaque microenvironment are 
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likely to play an important role in influencing macrophage (and most likely monocyte) 
polarisation and therefore influence plaque progression and regression.  
 
Despite the fairly extensive work on monocyte/macrophage subsets in vitro and in animal 
models of atherosclerosis, evidence of their patho-physiological relevance in a clinical setting 
remains scarce and in some cases conflicting  [171, 188]. Whilst my work has looked at the 
ex vivo phenotype on monocytes, the results presented here are in line with previous 
studies on human plaques that demonstrate the presence of both M1 and M2 
macrophages during developing atherosclerosis with a role for M2 macrophages during 
early stages [500]. More extensive work such as plaque biopsies would therefore be 
needed to investigate the roles of M1 and M2 macrophages in SLE patients with 
atherosclerosis.  
 
Importantly, SLE-P serum was able to induce M2-like macrophage polarisation but only 
in the presence of iNKT cells. This finding corroborates previous observations in 
experimental autoimmune encephalomyelitis, where iNKT cell deficient mice have fewer 
M2 macrophages and worse disease [433]. Similarly, treatment with α-GalCer in a 
mouse model of obesity significantly increased both iNKT cell numbers and M2 
macrophage polarisation, and reduced M1 macrophage-associated iNOS expression 
[251]. I observed increased expression of the CD206 and CD200R genes in THP-1 
macrophages upon co-culture with iNKT cells preconditioned using SLE-P serum. Such 
genes are known to be upregulated in response to IL-4 [501, 503], suggesting that iNKT 
cells promote M2 macrophage differentiation through IL-4 production.   
 
Whilst I have uncovered a potential role for M2 macrophages in preclinical 
atherosclerosis within the context of autoimmunity, I hypothesise that during the later 
stages of atherosclerosis this protective response is probably overwhelmed as can be 
seen through the predominance of M1 macrophages in more advanced rupture prone 
lesions [188, 189, 575], shifting the balance from tissue repair in favour of chronic 
inflammation. This is likely associated with the increase in iNKT cell frequency and a shift 
from IL-4 to IFN-γ production observed in animal models of atherosclerosis [459-461] 
and could be driven by alterations in other cell types, such as vascular smooth muscle 
cells, which have been shown to induce iNKT cell proliferation and the characteristic Th1 
response observed in atherosclerotic lesions [578]. 
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8.10 iNKT cells and interactions with Tregs 
 
In addition to IL-4, M2 macrophage polarisation can also occur through IL-10; the role of 
which remains to be determined in our patients. Previous work by Lynch et al. 
demonstrated a role for iNKT cells in M2 macrophage polarisation, mediated by both IL-
4 and IL-10 in murine adipose tissue [251]. They also observed that iNKT cells could 
transactivate Tregs to induce M2 macrophage via IL-10, suggesting a role for Tregs in 
iNKT cell-mediated macrophage polarisation [251]. Indeed, increased levels of IL-10 
have previously been observed in SLE patient serum [579], which could be due to 
increased M2 macrophage polarisation as a result of immune complex formation and 
TLR stimulation [580]. 
 
Whilst IL-10 can also contribute to M2 macrophage polarisation [581], the little difference 
in IL-10 secretion observed between SLE-NP and SLE-P patients suggests that IL-10 is 
not required for the M2 macrophage polarisation observed in the SLE-P patients.  This 
is supported by Brochériou et al. where the addition of IL-10 to M-CSF cultures induced 
comparable M2 macrophage gene expression compared to cultures with M-CSF alone 
[500]. Brochériou et al. also show that M2 macrophage polarisation by GM-CSF is 
associated with decreased CD36 expression in monocytes [500]; this supports the 
previously described trend towards decreased CD36 expression in monocytes from SLE-
P patients, which although not significant may have  been associated with increased M2 
macrophage polarisation.  
Previous work has indicated that a lack of iNKT cells in adipose tissue induces a 
proinflammatory environment, with increased polarisation towards M1-like macrophages 
[199, 229], and as such suggests that the presence of iNKT cells enhances M2 
macrophage polarisation. This is supported by the finding that treatment with α-GalCer 
can increase the frequency of CD206+ macrophages, whilst decreasing CD11c+ M1 
macrophages, in models of both obesity, as well as EAE [433]. This increase in M2 
macrophages was found to be IL-4-dependent in EAE, but IL-10-dependent in obesity; 
the iNKT cells being the source of each cytokine in both case [251].  
Since α-GalCer treatment has also been associated with an increase in Treg frequency 
in the adipose tissue but not the spleen of mice, it appears that this iNKT cell regulatory 
environment is tissue–specific, whilst indicating that iNKT cells can control Tregs and 
promote immunoregulation [251]. Adipose tissue Treg show a higher expression of IL-
10 in the resting state [230], and increased expression of lectin-like inhibitory receptor 
KLRG1, indicating a strong immunoregulatory function [251]. The role of Tregs in this 
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model would therefore warrant further investigation as it may be that iNKT cell-Treg 
interactions are confined to the plaque site in SLE patients with preclinical 
atherosclerosis.  
 
8.11 Lipid biosynthesis and iNKT cell responses in SLE patients 
with atherosclerosis 
 
The finding of differences in the ability of endogenous monocytic lipids from SLE-NP 
compared to SLE-P patients to activate iNKT cells suggested potential differences in lipid 
biosynthesis in APCs from healthy donors, SLE-NP and SLE-P patients. Furthermore, 
differences in cholesterol expression on B cells and monocytes from healthy and SLE-
NP patients could indicate potential differences in lipid metabolism and lipid raft 
expression, similar to differences previously described in T cells from SLE patients [380]. 
To confirm this I would need to be increase sample numbers for membrane order and 
ABCA1 expression, and repeat HPLC analysis of B cell and monocyte GSL species. An 
alternative approach would be to carry out qPCR on genes involved in lipid metabolism 
in APCs from healthy donors, SLE-NP and SLE-P patients. 
 
Whilst it is hard to come to any major conclusions on whether PPARγ and LXR agonist 
can influence CD1d and lipid raft expression due to lack of sample numbers and donor 
variability, trends in the data suggest that PPARγ and LXR differentially regulate lipid raft 
expression in monocytes and B cells. Previously published literature shows that PPARγ 
regulates CD1d gene expression in dendritic cells, but more work is needed to confirm 
whether this is true for B cells and monocytes in humans [383]. Furthermore, I observed 
that such differences in lipid metabolism in APCs could have a knock-on effect on iNKT 
cell function. This was most striking for iNKT cell frequency where PPARγ stimulation of 
B cells resulted in iNKT cell expansion, in contrast to LXR stimulation which resulted in 
a decrease in iNKT cell frequency. This is in support of data from patients with obesity 
where defects in PPARγ function were associated with altered CD1d expression and a 
decrease in iNKT cell frequency [384]. Unexpectedly, LXR-stimulated B cells were found 
to promote a Th1 response in iNKT cells, characterised by increased intracellular IFN-γ 
and decreased IL-4. Despite not supporting the well-described anti-inflammatory role for 
LXR [374, 380], this finding suggests that differences in lipid rafts (as a consequence of 
lipid biosynthesis) can influence iNKT cell cytokine production in support of data by Im 
et al [377]. 
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Differences in lipid metabolism in APCs from SLE-P patients could also contribute to the 
M2 polarisation observed in SLE patients with preclinical plaque. PPARγ is induced by 
oxLDL and is present in M1-like macrophage foam cells in atherosclerosis, where it 
exerts pro-atherosclerotic functions such as driving phagocytosis of oxLDL via CD36 
[582]. This is exemplified by the PPARγ agonist rosiglitazone, which was withdrawn from 
the market following trials where it increased the risk of MI in diabetes patients [583, 
584]. However, statin-induced PPARγ activation has been shown to induce M2 
macrophage polarisation, whilst having marked improvements on insulin sensitivity [585, 
586].  
LXR stimulation appears to protect against atherosclerosis by inducing cholesterol efflux 
from cells [587] and by inducing upregulation of the MERTK gene which encodes the 
Proto-oncogene tyrosine-protein kinase MER [588]. MerTK in turn prevents the uptake 
of lipoproteins and exerts anti-apoptotic effects on macrophages [589]. Importantly, the 
presence of IL-4 may contribute to atherosclerosis development in certain scenarios, 
since IL-4 can augment PPARγ expression in the presence of oxLDL, whilst 
downregulating LXR expression [573, 590]; the resultant defect in cholesterol efflux 
contributes to foam cell formation. Additionally, IL-4 decreases both MERTK and CD163 
expression resulting in poor clearance of apoptotic macrophages [588, 591], thus 
promoting both SLE- and atherosclerosis-associated inflammation.  Overall, these data 
suggest that altered lipid metabolism in B cells can influence CD1d-mediated iNKT cell 
activation in healthy donors; although it is unknown whether this plays a role in SLE 
patients. 
 
8.12 Limitations 
 
There are several limitations to this current study, which confines its clinical potential to 
SLE patients who have not previously suffered a cardiovascular event. Most important 
is the absence of ultrasound scan data for healthy individuals in order to act as a direct 
comparison to SLE patients who have not previously suffered a cardiovascular event 
(SLE-NP and SLE-P groups). 
Whilst comparison of SLE-CV with SLE-P patients has proved useful in understanding 
monocyte and iNKT cell phenotypes in SLE patients within a pre-clinical cardiovascular 
setting compared to those who had suffered a cardiovascular event, it is extremely 
difficult to control for factors such as length of time since event as well as type of event 
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(stroke or MI) due to low numbers of patients. Once again ultrasound scan data from 
these patients, as well as atherosclerosis patients with no previous history of 
autoimmune disease, would be useful for comparison to SLE-NP and SLE-P patients. 
Longitudinal analysis of these patients by performing follow up scans and through 
reassessment of their cardiovascular disease history would prove extremely useful in 
being able to monitor how iNKT cells may protect against or promote atherosclerosis at 
different stages of the disease in SLE patients. It would also be necessary to repeat 
these experiments with PBMCs from other patient groups in order to confirm whether a 
similar iNKT cell protective response is present in healthy donors with preclinical 
atherosclerosis. 
 
 
8.13 Therapeutic implications 
 
From this study there is much evidence to suggest that lipoprotein size, composition and 
concentration is a much better indicator of cardiovascular disease risk in SLE patients 
compared to the standard clinical measures used to diagnose dyslipidemia.  SLE 
patient’s serum lipids should therefore be routinely monitored, and a lower threshold 
should be used when diagnosing dyslipidaemia in these patients. This is particularly 
evident since SLE patients with preclinical atherosclerosis displayed significantly higher 
concentrations of triglycerides and greater cholesterol: HDL ratio compared to SLE-NP 
patients, despite being within normal range for healthy adults. This could lead to earlier 
intervention with statins, and consequentially improved prognosis for SLE patients.  
There is much controversy however surrounding serum lipid measurements as a 
predictor of atherosclerosis, termed “the lipid paradox”, where patients with lowest LDL 
levels have an increased cardiovascular risk compared to those with moderate LDL 
levels [592]. The cardiovascular risk profile of RA patients as determined by LDL levels 
is not significantly different to the general population [592], a finding which points to the 
lipid composition as perhaps playing more of a role than otherwise thought.   
Additionally, I would advocate a better system to identify patients at high risk of 
cardiovascular disease by taking into account SLE-specific factors. The use of an 
adjusted cardiovascular risk validation score has recently been investigated in RA, where 
patients are similarly at increased risk of cardiovascular disease [593].  Variables 
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identified for inclusion in an RA-specific cardiovascular risk model were RA disease 
activity and disease duration, which enabled the correct prediction of cardiovascular risk 
in 17% more RA patients [593].   
Interactions between antigen presenting cells and iNKT cells could also represent 
important therapeutic targets for atherosclerosis in SLE patients. The use of α-GalCer 
as a vaccine adjuvant has recently been explored in cancer treatment [594], although 
whether expansion of iNKT cells in SLE patients could prove beneficial remains to be 
determined. This would depend on the stage of atherosclerosis as the challenge would 
be to harness the protective iNKT cell function in SLE patients with preclinical plaque. 
Alternatively, more specific targeting of serum lipids in SLE patients, such as VLDL could 
prove beneficial in re-directing the iNKT cell response towards a NKT2-type response 
would also be useful; however this would require a greater understanding of the different 
lipoproteins present in patient serum as well as their effect on not only iNKT cell 
activation, but other immune cell types in the plaque.   
Finally, a recent publication from the group has suggested targeting of lipid biosynthesis 
in order to improve SLE disease activity since treatment with NB-DNJ was found to 
restore lipid raft function in SLE patients [380]. However, its effect on CD1d and lipid raft 
expression in antigen presenting cells as well as whether it could induce presentation of 
different endogenous lipid antigens to iNKT cells remains to be investigated.  
 
8.14 Summary 
 
In summary, I show evidence of a potentially atheroprotective iNKT cell response in SLE 
patients with preclinical atherosclerosis characterised by IL-4 production, which 
promoted macrophage polarisation towards an anti-inflammatory M2 phenotype. I also 
provide evidence that this protective iNKT cell response is specific to preclinical 
atherosclerosis in SLE patients due to impaired cytokine production and surface marker 
expression in SLE patients who have suffered a cardiovascular event. Whilst I have 
shown that there are differences in serum lipids (in particular VLDL size and composition) 
between SLE-NP and SLE-P patients the causal relationship between altered serum 
metabolites and iNKT cell function remains to be determined. Other factors which may 
be driving altered iNKT cell function in SLE patients with preclinical plaque include 
altered cellular lipid metabolism in monocytes, and differences in CD1d-lipid raft co-
localisation in B cells. Subject to further research, I would advocate targeting either 
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serum lipids or lipid biosynthesis in antigen presenting cells in order to enhance the 
atheroprotective NKT2-type response in SLE patients. 
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Accepted abstracts, talks and poster presentations 
 
 
Posters 
- 7th International symposium on CD1 and NKT cells  – Tours, France (2013) 
- British Society for Immunology – Liverpool, UK (2013) 
- Division of Medicine Research Retreat – London, UK (2014) 
- UCL Cardiovascular Science Symposium – London, UK (2016), for which I won a 
prize for the best use of the “3rs”.    
 
Talks 
- Institute of Child Health Symposium – London, UK (2014) 
- Royal Free Division of Medicine Postgraduate Research Day – London, UK (2014) 
- British Society for Immunology – Brighton, UK (2014) 
- UCL Rheumatology clinicians meeting – London, UK (2015) 
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